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Chapter 1 
Introduction 
Coordinating innate and adaptive tumour immunity: 
Role of human invariant NKT cells 
 
 
 Cancer is the second leading cause of death in the western world after circulatory 
diseases. In 2006, there were approximately 1.4 and 3.2 million new cancer cases and 600,000 
and 1.7 million estimated cancer deaths in the USA and Europe respectively [1;2]. Breast 
cancer is one of the most common cancer types among women, accounting for more than 1 in 
4 diagnosed. In Europe, breast cancer is the leading cause of death from cancer in women. A 
fall in breast cancer mortality rates in most European countries in the 1990s was reported by 
several studies [3;4]. The decline in mortality rate has been attributed to the combined effect 
of earlier detection and improved treatment, but it was observed mainly in young women, and 
because of the ageing of the European population the number of deaths from breast cancer is 
still rising (130,000 in 2004, 132,000 in 2006) [2]. A reduction in breast cancer mortality 
could be achieved by the implementation of organised screening programmes, in combination 
with the introduction of new therapies or improvement of the treatments already in use. New 
therapies are also needed for ovarian cancer, which is much less frequent than breast cancer 
but is the most lethal gynaecological malignancy and the sixth cause of death in women in the 
Netherlands [5]. 
 
 
1.  The immune system and cancer 
The complex relationship between the immune system and human cancer has been 
thoroughly investigated for decades. Observations that immune compromised patients have a 
higher incidence of tumours (reviewed in [6]), reveal the importance of an effective immune 
response to prevent the development of malignant disease.  
Dendritic cells (DC) play a crucial role in inducing an effective adaptive anti-tumour 
response by presenting tumour-associated antigens (TAA) in the context of Major 
Histocompatibility Complex (MHC) molecules to cells of the adaptive immune system, 
namely T cells. T cells can be differentiated into two subsets defined by cell surface 
molecular marker expression, i.e. CD4+ and CD8+ T cells. CD4+ T cells, known as helper T 
cells, are key players of the adaptive immune response because upon activation, they secrete a 
wide variety of Th1 or Th2 cytokines, regulating the immune response; whereas, CD8+ T 
cells, known as cytotoxic T lymphocytes (CTL) due to their cytolytic function, can destroy 
viral-infected or transformed cells. Activation of CD8+ T cells occurs through the engagement 
of the T cell receptor (TCR) and requires a second co-stimulatory signal provided mainly by 
CD4+ helper T cells or professional antigen presenting cells (APC). In this manner, CD4+ T-
cells provide help for the induction of effective TAA specific MHC class I-restricted CD8+ 
CTL. These TAA specific CTL may subsequently eradicate tumour cells [7]. Natural Killer 
(NK) cells are also capable of killing certain tumours, particularly those that down-regulate 
MHC class I expression [8], thereby evading destruction by CTL. Failure of this tight immune 
surveillance, due to the lack of TAA expression, the uncontrolled rapid growth of malignant 
cells that may out-run the immune response, or the development of different strategies to 
evade the immune system, might favour immune escape, leading to immune tolerance and 
thus the development of malignant disease. 
Is it possible to break this tolerance and induce a successful anti-tumour response? 
Many approaches have been developed in order to break the tolerance and induce an adequate 
immune response against the TAA that are presented on tumour cells, in such a way that 
cancer cells are selectively killed while other cells are left unaffected.  
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2.  Immunotherapy for cancer 
Various types of immunotherapy are under investigation. Non-specific immune 
therapies consist of a general activation of the immune system to overcome the tolerant state 
of the immune system towards the tumour, of which Bacillus Calmette-Guerin (BCG) 
injection and immunostimulatory cytokine therapy are two examples [9;10]. However, the 
clinical efficacy of these therapies is limited due to their lack of specificity and relatively high 
toxicity. 
 Conversely, active specific immune therapies aim at inducing the in vivo development 
of an immune response directed specifically against the tumour. Several immunisation 
strategies have been developed, including tumour-cell based vaccines, vaccines with defined 
TAA and DC based vaccines. The latter may be the most promising since this approach 
exploits the unique ability of DC to induce primary T-cell responses, and thus overcome 
tolerance (reviewed in [11]). Nevertheless, these approaches may be less suitable for immune 
compromised patients, like advance cancer patients, due to the general suppressed state of the 
immune system that hinders the development of a strong immune response.  
 Passive immune therapies can partially overcome immune suppression since the 
components of the immune response, such as antibodies or effector cells, are generated ex 
vivo or in vitro and are subsequently injected. In this category, two different approaches can 
be distinguished: adoptive T cell transfer and monoclonal antibody (mAb) therapy.  
Adoptive T cell transfer aims at enlarging tumour-reactive T-cell populations by ex 
vivo expansion followed by transfer of these cells back into the patient. Defined TAA 
recognized by tumour-reactive T cells are crucial for this approach [12].  
 Monoclonal antibodies are also directed to TAA. Despite the fact that there is no 
single antigen which is present on all tumour types and that most TAA are also present on 
normal cells, mAb have been produced and tested in clinical trials with distinct success. 
Trastuzumab (Herceptin) is one of the most successful recombinant humanized mAb 
clinically applied for the treatment of breast cancer. However, only 20-30% of human breast 
tumours express HER2/neu the TAA which is recognized by trastuzumab. Another mAb for 
breast cancer immunotherapy is huHMFG-1, a humanized mAb that recognizes MUC1. 
Contrary to HER2/neu, MUC1 is over-expressed in virtually all breast adenocarcinomas [13]. 
Due to its tandem-repeated extracellular sequence, MUC1 presents multiple antigenic regions 
per molecule, ensuring antibody binding even in low expressing tumours. Moreover, MUC1 
is overexpressed on 90% of adenocarcinomas, including ovarian cancer [14;15]. Clinical 
studies using mAb against MUC1, have recently been initiated and preliminary results have 
sometimes been inconclusive [16;17] or promising [18;19]. The MUC1 specific antibody, 
huHMFG-1, could therefore be a more widely applicable therapeutic agent. 
So far no consensus exists as to which of these approaches is most likely to result in a 
major clinical benefit for cancer patients. Clinical success of the different treatment modalities 
most probably depends on tumour type and stage. Independent of the type of therapy, any 
approach should overcome immune tolerance to induce a successful immune response 
towards the malignant cells.  
In this thesis, we explored the use of a relatively recently discovered T-cell subset, the 
CD1d-restricted invariant Natural Killer T (iNKT) cell, in cancer immune therapy. Due to 
their ability to coordinate both innate and adaptive immune responses, iNKT cells represent a 
promise for the development of strategies to improve anti-tumour immune responses.  
 
 3  iNKT cells 
NKT cells share phenotypic properties with both T cells and natural killer (NK) cells: 
they express both a TCR and NK receptors (reviewed in [20]). In contrast to conventional T 
cells, which recognize antigens presented by polymorphic MHC molecules, NKT cells 
recognize glycolipid antigens presented by the monomorphic CD1d molecule [20;21]. Within 
this CD1d-restricted NKT cell population at least two subsets have been defined. The 
classical or type I NKT cell is characterized by an invariant TCR using a unique Vα24.Jα18 
in humans paired with Vβ11; Vα14.Jα18 in mice, paired with Vβ2, Vβ7 or Vβ8.2, and called 
invariant NKT cell [21]. It is also characterized by its recognition of the glycolipid α-
galactosylceramide (α-GC). Type II NKT cells have a diverse TCR repertoire recognizing 
other glycolipids presented by CD1d, but do not respond to α-GC. Their physiological 
function has been less well studied and is still only poorly understood [22]. On the other hand, 
iNKT cells have been studied extensively, and their role in anti-tumour immunity has been 
repeatedly demonstrated in various murine models.  
There is some controversy about iNKT cell development, including origin, timing and 
selection. Like conventional T cells, iNKT cells arise in the thymus in the perinatal period and 
do not reach significant levels until at least three weeks after birth [23]. CD1d is required for 
positive selection of iNKT cells, which is mediated by thymocytes rather than by thymic 
epithelial cells. However, the mechanism of selection and the iNKT cell ligand involved 
remain unclear. Once iNKT cell have developed, the final maturation stages occur in the 
periphery, where the iNKT cell pool is maintained in a thymus-independent manner. 
Human and murine iNKT cells can either be CD4+ or CD4-CD8- (double negative, 
DN) and in humans a small proportion can express CD8. iNKT cells can be detected wherever 
conventional T cell are found, although the ratio iNKT to T cells varies widely in a tissue-
specific manner. iNKT cells represent ~0.5% of the T cell population in the blood and 
peripheral lymph nodes, ~2.5% of T cells in the spleen and bone marrow, and up to 30% of T 
cells in the liver and thymus [24]. Although the tissue distribution is less well studied in 
humans, iNKT cells appear to be approximately 10 times less frequent in all these locations. 
 
 
3.1 iNKT cell activation 
iNKT cell antigen recognition is restricted to the non-classical MHC class Ib-like 
molecule CD1d [25]. The CD1d molecule, consisting of a monomorphic glycoprotein heavy 
chain non-covalently associated with β2-microglobulin [26], effectively binds and presents 
lipid or glycolipid antigens. CD1d is widely expressed on haematopoietic cells. In mice, 
CD1d is constitutively expressed at low levels on lymphocytes, and it is highly expressed on a 
population of splenic marginal zone B cells [27], while in humans CD1d is detected on some 
circulating B and T cells [28]. CD1d has also been detected on APC, including monocytes, 
macrophages and some subsets of DC [27;29]. 
There are different mechanisms for iNKT cell activation depending on the nature of 
the ligand, which are described more in detail below. 
 
3.1.1 Detection of exogenous antigens 
Exogenous iNKT cell antigens presented by CD1d can directly activate iNKT cells. 
During infection, microbial-derived glycolipids can be taken up by DC and presented in the 
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context of CD1d to iNKT cells. Their activation is enhanced by IL-12 produced by DC 
(Figure 1a). These natural CD1d ligands are currently being identified. One example is 
lipophosphoglycan from Leishmania donovani, a component of the parasitic surface 
glycocalyx, which stimulates interferon (IFN)-γ secretion by hepatic mouse iNKT cells [30]. 
Glycosylceramides from the gram-negative bacteria Ehrlichia muris and certain 
Sphingomonas species, as well as phosphatidylinositol mannoside from mycobacterial 
membranes, are also recognized by human and mouse iNKT cells [31-33]. There is also 
evidence that glycolipids, possibly glycosylphosphatidylinositol from Plasmodium and 
Trypanosoma parasites, can be detected by iNKT cells [25]. iNKT cell stimulation by other 
pathogens such as Salmonella typhimurium, Staphylococcus aureus, and Pseudomonas 
aeruginosa has also been reported [25], but the specific CD1d ligands from these organisms 
have not been identified yet. These findings suggest that iNKT cells are primarily involved in 
the detection of bacterial and parasitic pathogens. 
Finally, the glycolipid α-GC, originally isolated from the marine sponge Agelas 
mauritianus, but possibly from microbial origin as well, and its synthetic homolog 
(KRN7000) are strong ligands for iNKT cells and induce iNKT cell proliferation and 
activation, and secretion of a broad spectrum of cytokines [34;35].  
DC
iNKT
CD1d
TCR
Exogenous
glycolipid
IL-12?
Tumour cell
iNKT
CD1d
TCR
Tumour-derived
glycolipid
DC
iNKT
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maturation
LPS
A B C D
DC
iNKT
CD1d
TCR
Endogenous
glycolipid
Tumour cell
Inflammatory 
signals?
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Figure 1: Possible mechanisms of iNKT cell activation. (a) Direct iNKT cell activation via uptake of exogenous 
glycolipid antigen by DC and presentation in the context of CD1d. (b) CD1d positive tumour cells or tumour-
associated tissue may present altered self-ligands. (c) Microbes containing TLR ligands, such as LPS, can 
activate iNKT cells by inducing IL-12 production by DC, which amplifies the weak response of the iNKT cell 
TCR to endogenous antigen–CD1d complexes. (d) Alternatively, tumour-associated inflammatory responses 
may induce DC to produce IL-12 or itself provide inflammatory cytokines such as IL-12 to amplify the weak 
TCR/CD1d signal. 
 
  
3.1.2 Recognition of endogenous antigens 
Invariant NKT cells are also able to detect endogenous antigens, such as tumour-
derived antigens. Tumour cells or tumour-associated tissue may present altered self-ligands in 
the context of CD1d (Figure 1b). The ganglioside GD3, which is overexpressed by human 
melanoma cells, can be presented in the context of CD1d to mouse iNKT cells [36]. 
Recently, the lysosomal glycosphingolipid isoglobotrihexosylceramide (iGb3) was 
shown to be a potent CD1d-restricted self-ligand [37]. DCs can be induced to present iGb3 
upon Toll-like receptor (TLR) ligation by gram-positive bacteria like Salmonella typhimurium 
[31;38]. Most recently, human DC have been reported to up-regulate the glycosphingolipid 
biosynthetic pathway after activation by TLR ligands [39]. In certain microbial infections, 
iNKT cells seem to be activated by IL-12 produced by TLR-stimulated DC in the presence of 
a weak CD1d/TCR signal, which is derived from the engagement of TCR to induced 
glycolipids presented by CD1d (Figure 1c). Similarly, iNKT cells might mediate anti-tumour 
responses without direct recognition of tumour-derived antigens as a result of iNKT cell 
activation by IL-12 (or other unknown inflammatory cytokines) produced during tumour-
associated inflammatory processes (Figure 1d).  
Therefore, both self- and foreign glycolipids presented on CD1d can elicit iNKT cell 
activation. However, it is still unclear whether iNKT cells can be directly activated by TLR 
ligands. 
 
 
3.2 iNKT cell function in innate and adaptive immunity 
Human iNKT cells acquire a memory-activated phenotype already before birth [40]. 
Upon stimulation by antigen recognition, iNKT cells have the remarkable capacity to rapidly 
produce large amounts of cytokines, e.g. IFN-γ and IL-4, leading to the trans-activation of 
other immune cells, such as DC, NK, T and B cells (Figure 2). In addition, the cytolytic 
machinery is activated. 
 
3.2.1 Innate immunity to tumour cells 
Invariant NKT cells express a wide variety of cell-death-inducing effector molecules, 
and murine iNKT cells have been reported to exhibit direct cytotoxicity against tumour target 
cells [41-44]. Freshly isolated and expanded human iNKT cells express granzyme B but not 
FasL [45]. However, FasL expression is inducible in human CD4+ iNKT cells after 
stimulation with PMA/ionomycin [46]. Human iNKT cells can express TRAIL, thus inducing 
apoptosis in TRAIL-sensitive cells [47]. Moreover, CD4- iNKT cells produce TNF-α and 
express perforin after activation [46]. Despite their full lytic machinery, human iNKT cells 
have little or no direct cytolytic effect against most tumour cells because these lack CD1d 
and/or a strong iNKT cell ligand. Indeed, direct killing of tumour cells has predominantly 
been described for CD1d positive leukemic cell lines [47;48]. Tumour cell lines of different 
origin are only susceptible to iNKT cell mediated killing after CD1d transfection and loading 
with α-GC [49]. 
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Figure 2: Cellular and molecular network activated by iNKT cells. Glycolipid ligands presented in the context 
of CD1d activate iNKT cells to secrete Th1 and Th2 cytokines, which trans-activate different immune cells, and 
up-regulate CD40L and cytotoxic molecule expression. CD40L on iNKT cells interacts with CD40 on DC, 
leading to DC maturation, and subsequent IL-12 secretion. IL-12 from DC induces IFN-γ production by iNKT 
cells, which in turn contributes to a Th1 immune response by stimulation of NK and CD8+ T cells. DC activation 
also leads to priming of adaptive CD4+ and CD8+ T cell responses. On the other hand, iNKT cell secretion of 
Th2 cytokines, i.e. IL-4, induces B cell activation. 
 
 
3.2.2 Cytokine secretion 
The main function of iNKT cells lies in the orchestration of immune responses 
through the production of a wide variety of both pro-inflammatory (Th1) and anti-
inflammatory (Th2) cytokines very swiftly upon their activation, rather than being effector 
cells themselves. Owing to the broad spectrum of cytokines, iNKT cells have the capacity to 
enhance host immunity to microorganisms and cancer as well as to prevent autoimmunity 
(reviewed in [50]). The question remains as to how iNKT cell activation results in different 
cytokine secretion patterns, leading to such diverse immune responses. Experimental evidence 
provides several possible explanations, which are not mutually exclusive. 1) Direct ex vivo 
analyses suggest that the different iNKT cell subsets secrete a different cytokine profile. The 
CD4+ iNKT cell subset produces both pro-inflammatory cytokines (TNF-α, IFN-γ) as well as 
anti-inflammatory cytokines (IL-4, IL-13), whereas the DN and CD8+ iNKT cell subsets 
produce primarily Th1 cytokines [46;51-53]. 2) The quality of the TCR signal, hence the 
nature of iNKT cell ligand, may influence the cytokine profile produced. For example, OCH, 
an α-GC analogue with shortened sphingosine, induces preferential production of IL-4 over 
IFN-γ [54], while a C-glycoside analogue of α-GC, α-C-GC, induces preferential production 
 of IFN-γ over IL-4 [55]. 3) The integration of signals from different types of receptors can 
influence the pattern of cytokine produced, e.g. IL-12 can selectively stimulate IFN-γ 
production by iNKT cells in the absence of α-GC [56;57]. 4) The context in which the iNKT 
cell ligand is presented has an influence on the pattern of cytokine produced. In this line, 
previous exposure to α-GC in the context of non-professional APC seems to favour a Th2 
response [58;59]. The resulting cytokine response has an effect on nearly every haemopoietic 
cell type, including DC, NK cells, and B and T lymphocytes, as discussed below (Figure 2).  
 
3.2.3 Cross-talk with DC 
DC maturation is a crucial event of the induction of most adaptive immune responses. 
The term maturation refers to an intricate differentiation process whereby DC respond rapidly 
to an environmental stimulus and become capable of eliciting an adaptive immune response. 
The type of stimulus determines the program of DC differentiation and the subsequent host 
immune response. Upon maturation, surface co-stimulatory molecules are up-regulated, 
cytokines and chemokines are secreted, antigen presentation is enhanced, and migration to 
secondary lymphoid tissues is initiated. 
Upon recognition of the CD1d presented molecules, e.g. microbial derived 
glycolipids, iNKT cells become activated and release cytokines, such as IFN-γ. In this 
process, they can induce DC maturation, which in turn expands the numbers and function of 
both innate and adaptive lymphocytes. Invariant NKT cell-induced DC maturation has been 
documented in vitro and in vivo after iNKT cell stimulation by α-GC presented on CD1d by 
DC [60;61]. Upon activation, iNKT cells up-regulate CD40L, which interacts with CD40 on 
DC to induce DC maturation as evidenced by increased expression of CD86, IL-12 
production, and priming of T cell responses [61-64] (Figure 2).  
 In turn, matured DC also stimulate iNKT cells for sustained innate immune responses 
[62]. IL-12, which is produced by maturing DC, enhances iNKT cell activation and cytokine 
secretion. The interaction between iNKT cells and DC results in the induction of antigen-
specific, IFN-γ-producing CD4+ and CD8+ T cells [65]. Thus, both innate responses and 
primary adaptive immune responses are augmented as a consequence of DC maturation by 
iNKT cells.  
 
3.2.4 Activation of T cells 
Activated iNKT cells in turn promote T cell activation without proliferation;  
activation markers such as CD69 are transiently up-regulated [66]. In particular, α-GC-
activated iNKT cells induce CD4+ T cell activation, as reflected by up-regulation of CD69 
expression and IFN-γ secretion [59]. Moreover, activated iNKT cells can affect the cytokine 
profile elicited by helper T cells, thus modulating the immune response [67]. In addition, 
iNKT cells can also provide effective help for CD8+ T cells [66]. α-GC-activated iNKT cells 
enhance CD8+ T cell activation, as evidenced by CD69 up-regulation, IFN-γ production and 
cytolytic function [68]. IL-12 is considered to be a crucial signal α-GC-mediated induction of 
functional antigen specific Th1-type and CTL responses [66;69]. Indeed, α-GC acts as an 
adjuvant in vivo that can increase the magnitude of the CD8+ T cell responses to protein 
antigens [70;71].  
In contrast to the vast number of studies in mice showing enhanced antigen specific T-
cell activation by α-GC and iNKT cells, the limited data on human iNKT cells demonstrate 
inhibition rather than enhancement of antigen specific CTL responses in vitro. Isolated human 
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CD4+ and CD8+ iNKT cells suppressed the expansion of antigen specific CTL by type 2 
cytokine (IL-4, IL-5 and IL-10) production and lysis of APC and activated T-cells 
respectively [72]. Further studies to elucidate the role of human iNKT cells on tumour-
specific CTL responses should clarify this dichotomy. 
 
3.2.5 Activation of NK cells 
NK cells are innate immune effectors that have critical cytolytic activity against 
infected or transformed cells, and they also produce immunoregulatory cytokines, including 
IFN-γ and tumour necrosis factor (TNF-α) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF), and chemokines [65;73]. NK cell function is regulated by a complex 
balance of inhibitory and activating signals that are generated by an array of different cell-
surface receptors after engagement by their specific cellular ligand. For example, NK cells 
sense MHC class I–deficient tumour cells and mediate spontaneous cytotoxicity against them. 
Another way of mediating tumour cell killing is through the IgG receptor, FcγRIII (CD16), 
which recognizes IgG antibodies bound to tumour cells and triggers the release of cytotoxic 
granules leading to tumour cell killing, in a process known as antibody-dependent cell-
mediated cytotoxicity (ADCC). This is one of the mechanisms by which several mAb used 
for cancer immunotherapy (e.g. the earlier mentioned trastuzumab and huHMFG-1) induce 
cancer cell death. 
In mice, IFN-γ production resulting from iNKT cell activation promotes a prompt NK 
cell activation, including proliferation, up-regulation of CD69 expression, additional IFN-γ 
secretion and increase in cytotoxic activity [74]. Likewise, activated human iNKT cells have 
also been shown to promote human NK cell activation, as defined by an increase in CD69 
expression, but not CD25 [49]. Moreover, NK cytotoxic function can be promoted by iNKT 
cell production of IL-2 [75]. Further studies to elucidate the mechanism of NK cell activation 
by human iNKT cells should help to improve iNKT cell-based anti-tumour therapies. 
 
3.2.6 Activation of B cells 
Rather than activating NK and T cells, iNKT cell secretion of Th2 cytokines, i.e. IL-4, 
induces B cell activation [58]. Activation of iNKT cells by α-GC promote a transient up-
regulation of CD69 activation marker on B cells [65], in the absence of proliferation [76]. In 
addition, activation of iNKT cells enhances antibody responses to protein antigens in vivo 
[77]. Similarly, it has been reported that human iNKT cells help B cells to produce Ig in vitro 
[78].  
 
 
3.3 Regulation of iNKT cell activity 
 As massive iNKT cell-derived cytokine release (“cytokine storm”) may profoundly 
influence the subsequent adaptive immune response, iNKT cell function has to be tightly 
regulated. Type II NKT cells may act as regulatory cells. Indeed, in vitro, type II NKT cells 
stimulated with sulfatide-loaded APC could suppress the proliferation and cytokine 
production by type I NKT cells upon stimulation with α-GC-loaded APC [78]. Furthermore, 
type II NKT cells repress iNKT cell-mediated anti-tumour responses. Data with culture 
supernatants and anti-cytokine antibodies suggest that the suppression is not simply cytokine 
mediated [79]. Thus, it is plausible that type I and II NKT cells might interact reciprocally to 
 repress each other’s function (principally type II can suppress type I NKT cells, while type I 
NKT cells seem to have a moderate effect on type II NKT cells), as a negative feedback loop 
to regulate immune responses.  
 In addition to type II NKT cells mentioned above, recent studies revealed the 
involvement of CD4+ CD25+ FoxP3+ regulatory T (Treg) cells in counter-acting iNKT cell 
function. It was reported that Treg cells can suppress the proliferation, cytokine production, 
and cytolytic activity of iNKT cells [20;35]. However, the precise mechanism of interaction 
between Treg and iNKT cells has not yet been revealed. 
 
 
3.4 iNKT cell in anti-tumour immune responses 
In spite of the low iNKT cell frequency within the T lymphocyte population, iNKT 
cells exert a critical influence on various components of the immune system as discussed 
above. Due to their ability to rapidly secrete high levels of a broad range of both pro- (Th1) 
and anti- (Th2) inflammatory cytokines within a few hours after activation [44;80], iNKT 
cells have the capacity to regulate the immune responses against cancer among others, by 
trans-activating down-stream immune cells. 
 
3.4.1 Natural immune response 
iNKT cells are thought to play an important physiological role in the 
immunosurveillance of cancers. iNKT cell-mediated anti-tumour immune responses can be 
initiated by iNKT cell recognition of endogenous antigens, most probably tumour-derived 
glycolipids, presented in the context of CD1d. The iNKT cell-derived IFN-γ, in turn, induces 
NK cell and CTL lytic activity against tumour cells (Figure 3a). Experiments using iNKT 
cell-deficient mice (Jα18-/- mice) indicated a critical role of iNKT cells in the protection from 
spontaneous tumours chemically induced with methylcholanthrene (MCA) [80]. Furthermore, 
protection against MCA-induced tumour growth could be restored by adoptive transfer of 
iNKT cells isolated from wild-type animals. Protection depends on CD1d, IFN-γ production 
by iNKT cells, and NK and CD8+ T-cell function [44], although the role of CD8+ T cell is still 
controversial [80]. Perforin is involved, but not essential, in rejection of MCA-induced 
tumour [81;82]. It will be of great interest to determine whether some tumours express 
glycolipid ligands that stimulate iNKT cell activity. 
Paradoxically, CD1d knock-out mice, which lack CD1d-restricted NKT cells, have 
heightened immunity to certain tumours, namely 15-12RM and CT26. In these experimental 
models CD4+ CD1d-restricted NKT cells and IL-13 have been shown to be responsible for the 
suppression of acquired immunity against tumour by inhibiting CTL-mediated tumour 
immunosurveillance [83]. In a subsequent study it became clear that the enhanced anti-tumour 
immunity was due to the deletion of the suppressive type II NKT cell subset, rather than type 
I NKT (iNKT), in these CD1d knock out mice. Jα18-/- mice, in which specifically type I NKT 
cells but not type II NKT cells are deleted, lacked the enhanced immune surveillance and 
developed tumours [65;84-86].  
 
3.4.2 α-GC-mediated anti-tumour immune response 
The capacity of in vivo α-GC-activated iNKT cells to enhance protection against 
experimental tumours has been studied extensively (Figure 3b). Administration of α-GC leads 
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to rapid Th1 and Th2 cytokine production by iNKT cells, followed by a profound but 
transient depletion of spleen and liver iNKT cells [86-89]. Several groups demonstrated that 
systemic injection of α-GC or α-GC-loaded DC to activate iNKT cells leads to the inhibition 
of metastasis formation predominantly via the down-stream activation of NK cells [90]. In 
vivo experiments using NKT cell-, NK cell-, IFN-γ- and RAG-deficient mice demonstrated 
that sequential production of IFN-γ by iNKT cells and NK cells is required to mediate α-GC-
induced anti-metastatic effect [44;90]. Endogenous IL-12 is important for an optimal effect 
[88]. Consequently, the anti-metastatic effect of α-GC can be enhanced by combined 
treatment with IL-12 [85;90]. In contrast, IL-4, the major Th2 cytokine produced by iNKT 
cells, is not required for α-GC-mediated anti-metastatic function. Neither FasL, perforin nor 
TRAIL are required for α-GC-mediated anti-metastatic function [66;86]. Some studies also 
implicate CD8+ T cells in the anti-metastatic activity of α-GC [61;91].  
Tumour
NK
CD8+ T
Endogenous glycolipid,
possibly tumour-derived Ag 
Mφ
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iNKT
CD1d
TCR
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 Figure 3:  Proposed models for iNKT cell-mediated tumour rejection in vivo. (a) In natural rejection, iNKT 
cells can mediate anti-tumour responses in the absence of exogenous stimulation. iNKT cells may be capable of 
responding to tumour-derived glycolipid antigens, since protection is dependent on CD1d. The natural role of 
iNKT cells is IFN-γ-mediated. NK cell function and possibly CD8+ T-cell recognition of tumour peptides are 
involved in immmunesurveillance. (b) In α-GC-mediated rejection, α-GC is presented by CD1d and can induce 
potent iNKT-cell-dependent tumour rejection. This process is IL-12- and IFN-γ-dependent. The significance of 
CD8+ T cells in iNKT cell induce tumour rejection is not yet clear. (c) In IL-12-mediated rejection, exogenously 
administered IL-12 can act on effector cells including iNKT and NK cells to mediate tumour rejection. IL-12 
induces IFN-γ production by iNKT and NK cells. Evidence exists for both perforin-dependent and IFN-γ-
dependent effector mechanisms, and the relative roles of the effector cells and associated molecules are likely to 
vary in a dose-dependent manner. In these three models, the effector role of macrophages (MØ) has yet not been 
confirmed. IFN-γ may act directly to inhibit tumour growth, tumour-associated angiogenesis or the activation of 
other effector cell types. It is also likely that others, yet unknown, iNKT cell-derived factors may also be 
important in these models. 
 
 Furthermore, murine studies combining i.v. free α-GC treatment with protein 
vaccination demonstrated that α-GC acts as an adjuvant for the induction of antigen specific 
CD4+ and CD8+ T cell mediated immunity [92]. This adjuvant effect may relate to the fact 
that α-GC activated iNKT cells can enhance the maturation of DC that subsequently are more 
efficient in (cross)-priming CD4+ and CD8+ T cells [93;94]. 
 
3.4.3 IL-12-mediated anti-tumour immune response 
Some studies suggested that iNKT cells are also essential for the anti-metastatic 
activity of IL-12, while others found that NK cells and perforin are sufficient. There is 
evidence that IL-12 exerts anti-tumour effect in a dose-dependent activation of both iNKT and 
NK cells [93]. In these studies, a lower dose of IL-12 promotes a greater relative role of iNKT 
cells, whereas at a higher IL-12 dose, NK cells mediate an anti-tumour response 
independently of iNKT cell activation (Figure 3c). Adoptive transfer of iNKT cells, but not 
NK cells, to NK and NKT cell-deficient mice restored the anti-tumour response mediated by 
low dose of IL-12 [94]. This mechanism was IFN-γ-dependent. Thus, low dose of IL-12 
induces iNKT cell activation and IFN-γ secretion, which may act directly on tumour cells 
whilst activating NK cells to mediate tumour cell killing in a perforin-dependent manner [95].   
The role of iNKT cells in mediating the anti-tumour activity of other cytokines 
remains to be established.  
 
3.4.4 Role of human iNKT cell in anti-tumour immune responses 
Despite some minor phenotypic and numeric discrepancies, the function of iNKT cells 
appears to be greatly conserved between species. Indeed, CD1d and relevant TCR regions are 
highly conserved between mice and human [96]. Similar to observations in mice, stimulation 
of human iNKT cells results in a rapid expansion and cytokine production [97-105]. The 
findings from pre-clinical studies illustrate the potential of iNKT cells as regulator of the 
tumour immune response and suggest the benefit of exploiting iNKT cells for the treatment of 
cancer. To date, inconsistent data has been obtained from studies in cancer patients, from 
mostly relatively small and sometimes poorly defined cohorts. Some investigators found that 
iNKT cells in peripheral blood of cancer patients were numerically and/or functionally 
compromised, whereas others observed no differences compared to healthy controls. 
Since most of our knowledge of iNKT cells was acquired from animal models, and 
because a few important discrepancies between mouse and human iNKT cell function have 
been observed, further investigation on the role of human iNKT cells in tumour immunity is 
imperative before iNKT cell-based immunotherapies can be implemented successfully.  
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4 Outline of this thesis 
The objective of our studies was to test the relevance of human iNKT cells in the 
activation of NK and T cells, on their turn promoting anti-tumour immune responses. We 
analysed the effectiveness of iNKT cells to enhance the efficacy of tumour cell killing in 
human in vitro studies. We then hypothesized that iNKT cell transfer might represent an 
effective immunotherapeutic approach, and developed murine iNKT cell lines that proved to 
be efficient in promoting anti-tumour immunity in vivo.  
 
Part I: Human iNKT cells as enhancers of anti-tumour immunity in vitro 
In chapter 2, iNKT cell activation by different TLR agonists is analyzed. The iNKT 
cell TLR profile was characterized by RT-PCR. Various TLR ligands that may exert an 
adjuvant function on iNKT cell activation were investigated. In addition, effects of cross-talk 
between DC and iNKT cells upon TLR-triggering were addressed. 
In chapter 3, the effects of iNKT cells on the induction of tumour-specific CTL is 
described. Next to tumour antigen specific CTL response induction, in chapter 4 it was 
analysed whether human iNKT cells can enhance NK cell functional activity as an approach 
to improve anti-tumour responses. In these chapters in vitro expanded iNKT cells were used 
to enhance antigen specific CTL responses and NK cell functional activity respectively. 
Furthermore, the mechanism of NK cell activation by iNKT cells was investigated.   
In chapters 5a and 5b, we aimed at validating adoptive transfer of human iNKT cells 
as an approach to improve the efficacy of cancer immunotherapies in an in vitro ADCC 
model. For this, huHMFG-1, a monoclonal antibody against MUC1 that is currently evaluated 
in clinical trials as a potential immunotherapy for breast cancer, was used. Identification of 
NK cells as the main effector cell mediating huHMFG-1-dependent tumour cell killing is 
described in chapter 5a. The effect of iNKT cells on the efficacy of NK cells to induce 
huHMFG-1 mediated ADCC is described in chapter 5b.  
 
Part II: Invariant NKT cells as enhancers of anti-tumour immunity in vivo. 
In this part of the thesis, the therapeutic potential of autologous adoptive transfer of 
iNKT cells for the treatment of cancer is addressed in vivo.  
The generation and characterization of mouse long term cultured iNKT cell lines is 
described in chapter 6a. In chapter 6b, we confirm the potential of these mouse iNKT cell 
lines as an anti-tumour immune therapeutic approach in a melanoma experimental model. 
 
Finally, in the concluding chapter 7, the different therapeutic approaches to exploit 
iNKT cells to improve the anti-tumour immunity are discussed. Evidence is provided that 
autologous adoptive transfer of iNKT cells represents a promising approach for the treatment 
of cancer. 
 
 
 
 References 
 
[1] Cancer Facts and Figures 2008, www.cancer.org.  2008. Ref Type: Internet Communication 
[2] J.Ferlay, P.Autier, M.Boniol, M.Heanue, M.Colombet, and P.Boyle, Estimates of the cancer incidence and 
mortality in Europe in 2006. Ann.Oncol. 18 (2007) 581-592. 
[3] F.Levi, C.Bosetti, F.Lucchini, E.Negri, and V.C.La, Monitoring the decrease in breast cancer mortality in 
Europe. Eur.J.Cancer Prev. 14 (2005) 497-502. 
[4] J.E.Tyczynski, I.Plesko, T.Aareleid, M.Primic-Zakelj, M.Dalmas, J.Kurtinaitis, A.Stengrevics, and 
D.M.Parkin, Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in 
young women, but still increasing in the elderly. Int.J.Cancer 112 (2004) 1056-1064. 
[5] Netherlands Cancer Registration (NKR). Available at IKCnet: www.ikcnet.nl.  2008. Ref Type: Internet 
Communication 
[6] I.Penn, Tumors of the immunocompromised patient. Annu.Rev.Med. 39 (1988) 63-73. 
[7] R.F.Wang, The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. 
Trends Immunol. 22 (2001) 269-276. 
[8] I.Algarra, A.Garcia-Lora, T.Cabrera, F.Ruiz-Cabello, and F.Garrido, The selection of tumor variants with 
altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. 
Cancer Immunol.Immunother. 53 (2004) 904-910. 
[9] S.A.Rosenberg and H.J.Rapp, Intralesional immunotherapy of melanoma with BCG. Med.Clin.North Am. 60 
(1976) 419-430. 
[10] M.J.Smyth, E.Cretney, M.H.Kershaw, and Y.Hayakawa, Cytokines in cancer immunity and 
immunotherapy. Immunol.Rev. 202 (2004) 275-293. 
[11] A.K.Palucka, H.Ueno, J.W.Fay, and J.Banchereau, Taming cancer by inducing immunity via dendritic cells. 
Immunol.Rev. 220 (2007) 129-150. 
[12] J.H.Kessler and C.J.Melief, Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21 
(2007) 1859-1874. 
[13] S.B.Ho, G.A.Niehans, C.Lyftogt, P.S.Yan, D.L.Cherwitz, E.T.Gum, R.Dahiya, and Y.S.Kim, Heterogeneity 
of mucin gene expression in normal and neoplastic tissues. Cancer Res. 53 (1993) 641-651. 
[14] Y.Dong, M.D.Walsh, M.C.Cummings, R.G.Wright, S.K.Khoo, P.G.Parsons, and M.A.McGuckin, 
Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J.Pathol. 183 (1997) 311-317. 
[15] J.Taylor-Papadimitriou, J.Burchell, D.W.Miles, and M.Dalziel, MUC1 and cancer. Biochim.Biophys.Acta 
1455 (1999) 301-313. 
[16] S.Nicholson, C.C.Bomphray, H.Thomas, A.McIndoe, D.Barton, M.Gore, and A.J.George, A phase I trial of 
idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol.Immunother. 53 (2004) 809-816. 
[17] R.H.Verheijen, L.F.Massuger, B.B.Benigno, A.A.Epenetos, A.Lopes, J.T.Soper, J.Markowska, R.Vyzula, 
T.Jobling, G.Stamp, G.Spiegel, D.Thurston, T.Falke, J.Lambert, and M.V.Seiden, Phase III trial of 
intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial 
ovarian cancer after a surgically defined complete remission. J.Clin.Oncol. 24 (2006) 571-578. 
[18] A.L.Oei, R.H.Verheijen, M.V.Seiden, B.B.Benigno, A.Lopes, J.T.Soper, A.A.Epenetos, and L.F.Massuger, 
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal 
consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. 
Int.J.Cancer 120 (2007) 2710-2714. 
María Moreno Jauge
20
  
 
 
I 
N 
T 
R 
O 
D 
U 
C 
T 
I 
O 
N 
 
 
[19] A.L.Oei, M.Moreno, R.H.Verheijen, F.C.Sweep, C.M.Thomas, L.F.Massuger, and S.von Mensdorff-
Pouilly. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. 
Int.J.Cancer 2008. Ref Type: In Press 
[20] D.I.Godfrey, K.J.Hammond, L.D.Poulton, M.J.Smyth, and A.G.Baxter, NKT cells: facts, functions and 
fallacies. Immunol.Today 21 (2000) 573-583. 
[21] S.Porcelli, C.E.Yockey, M.B.Brenner, and S.P.Balk, Analysis of T cell antigen receptor (TCR) expression 
by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and 
an invariant TCR alpha chain. J.Exp.Med. 178 (1993) 1-16. 
[22] S.Cardell, S.Tangri, S.Chan, M.Kronenberg, C.Benoist, and D.Mathis, CD1-restricted CD4+ T cells in 
major histocompatibility complex class II-deficient mice. J.Exp.Med. 182 (1995) 993-1004. 
[23] J.L.Matsuda and L.Gapin, Developmental program of mouse Valpha14i NKT cells. Curr.Opin.Immunol. 17 
(2005) 122-130. 
[24] G.Eberl, R.Lees, S.T.Smiley, M.Taniguchi, M.J.Grusby, and H.R.MacDonald, Tissue-specific segregation 
of CD1d-dependent and CD1d-independent NK T cells. J.Immunol. 162 (1999) 6410-6419. 
[25] M.Brigl and M.B.Brenner, CD1: antigen presentation and T cell function. Annu.Rev.Immunol. 22 (2004) 
817-890. 
[26] S.A.Porcelli and R.L.Modlin, The CD1 system: antigen-presenting molecules for T cell recognition of lipids 
and glycolipids. Annu.Rev.Immunol. 17 (1999) 297-329. 
[27] J.H.Roark, S.H.Park, J.Jayawardena, U.Kavita, M.Shannon, and A.Bendelac, CD1.1 expression by mouse 
antigen-presenting cells and marginal zone B cells. J.Immunol. 160 (1998) 3121-3127. 
[28] M.Exley, J.Garcia, S.B.Wilson, F.Spada, D.Gerdes, S.M.Tahir, K.T.Patton, R.S.Blumberg, S.Porcelli, 
A.Chott, and S.P.Balk, CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells 
and monocytes. Immunology 100 (2000) 37-47. 
[29] L.Brossay, D.Jullien, S.Cardell, B.C.Sydora, N.Burdin, R.L.Modlin, and M.Kronenberg, Mouse CD1 is 
mainly expressed on hemopoietic-derived cells. J.Immunol. 159 (1997) 1216-1224. 
[30] J.L.Amprey, J.S.Im, S.J.Turco, H.W.Murray, P.A.Illarionov, G.S.Besra, S.A.Porcelli, and G.F.Spath, A 
subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound 
lipophosphoglycan. J.Exp.Med. 200 (2004) 895-904. 
[31] J.Mattner, K.L.Debord, N.Ismail, R.D.Goff, C.Cantu, III, D.Zhou, P.Saint-Mezard, V.Wang, Y.Gao, N.Yin, 
K.Hoebe, O.Schneewind, D.Walker, B.Beutler, L.Teyton, P.B.Savage, and A.Bendelac, Exogenous and 
endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 (2005) 525-529. 
[32] Y.Kinjo, D.Wu, G.Kim, G.W.Xing, M.A.Poles, D.D.Ho, M.Tsuji, K.Kawahara, C.H.Wong, and 
M.Kronenberg, Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434 (2005) 520-525. 
[33] K.Fischer, E.Scotet, M.Niemeyer, H.Koebernick, J.Zerrahn, S.Maillet, R.Hurwitz, M.Kursar, M.Bonneville, 
S.H.Kaufmann, and U.E.Schaible, Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-
restricted T cells. Proc.Natl.Acad.Sci.U.S.A 101 (2004) 10685-10690. 
[34] T.Kawano, J.Cui, Y.Koezuka, I.Toura, Y.Kaneko, K.Motoki, H.Ueno, R.Nakagawa, H.Sato, E.Kondo, 
H.Koseki, and M.Taniguchi, CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by 
glycosylceramides. Science 278 (1997) 1626-1629. 
[35] F.M.Spada, Y.Koezuka, and S.A.Porcelli, CD1d-restricted recognition of synthetic glycolipid antigens by 
human natural killer T cells. J.Exp.Med. 188 (1998) 1529-1534. 
[36] D.Y.Wu, N.H.Segal, S.Sidobre, M.Kronenberg, and P.B.Chapman, Cross-presentation of disialoganglioside 
GD3 to natural killer T cells. J.Exp.Med. 198 (2003) 173-181. 
 [37] D.Zhou, J.Mattner, C.Cantu, III, N.Schrantz, N.Yin, Y.Gao, Y.Sagiv, K.Hudspeth, Y.P.Wu, T.Yamashita, 
S.Teneberg, D.Wang, R.L.Proia, S.B.Levery, P.B.Savage, L.Teyton, and A.Bendelac, Lysosomal 
glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789. 
[38] M.Brigl, L.Bry, S.C.Kent, J.E.Gumperz, and M.B.Brenner, Mechanism of CD1d-restricted natural killer T 
cell activation during microbial infection. Nat.Immunol. 4 (2003) 1230-1237. 
[39] M.Salio, A.O.Speak, D.Shepherd, P.Polzella, P.A.Illarionov, N.Veerapen, G.S.Besra, F.M.Platt, and 
V.Cerundolo, Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell 
activation. Proc.Natl.Acad.Sci.U.S.A 104 (2007) 20490-20495. 
[40] H.J.van der Vliet, N.Nishi, T.D.de Gruijl, B.M.von Blomberg, A.J.van den Eertwegh, H.M.Pinedo, 
G.Giaccone, and R.J.Scheper, Human natural killer T cells acquire a memory-activated phenotype before birth. 
Blood 95 (2000) 2440-2442. 
[41] J.Cui, T.Shin, T.Kawano, H.Sato, E.Kondo, I.Toura, Y.Kaneko, H.Koseki, M.Kanno, and M.Taniguchi, 
Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278 (1997) 1623-1626. 
[42] K.Takeda, S.Seki, K.Ogasawara, R.Anzai, W.Hashimoto, K.Sugiura, M.Takahashi, M.Satoh, and 
K.Kumagai, Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of 
experimental tumor metastasis. J.Immunol. 156 (1996) 3366-3373. 
[43] T.Dao, W.Z.Mehal, and I.N.Crispe, IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. 
J.Immunol. 161 (1998) 2217-2222. 
[44] M.J.Smyth, K.Y.Thia, S.E.Street, E.Cretney, J.A.Trapani, M.Taniguchi, T.Kawano, S.B.Pelikan, 
N.Y.Crowe, and D.I.Godfrey, Differential tumor surveillance by natural killer (NK) and NKT cells. J.Exp.Med. 
191 (2000) 661-668. 
[45] H.J.van der Vliet, N.Nishi, Y.Koezuka, B.M.von Blomberg, A.J.van den Eertwegh, S.A.Porcelli, 
H.M.Pinedo, R.J.Scheper, and G.Giaccone, Potent expansion of human natural killer T cells using alpha-
galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and 
IL-15. J.Immunol.Methods 247 (2001) 61-72. 
[46] J.E.Gumperz, S.Miyake, T.Yamamura, and M.B.Brenner, Functionally distinct subsets of CD1d-restricted 
natural killer T cells revealed by CD1d tetramer staining. J.Exp.Med. 195 (2002) 625-636. 
[47] M.Nieda, A.Nicol, Y.Koezuka, A.Kikuchi, N.Lapteva, Y.Tanaka, K.Tokunaga, K.Suzuki, N.Kayagaki, 
H.Yagita, H.Hirai, and T.Juji, TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in 
vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 97 (2001) 2067-2074. 
[48] L.S.Metelitsa, K.I.Weinberg, P.D.Emanuel, and R.C.Seeger, Expression of CD1d by myelomonocytic 
leukemias provides a target for cytotoxic NKT cells. Leukemia 17 (2003) 1068-1077. 
[49] L.S.Metelitsa, O.V.Naidenko, A.Kant, H.W.Wu, M.J.Loza, B.Perussia, M.Kronenberg, and R.C.Seeger, 
Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or 
indirectly by producing IL-2 to activate NK cells. J.Immunol. 167 (2001) 3114-3122. 
[50] H.J.van der Vliet, J.W.Molling, B.M.von Blomberg, N.Nishi, W.Kolgen, A.J.van den Eertwegh, 
H.M.Pinedo, G.Giaccone, and R.J.Scheper, The immunoregulatory role of CD1d-restricted natural killer T cells 
in disease. Clin.Immunol. 112 (2004) 8-23. 
[51] C.H.Kim, E.C.Butcher, and B.Johnston, Distinct subsets of human Valpha24-invariant NKT cells: cytokine 
responses and chemokine receptor expression. Trends Immunol. 23 (2002) 516-519. 
[52] P.T.Lee, K.Benlagha, L.Teyton, and A.Bendelac, Distinct functional lineages of human V(alpha)24 natural 
killer T cells. J.Exp.Med. 195 (2002) 637-641. 
[53] K.Seino and M.Taniguchi, Functionally distinct NKT cell subsets and subtypes. J.Exp.Med. 202 (2005) 
1623-1626. 
María Moreno Jauge
22
  
 
 
I 
N 
T 
R 
O 
D 
U 
C 
T 
I 
O 
N 
 
 
[54] K.Miyamoto, S.Miyake, and T.Yamamura, A synthetic glycolipid prevents autoimmune encephalomyelitis 
by inducing TH2 bias of natural killer T cells. Nature 413 (2001) 531-534. 
[55] J.Schmieg, G.Yang, R.W.Franck, and M.Tsuji, Superior protection against malaria and melanoma 
metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J.Exp.Med. 
198 (2003) 1631-1641. 
[56] M.C.Leite-de-Moraes, A.Hameg, A.Arnould, F.Machavoine, Y.Koezuka, E.Schneider, A.Herbelin, and 
M.Dy, A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR 
engagement. J.Immunol. 163 (1999) 5871-5876. 
[57] M.C.Leite-de-Moraes, G.Moreau, A.Arnould, F.Machavoine, C.Garcia, M.Papiernik, and M.Dy, IL-4-
producing NK T cells are biased towards IFN-gamma production by IL-12. Influence of the microenvironment 
on the functional capacities of NK T cells. Eur.J.Immunol. 28 (1998) 1507-1515. 
[58] N.Burdin, L.Brossay, and M.Kronenberg, Immunization with alpha-galactosylceramide polarizes CD1-
reactive NK T cells towards Th2 cytokine synthesis. Eur.J.Immunol. 29 (1999) 2014-2025. 
[59] N.Singh, S.Hong, D.C.Scherer, I.Serizawa, N.Burdin, M.Kronenberg, Y.Koezuka, and K.L.Van, Cutting 
edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the 
acquisition of a Th2 phenotype. J.Immunol. 163 (1999) 2373-2377. 
[60] S.Fujii, K.Shimizu, M.Kronenberg, and R.M.Steinman, Prolonged IFN-gamma-producing NKT response 
induced with alpha-galactosylceramide-loaded DCs. Nat.Immunol. 3 (2002) 867-874. 
[61] I.F.Hermans, J.D.Silk, U.Gileadi, M.Salio, B.Mathew, G.Ritter, R.Schmidt, A.L.Harris, L.Old, and 
V.Cerundolo, NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct 
interaction with dendritic cells. J.Immunol. 171 (2003) 5140-5147. 
[62] S.Fujii, K.Liu, C.Smith, A.J.Bonito, and R.M.Steinman, The linkage of innate to adaptive immunity via 
maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 
costimulation. J.Exp.Med. 199 (2004) 1607-1618. 
[63] H.Kitamura, K.Iwakabe, T.Yahata, S.Nishimura, A.Ohta, Y.Ohmi, M.Sato, K.Takeda, K.Okumura, 
K.L.Van, T.Kawano, M.Taniguchi, and T.Nishimura, The natural killer T (NKT) cell ligand alpha-
galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by 
dendritic cells and IL-12 receptor expression on NKT cells. J.Exp.Med. 189 (1999) 1121-1128. 
[64] M.Tomura, W.G.Yu, H.J.Ahn, M.Yamashita, Y.F.Yang, S.Ono, T.Hamaoka, T.Kawano, M.Taniguchi, 
Y.Koezuka, and H.Fujiwara, A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production 
by antigen-presenting cells in the innate immune system. J.Immunol. 163 (1999) 93-101. 
[65] G.Eberl and H.R.MacDonald, Selective induction of NK cell proliferation and cytotoxicity by activated 
NKT cells. Eur.J.Immunol. 30 (2000) 985-992. 
[66] T.Nishimura, H.Kitamura, K.Iwakabe, T.Yahata, A.Ohta, M.Sato, K.Takeda, K.Okumura, K.L.Van, 
T.Kawano, M.Taniguchi, M.Nakui, M.Sekimoto, and T.Koda, The interface between innate and acquired 
immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the 
differentiation of antigen-specific cytotoxic T lymphocytes. Int.Immunol. 12 (2000) 987-994. 
[67] D.Stober, I.Jomantaite, R.Schirmbeck, and J.Reimann, NKT cells provide help for dendritic cell-dependent 
priming of MHC class I-restricted CD8+ T cells in vivo. J.Immunol. 170 (2003) 2540-2548. 
[68] M.L.Albert, M.Jegathesan, and R.B.Darnell, Dendritic cell maturation is required for the cross-tolerization 
of CD8+ T cells. Nat Immunol 2 (2001) 1010-1017. 
[69] G.Gonzalez-Aseguinolaza, K.L.Van, C.C.Bergmann, J.M.Wilson, J.Schmieg, M.Kronenberg, T.Nakayama, 
M.Taniguchi, Y.Koezuka, and M.Tsuji, Natural killer T cell ligand alpha-galactosylceramide enhances 
protective immunity induced by malaria vaccines. J.Exp.Med. 195 (2002) 617-624. 
 [70] L.P.Ho, B.C.Urban, L.Jones, G.S.Ogg, and A.J.McMichael, CD4-CD8{alpha}{alpha} Subset of CD1d-
Restricted NKT Cells Controls T Cell Expansion. J Immunol 172 (2004) 7350-7358. 
[71] T.Osada, M.A.Morse, H.K.Lyerly, and T.M.Clay, Ex vivo expanded human CD4+ regulatory NKT cells 
suppress expansion of tumor antigen-specific CTLs. Int.Immunol. 17 (2005) 1143-1155. 
[72] M.A.Cooper, T.A.Fehniger, and M.A.Caligiuri, The biology of human natural killer-cell subsets. Trends 
Immunol. 22 (2001) 633-640. 
[73] C.Carnaud, D.Lee, O.Donnars, S.H.Park, A.Beavis, Y.Koezuka, and A.Bendelac, Cutting edge: Cross-talk 
between cells of the innate immune system: NKT cells rapidly activate NK cells. J.Immunol. 163 (1999) 4647-
4650. 
[74] H.Lin, M.Nieda, V.Rozenkov, and A.J.Nicol, Analysis of the effect of different NKT cell subpopulations on 
the activation of CD4 and CD8 T cells, NK cells, and B cells. Exp.Hematol. 34 (2006) 289-295. 
[75] H.Kitamura, A.Ohta, M.Sekimoto, M.Sato, K.Iwakabe, M.Nakui, T.Yahata, H.Meng, T.Koda, S.Nishimura, 
T.Kawano, M.Taniguchi, and T.Nishimura, alpha-galactosylceramide induces early B-cell activation through IL-
4 production by NKT cells. Cell Immunol. 199 (2000) 37-42. 
[76] G.Galli, P.Pittoni, E.Tonti, C.Malzone, Y.Uematsu, M.Tortoli, D.Maione, G.Volpini, O.Finco, S.Nuti, 
S.Tavarini, P.Dellabona, R.Rappuoli, G.Casorati, and S.Abrignani, Invariant NKT cells sustain specific B cell 
responses and memory. Proc.Natl.Acad.Sci.U.S.A 104 (2007) 3984-3989. 
[77] G.Galli, S.Nuti, S.Tavarini, L.Galli-Stampino, C.De Lalla, G.Casorati, P.Dellabona, and S.Abrignani, 
CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J.Exp.Med. 197 (2003) 1051-
1057. 
[78] E.Ambrosino, M.Terabe, R.C.Halder, J.Peng, S.Takaku, S.Miyake, T.Yamamura, V.Kumar, and 
J.A.Berzofsky, Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new 
immunoregulatory axis. J.Immunol. 179 (2007) 5126-5136. 
[79] T.Azuma, T.Takahashi, A.Kunisato, T.Kitamura, and H.Hirai, Human CD4+ CD25+ regulatory T cells 
suppress NKT cell functions. Cancer Res. 63 (2003) 4516-4520. 
[80] N.Y.Crowe, M.J.Smyth, and D.I.Godfrey, A critical role for natural killer T cells in immunosurveillance of 
methylcholanthrene-induced sarcomas. J.Exp.Med. 196 (2002) 119-127. 
[81] M.Terabe, S.Matsui, N.Noben-Trauth, H.Chen, C.Watson, D.D.Donaldson, D.P.Carbone, W.E.Paul, and 
J.A.Berzofsky, NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 
pathway. Nat.Immunol. 1 (2000) 515-520. 
[82] J.M.Park, M.Terabe, L.T.van den Broeke, D.D.Donaldson, and J.A.Berzofsky, Unmasking 
immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. 
Int.J.Cancer 114 (2005) 80-87. 
[83] M.Terabe, J.Swann, E.Ambrosino, P.Sinha, S.Takaku, Y.Hayakawa, D.I.Godfrey, S.Ostrand-Rosenberg, 
M.J.Smyth, and J.A.Berzofsky, A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is 
sufficient for down-regulation of tumor immunosurveillance. J.Exp.Med. 202 (2005) 1627-1633. 
[84] Y.Hayakawa, K.Takeda, H.Yagita, K.L.Van, I.Saiki, and K.Okumura, Differential regulation of Th1 and 
Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J.Immunol. 166 (2001) 6012-6018. 
[85] Y.Hayakawa, K.Takeda, H.Yagita, S.Kakuta, Y.Iwakura, K.L.Van, I.Saiki, and K.Okumura, Critical 
contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of 
alpha-galactosylceramide. Eur.J.Immunol. 31 (2001) 1720-1727. 
[86] R.Nakagawa, I.Nagafune, Y.Tazunoki, H.Ehara, H.Tomura, R.Iijima, K.Motoki, M.Kamishohara, and 
S.Seki, Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-
galactosylceramide in mice. J.Immunol. 166 (2001) 6578-6584. 
María Moreno Jauge
24
  
 
 
I 
N 
T 
R 
O 
D 
U 
C 
T 
I 
O 
N 
 
 
[87] T.Kawano, J.Cui, Y.Koezuka, I.Toura, Y.Kaneko, H.Sato, E.Kondo, M.Harada, H.Koseki, T.Nakayama, 
Y.Tanaka, and M.Taniguchi, Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-
activated Valpha14 NKT cells. Proc.Natl.Acad.Sci.U.S.A 95 (1998) 5690-5693. 
[88] M.Nakui, A.Ohta, M.Sekimoto, M.Sato, K.Iwakabe, T.Yahata, H.Kitamura, T.Koda, T.Kawano, 
H.Makuuchi, M.Taniguchi, and T.Nishimura, Potentiation of antitumor effect of NKT cell ligand, alpha-
galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. 
Clin.Exp.Metastasis 18 (2000) 147-153. 
[89] M.J.Smyth, M.E.Wallace, S.L.Nutt, H.Yagita, D.I.Godfrey, and Y.Hayakawa, Sequential activation of NKT 
cells and NK cells provides effective innate immunotherapy of cancer. J.Exp.Med. 201 (2005) 1973-1985. 
[90] M.J.Smyth, N.Y.Crowe, D.G.Pellicci, K.Kyparissoudis, J.M.Kelly, K.Takeda, H.Yagita, and D.I.Godfrey, 
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the 
antimetastatic effect of alpha-galactosylceramide. Blood 99 (2002) 1259-1266. 
[91] S.Fujii, K.Shimizu, C.Smith, L.Bonifaz, and R.M.Steinman, Activation of natural killer T cells by alpha-
galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant 
for combined CD4 and CD8 T cell immunity to a coadministered protein. J.Exp.Med. 198 (2003) 267-279. 
[92] K.Liu, J.Idoyaga, A.Charalambous, S.Fujii, A.Bonito, J.Mordoh, R.Wainstok, X.F.Bai, Y.Liu, and 
R.M.Steinman, Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. 
J.Exp.Med. 202 (2005) 1507-1516. 
[93] K.Takeda, Y.Hayakawa, M.Atsuta, S.Hong, K.L.Van, K.Kobayashi, M.Ito, H.Yagita, and K.Okumura, 
Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int.Immunol. 12 (2000) 
909-914. 
[94] M.J.Smyth, M.Taniguchi, and S.E.Street, The anti-tumor activity of IL-12: mechanisms of innate immunity 
that are model and dose dependent. J.Immunol. 165 (2000) 2665-2670. 
[95] L.Brossay, M.Chioda, N.Burdin, Y.Koezuka, G.Casorati, P.Dellabona, and M.Kronenberg, CD1d-mediated 
recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian 
evolution. J.Exp.Med. 188 (1998) 1521-1528. 
[96] H.J.van der Vliet, J.W.Molling, N.Nishi, A.J.Masterson, W.Kolgen, S.A.Porcelli, A.J.van den Eertwegh, 
B.M.von Blomberg, H.M.Pinedo, G.Giaccone, and R.J.Scheper, Polarization of Valpha24+ Vbeta11+ natural 
killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and 
environmentally instructed dendritic cells. Cancer Res. 63 (2003) 4101-4106. 
[97] J.W.Molling, W.Kolgen, H.J.van der Vliet, M.F.Boomsma, H.Kruizenga, C.H.Smorenburg, 
B.G.Molenkamp, J.A.Langendijk, C.R.Leemans, B.M.von Blomberg, R.J.Scheper, and A.J.van den Eertwegh, 
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients 
independent of tumor type or tumor load. Int.J.Cancer 116 (2005) 87-93. 
[98] S.Motohashi, S.Kobayashi, T.Ito, K.K.Magara, O.Mikuni, N.Kamada, T.Iizasa, T.Nakayama, T.Fujisawa, 
and M.Taniguchi, Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer 
patients. Int.J.Cancer 102 (2002) 159-165. 
[99] M.V.Dhodapkar, M.D.Geller, D.H.Chang, K.Shimizu, S.Fujii, K.M.Dhodapkar, and J.Krasovsky, A 
reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant 
multiple myeloma. J.Exp.Med. 197 (2003) 1667-1676. 
[100] S.M.Tahir, O.Cheng, A.Shaulov, Y.Koezuka, G.J.Bubley, S.B.Wilson, S.P.Balk, and M.A.Exley, Loss of 
IFN-gamma production by invariant NK T cells in advanced cancer. J.Immunol. 167 (2001) 4046-4050. 
[101] J.Konishi, K.Yamazaki, H.Yokouchi, N.Shinagawa, K.Iwabuchi, and M.Nishimura, The characteristics of 
human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and 
decreased human NKT cell response in lung cancer patients. Hum.Immunol. 65 (2004) 1377-1388. 
 [102] K.Yanagisawa, K.Seino, Y.Ishikawa, M.Nozue, T.Todoroki, and K.Fukao, Impaired proliferative response 
of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J.Immunol. 168 (2002) 6494-
6499. 
[103] T.Kawano, T.Nakayama, N.Kamada, Y.Kaneko, M.Harada, N.Ogura, Y.Akutsu, S.Motohashi, T.Iizasa, 
H.Endo, T.Fujisawa, H.Shinkai, and M.Taniguchi, Antitumor cytotoxicity mediated by ligand-activated human 
V alpha24 NKT cells. Cancer Res. 59 (1999) 5102-5105. 
[104] L.S.Metelitsa, H.W.Wu, H.Wang, Y.Yang, Z.Warsi, S.Asgharzadeh, S.Groshen, S.B.Wilson, and 
R.C.Seeger, Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J.Exp.Med. 199 
(2004) 1213-1221. 
[105] K.M.Dhodapkar, B.Cirignano, F.Chamian, D.Zagzag, D.C.Miller, J.L.Finlay, and R.M.Steinman, Invariant 
natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic 
cell-mediated expansion. Int.J.Cancer 109 (2004) 893-899. 
 
 
María Moreno Jauge
26
  
 
 
 
 
 
 
 
 
 
 
Part I: Invariant NKT cells as enhancers of anti-tumour immunity in vitro 
 
Chapter 2 
 
Differential indirect activation of human invariant Natural Killer 
T-cells by Toll-like receptor (TLR) agonists 
 
 
María Moreno, Berber M. Mol, Silvia von Mensdorff-Pouilly, René H.M. Verheijen, 
Esther C. de Jong, B. Mary E. von Blomberg, Alfons J.M. van den Eertwegh, 
Rik J. Scheper, Hetty J. Bontkes 
Submitted for publication 
 
 
 
 
 
 
 
 Abstract 
Activation of CD1d restricted invariant Natural Killer T (iNKT) cells leads to a swift and 
potent cytokine response and trans-activation of dendritic cells (DC), NK and T cells. During 
an infection, iNKT cells can be directly activated by bacterial glycosphingolipids presented 
by CD1d on DC. It is not clear whether other bacterial products can activate iNKT cells via 
Toll-like receptors (TLR). Here we have examined TLR expression by iNKT cells and 
evaluated the ability of various TLR ligands to activate iNKT cells. Although human iNKT 
cells express all TLR, apart from TLR8, they did not respond directly to TLR ligands. 
However, iNKT cells became activated when total PBMC were stimulated with TLR ligands 
triggering TLR2/6, 7 and 8, and 9, but not TLR3, 4 and 5. TLR-stimulated monocyte-derived 
DC promoted iNKT cell activation and, in turn, these activated iNKT cells further enhanced 
DC maturation. IFN-γ production by iNKT cells and subsequent IL-12 production by DC was 
dependent on TCR triggering by α-galactosylceramide. Thus combinations of TLR2/6, TLR7, 
8 or 9 agonists with α-galactosylceramide may act as strong adjuvants for immunotherapy by 
enhancing type 1 cytokine production through combined and reciprocal activation of iNKT 
cells and DC. 
 
 
Keywords: human, invariant NKT cells, Toll-like receptor, monocyte-derived dendritic cell, 
cell activation 
 
 
Abbreviations: α-GC: α-galactosylceramide; iNKT: invariant natural killer T-cells; mDC: 
myeloid dendritic cells; moDC: monocyte-derived dendritic cells; pDC: plasmacytoid 
dendritic cells; PGN: peptidoglycan 
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Introduction 
Invariant NKT (iNKT) cells are T lymphocytes, characterized by an invariant TCRα 
chain gene rearrangement (Vα24-Jα18 paired with Vβ11 in humans) and co-expression of 
NK cell receptors [1]. They recognize glycolipid antigens in the context of the non-
polymorphic, MHC class I-like molecule CD1d via their highly restricted TCR repertoire. 
iNKT cells are considered to be auto-reactive recognizing endogenous lipids [2], but also 
bacterial derived glycolipids [3]. Upon activation, iNKT cells rapidly secrete both type 1 (e.g. 
IFN-γ, TNF-α) and type 2 (e.g. IL-4, IL-13) cytokines. iNKT cells activated by the strong 
synthetic glycolipid α-Galactosylceramide (α-GC) presented by CD1d on dendritic cells (DC) 
have the capacity to enhance host immunity to tumour cells as well as to micro-organisms. 
Bacterial glycosphingolipids presented by CD1d on DC can activate iNKT cells via 
their TCR, without the need of endogenous antigens [4-7]. Alternatively, iNKT cells can be 
indirectly activated by micro-organism derived toll-like receptor (TLR) ligands, such as LPS, 
mediated DC activation, amplifying the weak responsiveness of iNKT cells to endogenous 
glycolipids [7;8]. A possible third pathway of iNKT cell activation by micro-organisms would 
be directly through TLR triggering on the iNKT cell. 
 TLR recognize different pathogen-associated molecular patterns (PAMPs) and trigger 
innate and adaptive immune responses. The TLR-family consists of at least 11 members, 
although the function of TLR10 is not yet clear and TLR11 appears not to be functional in 
humans. Bacterial components are mainly recognized by cell surface TLR, for example, 
bacterial lipopeptides are recognized by the heterodimers TLR1/2 and TLR2/6, LPS by TLR4, 
and flagellin by TLR5. Endosomal-associated receptors are triggered by viral products, i.e. 
TLR3 by dsRNA, TLR7 and 8 by ssRNA, and TLR9 by hypomethylated CpG DNA 
(reviewed in [9]). TLR are mainly expressed by antigen presenting cells, but also by NK cells 
and cells of the adaptive immune response, such as T and B lymphocytes [10]. Upon TLR 
ligand stimulation, DC maturation is induced. This process takes place either directly through 
TLR triggering on DC, or indirectly though cytokines released by other TLR-activated cells. 
Induction of effector function of T cells depends on TLR-induced DC maturation and 
proinflammatory cytokine secretion, including IL-12 [11]. Activated T cells play an important 
role in this process providing key stimuli to DC, through e.g. CD40/CD40L interactions [12], 
which are required for the enhanced release of proinflammatory cytokines upon microbial 
stimulation [13]. 
In this study, we have examined TLR expression by iNKT cells and evaluated the ability 
of different TLR ligands to directly or indirectly trigger human iNKT cells.  
 
 
Materials and Methods 
Media and reagents 
IMDM (Cambrex, Verviers, Belgium) was supplemented with 10% Foetal Calf Serum 
(Perbio, Helsingborg, Sweden) for culture of peripheral blood mononuclear cells (PBMC) and 
DC derived from monocytes (moDC), or 8% human pooled serum (Sanquin, Amsterdam, The 
Netherlands) for the culture of iNKT cells. Both media were supplemented with 100 IU/ml 
sodium penicillin (Yamanouchi Pharma, Leiderdorp, The Netherlands), 100μg/ml 
streptomycin sulphate (Radiumfarma-Fisiopharma, Naples, Italy) and 0.01 mM β-
mercaptoethanol (Merck, Darmstadt, Germany). 
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 Table 1: TLR ligands 
TLR TLR agonist Source Concentration  
TLR 2/6 PGN S. aureus 10 μg/ml 
TLR 3 Poly (I:C) Synthetic viral dsRNA 25 μg/ml 
TLR 4 LPS E coli 1 μg/ml 
TLR 5 Flagellin S. typhimurium 5 μg/ml 
TLR 7 and 8 CL075 Synthetic viral ssRNA 0.72 μg/ml 
TLR 9 ODN A Synthetic bacterial CpG DNA 5 μg/ml 
 
The following TLR agonists were used: peptidoglycan (PGN) from Staphylococcus 
aureus (10μg/ml), polyionosinic-polycytidylic acid [Poly (I:C), 25μg/ml] and 
lipopolysaccharide (LPS, 1μg/ml) (Sigma-Aldrich, Buchs, Germany); flagellin from 
Salmonella thyphimurium (5μg/ml) and CL075 (3M-002, 0.72μg/ml) (InvivoGen, San Diego, 
CA, USA); and human specific stimulatory CpG ODN type A (ODN A 2216,  5μg/ml) (Coley 
Pharmaceuticals, Düsseldorf, Germany) (Table 1). TLR concentrations used were determined 
based on literature for optimal NK cell activation and moDC maturation. 
 
Isolation of peripheral blood mononuclear cells (PBMC) and PBMC stimulation 
PBMC were isolated from buffycoats from healthy donors obtained from the Blood 
Bank (Sanquin, Amsterdam, The Netherlands) by density gradient centrifugation using 
Lymphoprep (Nycomed, Oslo, Norway). The number of cells was determined and PBMC 
were cryopreserved in separate batches until use. The use of healthy donor blood has been 
approved by the local ethical committee. 
PBMC cultures containing 4 x106 cells/ml were stimulated with different TLR agonists 
or combination of those for 48h. In some experiments, PBMC were stimulated with TLR 
ligands in combination with 100ng/ml α-GC (KRN7000, kindly provided by Dr Shigeyuki 
Yamano, KIRIN Brewery, Gunma, Japan). PBMC were incubated in the absence of any 
stimulus or with 100 U/ml IL-2 as negative and positive controls, respectively.  
 
moDC cultures and iNKT cell expansion 
To set up moDC cultures, 50x106 PBMC were allowed to adhere in a T75 flask for 60-
90 minutes. Adherent monocytes were subsequently cultured in the presence of 1000 IU/ml 
GM-CSF (Schering-Plough, Kenilworth, NJ, USA) and 10 ng/ml IL-4 (R&D Systems, 
Abingdon, UK) for 7 days. Maturation was induced by 48hs culture in the presence of 30% 
v/v monocyte conditioned medium (MCM) and 50 ng/ml TNF-α (Strathmann Biotech, 
Hanover, Germany) as a positive control [14] or with different TLR agonists (as specified 
above). 
Vα24+ Vβ11+ iNKT cells were enriched from PBMC by positive selection using the 
iNKT cell specific antibody 6B11 (BD Biosciences, San Jose, CA, USA) and anti-mouse Ig-
coated magnetic beads mAb (Milteny Biotec, Bergisch Gladbach, Germany) by MACS 
sorting. iNKT cells were expanded by weekly stimulation with  irradiated autologous PBMC 
at a 1:1 iNKT : PBMC ratio in the presence of 100ng/ml α-GC, 40 IU/ml recombinant human 
(rh) IL-2, 5 ng/ml rhIL-7 and 5 ng/ml rhIL-15 (all purchased from Strathmann Biotech, 
Hanover, Germany). After 2 expansion rounds, purity of iNKT cells was more than 90%, and 
the cells exhibited an activated phenotype, expressing higher levels of CD69 and in particular 
CD25, compared to resting iNKT cells. 
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In order to analyze the effects of TLR-matured moDC on iNKT cells and vice versa, 
moDC were pulsed with the α-GC or vehicle for 2h. After α-GC pulsing, moDC were washed 
and cultures containing 2x105 in vitro expanded iNKT cells and 2x105 pulsed autologous 
moDC were set up. After 4h, iNKT cells were analyzed for IFN-γ secretion by intracellular 
cytokine staining (ICCS). On day 2, supernatants were harvested for IFN-γ and IL-12 
determination by ELISA and iNKT cells and moDC were characterized.  
 
Surface marker expression on iNKT cells and moDC 
FITC-, PE- PerCP-Cy5- or APC-labelled isotype controls and mouse mAbs to CD1a, 
CD3, CD4, CD14, CD25, CD40, CD69, CD80, CD86, iNKT TCR (6B11) (BD Pharmingen, 
Heidelberg, Germany), CD83, Vα24 and Vβ11 (Immunotech, Marseille, France) were used to 
determine the phenotype of iNKT cells and moDC. The CD1d specific clone 51.1.3 was a 
kind gift from Dr Mark Exley, Harvard Medical School, Boston, MA. Cells were incubated 
with the antibodies for at least 30 min at 4ºC. Flow cytometry was performed on a 
FACSCALIBURTM apparatus and data were analyzed using CellQuestTM software (BD 
Biosciences, San Jose, CA, USA). Mean fluorescence index was calculated as follows: MFI = 
mean fluorescence intensity marker / fluorescence intensity isotype.   
 
IFN-γ intracellular cytokine staining (ICCS) 
Intracellular IFN-γ staining was performed using the BD cytofix/cytoperm plus kit (BD 
Bioscience, San Jose, CA, USA) according to the manufacturer’s instructions. After 5 h of 
iNKT cell stimulation with moDC, GolgiPlug was added to each well (0.1% v/v) and after 4 
hours, cells were washed and stained. iNKT cells were stained with FITC-labelled 6B11 and 
APC-labelled CD3 respectively, followed by intracellular staining with PE-labelled anti-IFN-
γ (BD Bioscience, San Jose, CA, USA). 
 
IFN-γ and IL-12 secretion 
For determination of cytokine secretion, supernatants were harvest after 5 days of 
culture. Supernatants were analyzed for IFN-γ by ELISA using PeliKine Compact human 
IFN-γ ELISA kit (Sanquin, Amsterdam, The Netherlands) according to manufacturer’s 
recommendations. IL-12 p70 determination by ELISA was performed as described before 
[15]. 
 
Real-time quantitative RT-PCR analysis of TLR expression on iNKT cells 
iNKT cells were purified from PBMC by MACS sorting as described above, followed 
by FACS sorting based on forward side scatter and their CD3, Vα24 and Vβ11 expression, 
and divided into CD4- and CD4+. In some cases, iNKT cells were expanded for 2 weeks 
before FACS sorting was performed. mRNA was extracted using TRIzol(TM) Reagent 
(Invitrogen Life Technologies, The Netherlands) according to the manufacturer's instructions. 
Isolated RNA was treated with DNase (RQ1 DNase; Promega, The Netherlands) to eliminate 
possible contamination with genomic DNA. mRNA was reverse transcribed using the kit 
“RevertAid H Minus First Strand cDNA” (Fermentas, Germany) and quantified by real-time 
quantitative PCR (iCycler iQ MultiColor Real-Time PCR Detection System; Bio-Rad 
Laboratories, The Netherlands) with specific primers [16] and general SYBR green (Bio-Rad 
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 Laboratories, The Netherlands) fluorescence detection. mRNA expression of each sample was 
normalized to GAPDH [17]. 
 
Statistics 
Normality of distribution of the data was analysed with the Kolmogorov-Smirnov test 
and Q-Q plots. Wilcoxon signed rank test or Student T-test for paired samples were 
performed to analyse iNKT cell phenotype, as well as IFN-γ production. A two-tailed p value 
of < 0.05 was considered significant. All data were analysed using the SPSS 14.0 software. 
 
 
Results 
PBMC stimulation with different TLR agonists (PGN, CL075 and ODN A) induces iNKT cell 
activation and IFN-γ secretion  
Effect of TLR stimulation on iNKT cell activation was studied by stimulating PBMC 
from healthy donors with different TLR agonists (PGN ligand for TLR2/6, Poly (I:C) for 
TLR3, LPS for TLR4, flagellin for TLR5, CL075 for TLR8 and to a lesser extend for TLR7, 
and ODN A  for TLR9, see  Table 1). No  significant changes were observed in the proportion  
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Figure 1: CD69 expression by iNKT cells upon PBMC stimulation with different TLR agonists. PBMC were 
cultured for 48h in medium (no stimulus) or in the presence of PGN, Poly (I:C), LPS, Flagellin, CL075 or ODN 
A. a) CD69 expression on iNKT cells (defined as CD3+ 6B11+ cells). FACS plots from one representative 
experiment out of 6 performed are shown. Numbers in the upper right corner represent the percentage of CD69+ 
iNKT cells (mean of 6 experiments). Results of all donors represented as: b) % CD69+ iNKT cells of total iNKT 
cells and c) Mean fluorescence intensity (MFI) of CD69 expression on iNKT cells. Horizontal lines represents 
mean. * Paired Student’s T-test: p<0.05 
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Figure 2: IFN-γ secretion by PBMC upon stimulation with different TLR agonists. PBMC were cultured in 
medium (no stimulus) or in the presence of PGN, Poly (I:C), LPS, Flagellin, CL075 or ODN A. After 48h, 
supernatants were harvested and IFN-γ secretion was determined by ELISA. The graph shows the results of 
individual donors. The horizontal lines represent the median IFN-γ secretion. Wilcoxon signed rank test: 
*p<0.05. 
 
of iNKT cells (0.07 ± 0.05 % of 6B11+ cells among the CD3+ T cell population). However, 
iNKT cell activation was observed upon TLR stimulation in the absence of α-GC. PGN, 
CL075 and ODN A significantly induced an increase in CD69 expression on iNKT cells (fig. 
1a), both the number of iNKT cells expressing CD69 (% CD69+ iNKT cells, fig. 1b, paired 
Student’s T-test, p = 0.011, 0.008 and 0.003, respectively), as well as the intensity of CD69 
(MFI CD69 on iNKT cells, fig. 1c, paired Student’s T-test, p = 0.021, 0.026 and 0.003, 
respectively) were increased. 
In addition to iNKT cell activation, the effect of TLR triggering on IFN-γ production 
was also addressed. After 48h, supernatants were harvested and IFN-γ production was 
determined by ELISA. Although there was a large variation between donors, IFN-γ secretion 
was consistently increased in supernatants of PBMC stimulated with PGN, CL075 and ODN 
A (fig. 2, Wilcoxon signed rank test, p=0.008, 0.016, 0.008 respectively), the ligands which 
significantly induced an increase in CD69 expression on iNKT cells as well. A trend in an 
increased IFN-γ production was observed after Poly (I:C), LPS and flagellin stimulation. 
Intracellular cytokine staining (ICCS) 24h after treatment of PBMC with the different TLR 
ligands revealed that PGN, CL075 and ODN A induced IFN-γ production by NK cells,  as 
well as by CD3+ T cells (in all cases less than 3%); but hardly any IFN-γ production by iNKT 
cells was observed (data not shown). 
 
Increased activation of iNKT cells after combined TLR stimulation  
To determine whether combined TLR triggering had an additive and/or synergistic 
effect on iNKT cell activation, PBMC from two different donors were cultured for 48h with 
combinations of PGN, CL075 and ODN A (the TLR ligands that induced the strongest IFN-γ 
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 secretion and iNKT cell activation). Combined TLR stimulation had a synergistic effect on 
IFN-γ production (fig. 3a). The percentage of iNKT cells remained unaltered after combined 
TLR agonist stimulation (data not shown), but their activation status was increased. While the 
proportionate increase in CD69 expressing iNKT cells was limited after combined TLR 
triggering (data not shown), there was an additive, though not synergistic, effect on the level 
of CD69 expression (fig. 3b).  
We have shown iNKT cell activation by TLR agonists in the absence of exogenous 
iNKT cell TCR ligand. Since iNKT cells can be activated by α-GC, we tested the effect of 
combined α-GC and PGN, CL075 or ODN A stimulation. There was a synergistic increase in 
IFN-γ secretion when CL075 or ODN A, but not PGN stimulation was combined with α-GC 
(fig. 3c), suggesting that upon CL075 and ODN A stimulation, iNKT cells are directly or 
indirectly involved in IFN-γ secretion. Moreover, a slight additional effect of α-GC on CD69 
expression by iNKT cells was observed (data not shown). The effect on iNKT cell activation 
may be underestimated due to experimental limitations to detect α-GC-activated iNKT cells. 
iNKT cell determination was performed using an antibody against the invariant TCR, which 
is internalized after α-GC stimulation, as seen by a reduction in 6B11+ iNKT cell number 48h 
after α-GC stimulation. Yet, the few detectable iNKT cells, which did not internalize their 
TCR, showed an increase in CD69 expression. 
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Figure 3: PBMC stimulated with 
combinations of different TLR 
agonist and α-GC. PBMC were 
cultured for 48h in medium (no 
stimulus) or in the presence of 
PGN (P), CL075 (C) or ODN A 
(O) or a combination of these. a) 
IFN-γ secretion in supernatants 
was determined by ELISA. b) 
CD69 expression level (MFI) on 
iNKT cells (defined as CD3+ 
6B11+ cells) was analysed by flow 
cytometry. Graphs show results of 
2 individual experiments: donor 1 
(0.14% iNKT cells, left panel) and 
donor 2 (0.13% iNKT cells, right 
panel). c) PBMC cultured for 48h 
in medium (no stimulus) or in the 
presence of PGN, CL075 or ODN 
A in the absence (open bars) or 
presence (closed bars) of the 
iNKT cell ligand, α-GC. IFN-γ 
secretion in supernatants was 
determined by ELISA. The graphs 
show the results of 2 individual 
experiments: donor 3 (0.19% 
iNKT cells, left panel) and donor 
4 (0.14% iNKT cells, right panel). 
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Figure 4: TLR expression profile of iNKT cells. a) Isolation of iNKT cells. PBMC were stained for Vα24, Vβ11, 
CD3 and CD4 and analysed by flow cytometry to determine iNKT cell frequency (left panel, gated on CD3+ 
lymphocytes). Next, PBMC were enriched for iNKT cells by positive MACS selection using the iNKT cell 
specific antibody 6B11 (middle panel, gated on CD3+ lymphocytes). Subsequently, iNKT cells were sorted 
based on Vα24, Vβ11 and CD3 expression (right panel, no gate). In some cases, CD4- and CD4+ iNKT cells 
population were isolated separately. b) TLR1-10 mRNA expression relative to GAPDH mRNA was determined 
by quantitative real-time RT-PCR and is depicted as arbitrary units (AU). Results are shown as mean ± SEM 
(n=9). 
 
 
iNKT cells express different TLR, but do not respond directly to TLR agonist stimulation 
To determine whether iNKT cells can be directly activated by TLR ligands, we have 
analyzed TLR mRNA expression by iNKT cells. Purified iNKT cells from healthy donors 
(fig. 4a, n=9, purity 93.3 - 100.0%) expressed TLR1, TLR2, TLR4, TLR6, TLR7 and TLR9 
mRNA, whereas TLR3, TLR5 and TLR10 mRNA expression was low and TLR8 mRNA was 
absent (fig. 4b). With the exception of TLR6 and TLR7, expression levels are relatively low 
compared to APC [18]. Ex-vivo isolated and purified iNKT cells (n=4) showed the same TLR 
expression profile as in vitro expanded iNKT cells (n=5). Moreover, there was no difference 
in TLR expression profile between CD4+ (n=4) and CD4- (n=3) iNKT cell populations.  
Despite the fact that iNKT cells express TLR mRNA, isolated iNKT cells did not respond 
directly to the different TLR agonists. No increase in iNKT cell activation status (CD25 and 
CD69 expression, n=4), cytokine production (IFN-γ and IL-4, n=6), proliferation (n=3) or 
enhancement of survival (n=2) was observed upon TLR agonist stimulation (data not shown). 
Furthermore, no effects were observed when TLR triggering was combined with TCR (anti-
CD3) and/or co-stimulatory molecule (anti-CD28) triggering or in the presence of suboptimal 
concentrations of IL-2 (data not shown). Of note, all TLR ligands tested have previously been 
shown to activate NK cells (at the concentrations used in this study). 
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Figure 5: TLR-stimulated moDC induce iNKT cell activation. moDC were cultured in medium (no stimulus) or 
in the presence of different TLR agonists. As positive control, moDC maturation was induced with MCM and 
TNF-α. a) Phenotype of moDC after 48h. FACS plots show one representative experiment out of 4 performed. 
Grey histograms represent cells stained with the CD86, CD80, CD83 or CD40 specific antibodies, open 
histograms (bold line) represent cells stained with the appropriate isotype control. Numbers in the upper right 
corner represent the mean of MFI of 4 experiments performed. b) Immature, TLR-stimulated and MCM/TNF-α-
matured moDC were pulsed with α-GC or vehicle, and subsequently co-cultured with in vitro expanded 
autologous iNKT cells. After 4h, IFN-γ secretion by iNKT cells was analysed by ICCS. iNKT cells stimulated 
with HeLa cell line transfected with CD1d were used as a positive control. The graph shows the results of one 
experiment out of 2 performed. c) After 48h, supernatants were harvested and IFN-γ secretion was determined 
by ELISA. Results of one representative experiment out of 4 performed are shown. Intracellular IFN-γ 
production and IFN-γ secretion results shown are from the same donor for comparison (donor 5). iNKT cell 
activation was determined by d) CD69 and e) CD25 expression on iNKT cells by flow cytometry. Results are 
shown as mean ± SEM (n=5).  
 
 
TLR-stimulated monocyte-derived DC (moDC) induce IFN-γ secretion by iNKT cells 
Human DC respond to different TLR agonists. As iNKT cells are unresponsive to direct 
TLR stimulation but are activated upon PBMC stimulation with different TLR ligands, TLR 
effects may occur indirectly through myeloid DC (mDC) or plasmacytoid DC (pDC) present 
in PBMC. In order to study the role of mDC, isolated and in vitro expanded iNKT cells were 
co-cultured with TLR-matured autologous moDC, as a model for mDC. We focused on PGN, 
CL075 and ODN A, which were the most effective in inducing IFN-γ secretion and activating 
iNKT cells. As positive control, moDC maturation was induced with MCM and TNF-α. PGN 
and CL075 promoted moDC maturation as evidenced by up-regulation of CD80, CD83, 
CD86 and CD40 expression (fig. 5a), but not IL-12 secretion (data not shown). As expected, 
ODN A had no effect since moDC lack TLR9, and CpG stimulation was used as a negative 
control next to medium control (no stimulus) in subsequent experiments. Of note, CD1d 
expression remained unchanged upon TLR-triggering (data not shown). 
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To analyse whether TLR agonists could have an indirect effect on iNKT cells through 
DC, TLR-stimulated moDC were pulsed with α-GC or vehicle, and co-cultured with in vitro 
expanded iNKT cells. After 4h, α-GC-pulsed, but not vehicle-pulsed, moDC induced IFN-γ 
secretion by iNKT cells as determined by ICCS (fig. 5b). iNKT cell IFN-γ production was 
also detected by ELISA in supernatants harvested at 48h (fig. 5c). IFN-γ secretion correlated 
with DC maturation status; MCM/TNF-α, PGN and CL075 induced the strongest moDC 
maturation and the highest IFN-γ production, whereas ODN A that did not induce moDC 
maturation had little or no effect on IFN-γ secretion by iNKT cells as compared to immature 
moDC. However, all moDC, irrespective of their initial maturation status (immature, TLR-
stimulated and mature), induced phenotypic activation of iNKT cells, as determined by 
increase in CD69 and CD25 expression (fig. 5d and 5e). While CD69 up-regulation appeared 
to be α-GC-independent, CD25 expression was higher in the presence of α-GC-loaded 
compared to vehicle-loaded moDC, mature moDC (PGN, CL075 and MCM+TNF-α) in 
particular. 
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Figure 6: iNKT cells promote further activation of TLR-stimulated moDC. Immature, TLR-stimulated and 
MCM/TNF-α-matured moDC were pulsed with α-GC, and subsequently co-cultured with iNKT cells. a) 
Phenotype of differentiated moDC after 48h. Results are shown as mean ± SEM (n=3). * Paired Student’s T-test: 
p<0.05. b) After 48hs, supernatants were harvested and IL-12 secretion was determined by ELISA. The graphs 
show the results of 2 individual experiments: donor 6 (left panel) and donor 7 (right panel). 
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 Maturation of moDC is enhanced by iNKT cells  
Next to the effect of TLR-stimulated moDC on iNKT cells, the effect of pre-activated 
iNKT cells on TLR-stimulated moDC was also studied. Phenotypical characterization of 
TLR-activated moDC was performed after 48h of co-culture with iNKT cells. Interaction 
between moDC and iNKT cells led to further moDC maturation, independent of the moDC 
initial maturation status (fig. 6a) and of the presence of α-GC (data not shown). Up-regulation 
of CD40, CD80, CD83 and CD86 expression occurred on α-GC-, as well as vehicle-, loaded 
moDC and on immature, as well as mature moDC. Apart from the increased expression of 
maturation marker on moDC induced by iNKT cells, iNKT cells also triggered IL-12 
production by TLR-activated moDC (fig. 6b). This IL-12 production was α-GC–dependent. 
Thus the reciprocal phenotypic activation of iNKT cells and (TLR) matured DC is 
independent of α-GC, while the reciprocal induced cytokine production (i.e. IFN-γ and IL-12 
respectively) is α-GC dependent. 
 
 
Discussion 
Invariant NKT cells are thought to regulate immune responses against various microbial 
infections. Here we investigated the effect of various TLR agonists, isolated either from 
bacteria or synthetic compounds based on ligands found in both viruses and bacteria, on 
iNKT cell activation. PGN, CL075 and ODN A, the ligands for TLR2/6, TLR7 and 8, and 
TLR 9 respectively, strongly induce in vitro activation of human iNKT cells. Since the iNKT 
cell activation was observed upon stimulation of whole PBMC, the mechanism behind the 
iNKT cell activation we observed is not yet clear. To determine whether iNKT cells could be 
directly stimulated by TLR ligands, we first investigated TLR expression in human iNKT 
cells and demonstrated mRNA expression of all TLR with the exception of TLR8. The TLR 
expression profile we observed here was different from the profile previously described by 
Marschner et al. [19]. In contrast to our observations, they observed high TLR 5 and low TLR 
4 and 6 expression levels. However, in that particular study purified Vα24+ CD3+ cells were 
used, which contained only 40% actual Vβ11+ iNKT cells and 60% contaminating 
conventional T cells. Indeed, TLR expression of this population was similar to that of 
conventional T cells described by Hornung et al. [10]. With the exception of TLR6 and 
TLR7, expression levels are relatively low (up to 100-fold lower) compared to APC, such as 
Langerhans cells, dendritic cells and moDC [18]. Despite expression of most TLR at the 
mRNA level, various in vitro assays could not demonstrate direct TLR triggering on iNKT 
cells. Our results are in agreement with previous studies that demonstrate a lack of iNKT cell 
responsiveness to TLR4, 7, 8 and 9 agonists [19-21]. Agonists of intracellular TLR, such as 
poly (I:C) for TLR3, CL075 for TLR7 and 8, or ODN A for TLR9, would most likely activate 
iNKT cells indirectly through phagocytic cells. On the other hand, cell surface expressed TLR 
should in principle be responsive to TLR agonists and activate iNKT cells. The lack of 
responsiveness to these ligands may be related to 1) the absence of accessory molecules on 
iNKT cells, such as CD14 that belongs to the LPS-receptor complex, 2) absent or low TLR 
protein expression, 3) the intracellular localization of the TLR proteins that can be modified 
upon activation, as previously reported for TLR2 and 4 in activated T cells [22], 4) presence 
of negative regulatory mechanisms that attenuate TLR signalling [23], which may be active as 
a feedback mechanism to maintain immunological balance, or 5) requirement of co-
stimulatory molecules for TLR triggering of iNKT cell activation, as many TLR have been 
shown to do in T cells [22;24;25], although we and others [21] could not confirm this latter 
hypothesis.  
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The present results show that stimulation of PBMC with PGN, CL075 and ODN A 
induces a significant up-regulation of the activation marker CD69 on iNKT cells and an 
increase in IFN-γ production, suggesting an association between iNKT cell activation and 
IFN-γ secretion. This observation is supported by the results obtained with the other TLR 
agonists; LPS induced a modest increase in iNKT cell activation and IFN-γ production, while 
Poly (I:C) and flagellin, which did not lead to iNKT cell activation, hardly induced IFN-γ 
production. Activated iNKT cells are known to be involved in the early production of large 
amounts of IFN-γ. However, we could not detect any IFN-γ in iNKT cells by ICCS shortly 
after stimulation, the few IFN-γ+ cells detected were NK or conventional T cells (less than 
3%, data not shown). Since iNKT cells typically comprise less than 0.2% of the total CD3+ T 
cell population, reliable IFN-γ staining of activated iNKT cells is difficult. The fact that the 
IFN-γ production by PBMC was synergistically increased by combining ODN A or CL075 
stimulation with the iNKT cell antigen, α-GC, indicates that IFN-γ production was mediated 
by iNKT cells, if not produced by iNKT cells (fig. 3c). Marschner et al. [19] also observed a 
synergistic effect on IFN-γ secretion when NKT-cell enriched PBMC were stimulated with 
ODN A, which can activate pDC but not TLR9 negative mDC, combined with α-GC. They 
demonstrated that ODN A is required to induce pDC-derived type I IFN secretion, which in 
turn promotes mDC maturation, enhancing α-GC presentation by mDC (but not by pDC as 
they lack CD1d), and thus promoting iNKT cell IFN-γ secretion. Since TLR7 ligands, like 
CL075, have been shown to activate pDC as well, the same sequence of events may take 
place upon combined stimulation with α-GC, resulting in increased IFN-γ secretion by iNKT 
cells. On the other hand, α-GC had no additive effect on PGN induced IFN-γ secretion. This 
may be explained by  an upregulation of the glycosphingolipid synthesis pathway by PGN, 
resulting in enhanced recognition of CD1d-associated endogenous lipids by iNKT cells 
[21;26] and subsequent iNKT cell IFN-γ secretion, without the need for α-GC. PGN, CL075, 
Poly (I:C) and flagellin are all known mDC activating TLR agonists, however only PGN and 
CL075 showed a strong effect on iNKT cell activation when added to total PBMC. This may 
be explained by the complex combination of activating and inhibiting signals induced by TLR 
agonists. For example, next to DC maturation and CD4+ T cell activation, flagellin has also 
been shown to activate suppressor functions of Tregs [27], while LPS has been shown to 
induce Treg expansion and enhance their suppressive function [28]. In contrast, triggering of 
TLR2 induces Treg proliferation accompanied by transient loss of suppressive activity 
[29;30]. Moreover, TLR8 activation by CpG poly-G oligonucleotides reverses the suppressive 
function of Tregs [31]. Based on these observations, PGN, CL075 and CpG may not only 
activate DC but also temporally inactivate Tregs in total PBMC, allowing for iNKT cell 
activation. Of note, two independent groups have shown that iNKT cells can be indirectly 
activated by LPS, which induces IL-12 production by DC, amplifying the weak 
responsiveness of iNKT cells to endogenous glycolipids [7;8]. However, we did not observe 
iNKT cell activation upon LPS stimulation. This discrepancy could be due to different 
experimental settings. While the mentioned studies were performed using isolated DC and 
iNKT cell populations, we stimulated total PBMC with LPS allowing, as discussed above, for 
activation of e.g. Tregs that may impair iNKT cell activation [32].  
Since PGN and CL075 induced the strongest iNKT cell activation (next to ODN A) and 
are known to activate mDC, interactions between PGN- or CL075-stimulated moDC and 
isolated and expanded iNKT cells were studied. Indeed, PGN- and CL075-stimulated moDC 
induce phenotypic activation of human iNKT cells. Functional activity as measured by IFN-γ 
production was observed only when DC were pulsed with α-GC. Although Raftery et al. [33] 
have recently shown modulation of CD1d expression, i.e. CD1d up- and down-regulation 
upon TLR7- and TLR2-triggering respectively, we have not been able to detect any variation 
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 in CD1d expression. This discrepancy may be due to different moDC preparations (2 day vs 6 
day immature moDC) or the different ligands and ligand concentrations used. Our results are 
in agreement with other previous reports demonstrating no changes in CD1d expression in 
human DC matured with TNF-α and CD40L, pDC-derived cytokines upon CpG stimulation 
or directly with a broad panel of TLR agonists [19;21;34]. In addition to iNKT cell activation 
by moDC, iNKT cells could in turn induce further phenotypic maturation of TLR-matured 
DC independent of α-GC, which is in agreement with the observations of Hermans et al. [35] 
who demonstrated that DC maturation triggered by monophosphoryl lipid A, a TLR4 agonist, 
could be enhanced by iNKT cells. As we observed for cytokine production by iNKT cells, full 
DC activation as measured by IL-12 was dependent on α-GC as well, which is most likely 
related to the α-GC dependent iNKT cell-derived IFN-γ. Our results support the following 
sequence of events: TLR triggering induces phenotypic maturation of DC without IL-12 
production, subsequent iNKT cell CD28-CD86/CD80 interactions induce further phenotypic 
maturation while additional TCR-CD1d/α-GC interactions trigger IFN-γ production by iNKT 
cells. This IFN-γ subsequently augments the IL-12 production by the DC induced by 
CD40/CD40L interactions, which in turn further enhances iNKT cell activation. This is 
supported by the fact that no IFN-γ secretion is observed in the absence of iNKT cell ligand, 
and that IFN-γ production is related to the initial maturation state, i.e. expression level of 
CD86 and CD80, of moDC (fig. 5). Recently, it has been demonstrated that activation of 
human APC by TLR ligands modulates glycosphingolipid synthesis pathway, resulting in 
enhanced recognition of CD1d-asociated lipids by iNKT cells [21;26]. The α-GC dependency 
we observe here may be due to the fact that these iNKT cells were generated by repeated α-
GC stimulation. However, Vincent and co-workers [36] have previously demonstrated that 
IL-12 production induced by self-reactive iNKT cells was dependent on α-GC. Thus iNKT 
cell induced IL-12 production by DC may depend on strong iNKT cell TCR agonists such as 
α-GC.  
In conclusion, our in vitro results demonstrate a differential indirect activation of iNKT 
cells by TLR ligands. Combinations of TLR2/6, TLR7, 8 or 9 rather than TLR3, 4 or 5 
agonists with α-GC may act as strong adjuvants for immunotherapy by enhancing iNKT cell 
activation and type 1, IFN-γ mediated immune responses.  
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 Abstract 
CD1d restricted invariant Natural Killer T (iNKT) cells can enhance immunity to cancer or 
prevent autoimmunity, depending on the cytokine profile secreted. Anti-tumor effects of the 
iNKT cell ligand, αGalactosylceramide (αGC) and iNKT cell adoptive transfer have been 
demonstrated in various tumor models. Together with reduced numbers of iNKT cells in 
cancer patients, which have been linked to poor clinical outcome, these data suggest that 
cancer patients may benefit from therapy aiming at iNKT cell proliferation and activation. 
Here we investigated the effects of human iNKT cells on antigen specific CTL responses. 
iNKT cells were expanded using αGC pulsed allogeneic DC derived from the acute myeloid 
leukemia cell line MUTZ3, transduced with CD1d to enhance iNKT cell stimulation, and with 
IL-12 to stimulate type 1 cytokine production. Enhanced activation and increased IFNγ 
production was observed in iNKT cells, irrespective of CD4 expression, upon stimulation 
with IL-12 over-expressing DC. IL-12 stimulated iNKT cells strongly enhanced the MART1 
specific CD8+ CTL response, which was dependent on iNKT cell derived IFNγ. Furthermore, 
autologous IL-12 over-expressing DC, loaded with antigen as well as αGC were superior in 
stimulating both iNKT cells and antigen specific CTL. This study shows that IL-12 over-
expressing allogeneic DC expand IFNγ producing iNKT cells, which may be more effective 
against tumors in vivo. Furthermore, the efficacy of autologous antigen loaded DC vaccines 
may well be enhanced by IL-12 over-expression and loading with αGC. 
 
 
Keywords: human; T cells, Cytotoxic, Cytokines, Cell activation, Tumor Immunity 
 
 
Abbreviations: αGC: α-galactosylceramide; DC: dendritic cells; iNKT: invariant natural 
killer T-cells; iNKTIL-12: IL-12 stimulated iNKT cells; IRES: internal ribosome entry site; 
MART-1: melanoma antigen recognized by T cell-1; MoDC: monocyte derived dendritic 
cells; MUTZ-3: M3; CD1d transduced M3: M3CD1d; IL-12 and CD1d double transduced 
M3: M312CD1d; NGFR: nerve growth factor receptor; TAA: tumor associated antigen; Tm: 
tetramer. 
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Introduction 
 Invariant Natural Killer T (iNKT) cells are T lymphocytes, characterized by an 
invariant TCRα chain gene rearrangement (Vα24-Jα18 paired with Vβ11 in humans) and co-
expression of NK cell receptors (1). iNKT cells recognize glycolipid antigens in the context 
of the non-polymorphic, MHC class I-like molecule CD1d via their highly restricted TCR 
repertoire. iNKT cells are considered to be primarily auto-reactive recognizing endogenous 
lipids (2), but can also recognize bacterially derived glycolipids, suggestive for a role in anti-
microbial defense (3). The synthetic glycolipid αGalactosylceramide (αGC) induces 
activation and proliferation of iNKT cells in vitro as well as in vivo. The main physiological 
function of iNKT cells remains to be elucidated, but based primarily on murine studies, 
modulation of innate and adaptive immune responses through activation or elimination of 
dendritic cells (DC) is thought to be the main function of iNKT cells (4-9). Upon activation, 
iNKT cells rapidly secrete both type 1 (e.g. IFNγ, TNFα) and type 2 (e.g. IL-4, IL-13) 
cytokines. Owing to this broad spectrum of cytokines, iNKT cells have the capacity to 
enhance host immunity to microorganisms and cancer, as well as to prevent autoimmunity. 
This has been experimentally demonstrated in various animal models and is also strongly 
suggested by low numbers of circulating iNKT cells in patients suffering from autoimmune 
diseases or cancer (10-14). We have recently demonstrated that a severe circulating iNKT cell 
deficiency predicts poor clinical outcome in head and neck squamous cell carcinoma patients 
(15). In addition, increased iNKT cell infiltration at tumor sites is associated with prolonged 
survival in colon cancer and neuroblastoma patients (16,17). These data suggest a critical 
contribution of iNKT cells to anti-tumor immune responses in humans. Subtypes of iNKT 
cells, based on CD4 expression, have been shown to express different cytokine profiles when 
analyzed directly ex vivo. Human CD4+ iNKT cells produce both type 1 and type 2 cytokines, 
whereas CD8+ and CD4-CD8- double negative iNKT cells primarily produce type 1 cytokines 
(18,19). Although iNKT cells possess the full lytic machinery, direct killing of tumor cells has 
predominantly been described for CD1d positive leukemic cell lines (20,21). Tumor cell lines 
of different origin were only susceptible to iNKT cell mediated killing after CD1d 
transfection and pulsing with αGC (22). The anti-tumor effect of αGC in various tumor 
models has been shown to primarily depend on IL-12 (23-25). iNKT cells induce IL-12 
production by DC through CD40 ligation and IFNγ production (26). IL-12 is a strong NK cell 
activator and is also considered to be a crucial third signal for induction of functional antigen 
specific type 1 Th cell and CTL responses (27). In contrast to the vast number of studies in 
mice showing enhanced antigen specific T-cell activation by αGC and iNKT cells, the limited 
data on human iNKT cells demonstrate inhibition rather than enhancement of antigen specific 
CTL responses in vitro. Isolated human CD4+ and CD8+ iNKT cells suppressed the expansion 
of antigen specific CTL by type 2 cytokine production and lysis of APC and activated T-cells 
respectively (28,29). Here we expanded and stimulated human iNKT cells using αGC pulsed 
allogeneic DC derived from the acute myeloid leukemia cell line MUTZ3, transduced with 
CD1d to enhance iNKT cell stimulation, and with IL-12 to stimulate IFNγ production. These 
MUTZ3 variants provided us with a standardized unlimited source of precursors to generate 
DC expressing CD1d and secreting IL-12. Effects of IL-12 on CD4- and CD4+ iNKT cell 
activation and cytokine production were analyzed, as well as the effect of IL-12 stimulated 
iNKT cells on tumor associated antigen (TAA) specific CTL responses induced by autologous 
MoDC. In a more physiological and clinically relevant set-up, it was examined whether iNKT 
cells in total PBL can also enhance CTL expansion. To this end PBL were cultured with 
αGC/MART1 double loaded, IL-12 over-expressing, autologous MoDC to simultaneously 
stimulate MART1 specific CTL and iNKT cells. 
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 Materials and Methods 
Media, reagents and cell lines 
Recombinant human TNFα (50 ng/ml), IL-7 (5 ng/ml), IL-15 (5 ng/ml) and IL-2 (10 
or 50 IU/ml) were purchased from Strathmann Biotech, Hanover, Germany. Recombinant 
human GM-CSF (Schering-Plough, Kenilworth, NJ) was used at 100ng/ml; IL-4 (R&D 
systems, Abingdon, UK) was used at 10 ng/ml; IFNγ (Biosource, Camarillo, CA) was used at 
400U/ml; blocking antibodies against IL-4, IFNγ and IL-10 (R&D systems) were used at 
4μg/ml. IMDM (Cambrex, Verviers, Belgium) was supplemented with 10% FCS (Perbio, 
Helsingborg, Sweden), for culture of the melanoma cell lines Mel-JKO and Mel-AKR, the 
EBV-LCL JY and CD1d transfected Hela cells (a kind gift of Dr M. Kronenberg, LIAI, San 
Diego, CA),  8% human pooled serum (Sanquin, Amsterdam, The Netherlands) for culture of 
iNKT cells or Yssels supplement (30) and 1% human AB serum (ICN Biomedicals, 
Zoetermeer, The Netherlands) for CTL cultures. The CD34+ human acute myeloid leukemia 
cell line MUTZ3 (Deutsche Sammlung von Mikroorganismen und Zellkulturen [DSMZ], 
Braunschweig, Germany) was cultured in MEM-α medium containing ribonucleosides and 
deoxyribonucleosides (Life Technologies, Paisley, UK) supplemented with 20 % FCS 
(Perbio) and 10% 5637 (ATCC, Manassas, VA, USA) conditioned medium. All media were 
supplemented with 100 IU/ml sodium penicillin (Yamanouchi Pharma, Leiderdorp, The 
Netherlands), 100 μg/ml streptomycin sulphate (Radiumfarma-Fisiopharma, Naples, Italy), 
2.0 mM L-glutamine (Invitrogen, Breda, Netherlands) and 0.01 mM 2-mercapo-ethanol 
(Merck, Darmstadt, Germany). FITC-, PE- PerCPCy5- or APC-labeled isotype controls and 
mouse mAbs to CD1a, CD1d (clone CD1d42), CD40, CD80, CD86, iNKT TCR (6B11), 
CD8, CD4, CD3, CD69, CD161, CTLA4, CD25, IFNγ, IL-4, IL-10 (BD Pharmingen, 
Heidelberg, Germany), CD83, Vα24, Vβ11 (Immunotech, Marseille, France), Granzyme B 
(Sanquin) and CD56 (IQ products, Groningen, The Netherlands) were used to determine the 
phenotype of iNKT cells and DCs. The CD1d specific clone 51.1.3 was a kind gift from Dr 
Mark Exley, Harvard Medical School, Boston, MA. Mean fluorescence index was calculated 
as follows: MFIndex = mean fluorescence intensity marker / fluorescence intensity isotype.   
 
Retroviral  transduction 
The human CD1d (Open Biosystems, Huntsville, AL) and the IL-12elasti cassette 
containing the p35 and p40 subunits of IL-12 joined together by a flexible linker (Invivogen, 
San Diego, CA) open reading frames were cloned into the Moloney murine leukemia virus-
based retroviral vector LZRS (31). IL-12 was inserted into the multiple cloning site (mcs) of 
the bicistronic LZRS vector containing an internal ribosome entry site (IRES) followed by the 
truncated version of the nerve growth factor receptor (ΔNGFR) (LZRS-IL-12-IRES-ΔNGFR) 
(32). CD1d was cloned behind the IRES sequence (LZRS-mcs-IRES-CD1d). The constructs 
were transfected into the packaging cell line Phoenix-A using lipofectamine (Invitrogen), 
retroviral supernatant was produced, followed by retroviral transduction of MUTZ3 as 
described previously (33). Briefly, 5x105 MUTZ-3 cells, were resuspended in retroviral 
supernatant supplemented with 10% 5367 conditioned medium and transferred to a 
fibronectin (RetroNectin; Takara, Otsu, Japan)-coated well of a non-tissue-culture-treated 24-
well plate (BD Biosciences). Plates were centrifuged, followed by 5h incubation at 37°C. The 
next day, retroviral transduction was repeated. NGFR-specific (Chromoprobe, Aptos, CA) 
and CD1d specific (clone CD1d42, BD Biosciences, Heidelberg, Germany) antibodies were 
used to analyze transduction efficiency and isolate transduced cells by flow cytometry. IL-12 
María Moreno Jauge
46
 
 
 
 
 
 
 
 
 
 
 
I 
N 
 
V 
I 
T 
R
O 
 
 
transduced cells were transduced with LZRS-mcs-IRES-CD1d after sorting of NGFR positive 
cells to obtain double transduced MUTZ3 cells. 
 
Expansion of  iNKT cells and  MART126-35A27L  peptide specific  CD8+ T-cells  
DC derived from monocytes (MoDC) and wild-type MUTZ3 (M3) as well as CD1d 
(M3CD1d) and IL-12 and CD1d double transduced (M312CD1d) cells were generated as 
described previously (34). Maturation was induced by 48 hours culture in the presence of 
30% v/v MCM and TNFα as described (35). iNKT cells were enriched from 500x106 PBMC, 
isolated from buffy coats from healthy blood donors obtained after informed consent, by 
positive selection using the iNKT cell specific antibody 6B11 (BD Pharmingen) and anti-
mouse Ig coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) by MACS 
sorting. iNKT cells were expanded by weekly stimulation with irradiated αGC (KRN7000, 
kindly provided by Dr. Shigeyuki Yamano, KIRIN Brewery, Gunma, Japan) pulsed 
(100μg/ml) mature M3CD1d-DC in the presence of IL-2 (50U/ml), IL-15 and IL-7. If 
necessary, iNKT cells were further purified by MACS sorting (>90%). To enhance type 1 
cytokine production, iNKT cells were stimulated for 5 days with αGC pulsed mature 
M312CD1d-DC. To study proliferation of iNKT cell lines in response to various DC types, 
iNKT cell lines (>90% pure) were labeled with CFSE (1 μM; Molecular Probes, Eugene, OR) 
for 10 minutes at 37°C, washed twice in ice-cold PBS and cultured in medium (supplemented 
with IL-2, IL-7 an IL-15) only or in the presence of αGC pulsed MoDC or M3, M3CD1d or 
M312CD1d derived DC. Intensity of CFSE was measured or cell counts were performed after 
1 week culture. The relative CFSE intensity on 6B11 positive iNKT cells was calculated as 
follows: mean CFSE fluorescence intensity of iNKT cells cultured with DC / mean CFSE 
fluorescence intensity of iNKT cells cultured in medium. 
CD8β-positive CTL precursors were isolated from buffy coats of HLA-A2.1-positive 
healthy donors using a CD8β specific antibody (Beckman Coulter, Marseille, France) by 
MACS sorting. Mature MoDC were pulsed with the HLA-A2.1 restricted epitope MART126-
35A27L or transfected with mRNA encoding a minigene of this epitope ubi(MART)4 mRNA 
or with ubi(MART)4-2A-IL12 mRNA, encoding both the MART minigene and IL-12. In 
vitro transcription and transfection methods were described in detail previously (35). After 
αGC and peptide pulsing or mRNA transfection, DCs were washed and multiple bulk cultures 
containing 0.5-1x106 CD8β T-cells or PBL and 0.5-1x105 αGC and peptide pulsed or mRNA 
transfected DCs were set up. 1000-2000 (corrected for purity) autologous in vitro expanded 
(iNKT) and IL-12 stimulated iNKT cells (iNKTIL-12) were added as indicated. 0.25-0.5x106 
irradiated autologous CD8β T-cell/iNKT cell/monocyte depleted PBL were added as helper 
cells to the CD8β cultures. The next day IL-7 was added. After 10 days, T-cells were 
analyzed for specificity using PE- and/or APC-labeled HLA-A*0201 tetramers (Tm) 
presenting the MART126-35A27L epitope (35). On day 10 the bulk cultures were restimulated 
with DCs and irradiated autologous CD8β T-cell/iNKT cell/monocyte depleted PBMC, fresh 
iNKT cells were added to the appropriate wells, the next day IL-2 (10U/ml) was added. Tm 
staining and functional analysis was performed after 7 days. In order to analyze the 
involvement of soluble factors, some experiments were done in trans-wells (0.4μm pore size, 
Corning Life Sciences, Schiphol-Rijk, The Netherlands) or in the presence of cytokine 
blocking antibodies as indicated. 
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 Expansion of iNKT cells and MART126-35A27L peptide specific CD8+ T-cells from melanoma 
patients 
Thirty to forty ml of blood were drawn from four patients (two HLA-A2.1 positive 
and two HLA-A2.1 negative) with metastasized melanoma WHO stage 0 or 1. Patients did 
not receive any immune suppressive agents or chemotherapy in the four weeks preceding 
blood sampling. iNKT cells were enriched from isolated PBMC and expanded and stimulated 
as described above. iNKT cells form HLA-A2 positive patients were added to co-cultures of 
their autologous CD8β T-cells and allogeneic MART peptide, αGC pulsed, HLA-A2 matched 
MoDC. The iNKT cells derived from the HLA-A2 negative patients were added to co-
cultures of allogeneic HLA-A2 positive, healthy donor derived CD8β T-cells and MART 
peptide, αGC pulsed MoDC. The medical ethics committee of the VU Medical Center, 
Amsterdam, The Netherlands, approved the study and all patients gave informed consent. 
 
Functional assays 
 Seven days after the second DC stimulation the T-cell bulk cultures were harvested 
and pooled per condition, and incubated with target cells (JY, MART126-35A27L pulsed JY, 
Mel-JKO or Mel-AKR).  iNKT cells were harvested 5 days after stimulation with M3CD1d-
DC or M312CD1d-DC and incubated with vehicle or αGC pulsed target cells (Jurkat, Daudi 
or Hela-CD1d). Intracellular IFNγ/IL-4 staining was performed using the BD 
cytofix/cytoperm plus kit (BD Biosciences) according to the manufacturer’s instructions. One 
hour after the start of the stimulation, GolgiPlug was added to each well (0,1% v/v). After 5 
hours cells were washed and stained. CTL cultures were stained with APC-labeled tetramers 
and PE-labeled CD8 followed by intracellular staining with FITC-labeled anti-IFNγ. iNKT 
cells were stained with PE-labeled 6B11, PerCPCy5-labeled CD3 and APC-labeled CD4 
followed by intracellular staining with FITC-labeled anti-IFNγ or anti-IL-4. Cytolytic activity 
of the iNKT cells to Daudi and Jurkat cells was determined using a standard chromium 
release assay as described (36).  
 
Statistics 
When n≥5, parametric tests were used after confirmation of Gaussian distribution 
(normal distribution was confirmed in all cases); non-parametric tests were used when n<5. 
Differences in iNKT cell characteristics after culture with or without IL-12 were analyzed 
with either the parametric two-sided paired Student’s T-test, or the non-parametric Wilcoxon 
rank sum test. Differences in MART1 specific CTL frequencies were analyzed with either a 
two sided Student’s T-test or a two sided Mann Whitney U (MWU) test. 
 
 
Results 
Dendritic cells derived from CD1d transduced MUTZ3 support iNKT cell expansion  
αGC loaded autologous DC efficiently induce iNKT cell proliferation in vitro (37). 
Since iNKT cells are restricted by the non-polymorphic CD1d molecule, allogeneic DC may 
be used to induce iNKT cell proliferation and activation, precluding the generation of 
autologous MoDC for each donor. Previously we have shown that the human acute myeloid 
leukemia cell line MUTZ3 (M3) can be induced to differentiate into immature and mature DC 
upon cytokine stimulation. These DC display the full range of functional MHC-mediated 
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antigen processing and presentation pathways and produce relatively low levels of IL-12 upon 
CD40 triggering (38). To further promote CD1d antigen presentation and type 1 cytokine 
production by iNKT cells, CD1d and IL-12 were introduced into M3 cells by retroviral 
transduction. CD1d expression was analyzed on wild-type M3, CD1d transduced M3 
(M3CD1d), IL-12/CD1d double transduced M3 (M312CD1d) and monocytes before and after 
generation of mature DC using two antibodies (figure 1a and b). Expression levels were low 
to undetectable on wild-type M3 precursors, and their derived mature DC. Monocytes, 
M3CD1d and M312CD1d precursors strongly expressed CD1d (particularly demonstrated 
with the 51.1.3 clone, the CD1d42 clone worked less well in our hands, figure 1b), which was 
reduced upon DC differentiation. Thus both natural and ectopic CD1d expression was reduced 
upon DC differentiation. The 51.1.3 clone (more so than the CD1d42 antibody) has some 
cross-reactivity with CD1b, and it can therefore not be excluded that the remaining staining 
detected on mature DC is in fact CD1b. However, the GC dependent iNKT cell proliferation 
observed with GC pulsed mature DC (figure 1c and d; table 1), strongly suggests that the 
staining observed with 51.1 on mature DC is, at least in part, CD1d. 
Mature MoDC, M3-DC, M3CD1d-DC and M312CD1d-DC expressed similar high 
levels of CD40, CD80, CD83 and CD86 [not shown and (38,39)]. IL-12 transduced M3 
precursors (M312CD1d) released 495 (SD 192) pg IL-12 / 2x10
5
 cells / 24h and M312CD1d-
DC produced 1600 (SD 586) pg IL-12 / 2x10
5
 cells / 24h.  
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Figure 1: Dendritic cells derived from CD1d transduced MUTZ3 support iNKT cell expansion. CD1d expression 
by MUTZ3 (M3), CD1d transduced M3 (M3CD1d), IL-12 and CD1d transduced M3 (M312CD1d) and 
monocytes (Mo) precursors (prec) and their derived mature DC (DC) using the a) CD1d42 and b) 51.1.3 
antibodies. Grey histograms represent cells stained with the CD1d specific antibodies, open histograms (bold 
line) represent cells stained with the appropriate isotype control. Numbers in the upper right corner represent the 
mean fluorescence index (mean of 3 experiments). c) Example of CFSE dilution of an iNKT cell line after 7 
days culture with the indicated GC pulsed mature DC. The vertical dotted line represents mean CFSE 
fluorescence of the medium control. d) relative CFSE intensity (mean CFSE fluorescence intensity of iNKT cells 
cultured with DC / mean CFSE fluorescence intensity of iNKT cells cultured in medium) of iNKT cell lines after 
culture with the indicated GC pulsed DC (mean SD of 4 independent experiments). 
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 Next it was investigated whether ectopic CD1d and IL-12 expression had any effect on 
iNKT cell proliferation. Four iNKT cell lines were labeled with CFSE and cultured in 
medium supplemented with cytokines in the absence or presence of the different αGC pulsed 
DC. CFSE dilution as a measure for proliferation was determined after 1 week of culture 
(figure 1c). Proliferation rate was very low in response to M3DC, but high in response to 
M3CD1d-DC, M312CD1d-DC and allogeneic MoDC, demonstrating that the increased 
ectopic CD1d expression in M3DC lead to enhanced iNKT cell proliferation (figure 1c and 
d). These results were confirmed with 4 other iNKT cell lines; 1.5x106 cells were stimulated 
with αGC pulsed DC and counted after one week (Table 1). Proliferation induced by M3-DC 
was increased after CD1d transduction and CD1d transduced M3-DC were as effective as 
MoDC to induce iNKT cell proliferation. Based on these data, M3CD1d-DC and M312CD1d-
DC were used to expand iNKT cells.  
 
Table 1: Dendritic cells derived from CD1d transduced MUTZ3 support iNKT cell expansion. 
        iNKT cell line
Stimulation A B C D 
M3DC 1.8* 4.4 2.5 2.8 
M3CD1dDC 4.4 8.0 8.8 4.4 
M312CD1dDC 5.2 6.4 9.6 3.2 
MoDC NT 8.4 9.2 4.4 
* iNKT cell counts (x106) after 1 week stimulation with the indicated DC pulsed with αGC. All cultures were 
started with 1.5x106 iNKT cells. All iNKT cells were >90% pure before and after culture.  
 
 
 
Stimulation with M312CD1d-DC induces iNKT cell activation and increased IFNγ production 
 Several investigators have demonstrated that CD4- and CD4+ iNKT cells represent 
different subsets with different cytokine secretion patterns when isolated directly ex vivo; 
CD4- iNKT cells produce predominantly type 1 cytokines and CD4+ iNKT cells produce both 
type 1 and type 2 cytokines (18,19). Here, we investigated whether this also holds true after in 
vitro expansion using IL-12 producing DC. iNKT cells isolated from peripheral blood were 
expanded for 2-3 weeks using αGC pulsed M3CD1d-DC followed by a 5 day culture with 
αGC pulsed M3CD1d-DC or M312CD1d-DC. The proportion of CD4+ iNKT cells was 
similar in cultures stimulated with or without IL-12 [67% (range 10-82%) and 68% (range 10-
86%) respectively]. Stimulation with M312CD1d-DC induced increased activation as 
measured by CD161, CD56, CD25 and intracellular CTLA4 and Granzyme B expression 
compared to M3CD1d-DC (0.001<p<0.015 for all parameters, figure 2a). The increase was 
observed in both CD4- and CD4+ iNKT cells (not shown). Rather than inducing a type 1 
skewed cytokine secretion profile, i.e. increase in IFNγ and a decrease in IL-4 production, IL-
12 stimulation resulted in increased numbers of IFNγ (p=0.0003) producing iNKT cells, 
without significantly changing the number of  IL-4 producing iNKT cells (figure 2b). The 
effect of IL-12 was the same on both CD4- and CD4+ iNKT cells (figure 2c and d). The 
modulation of cytokine production by IL-12 resulted in a slight increase in the ratio of IFNγ 
and IL-4 producing iNKT cells, which was statistically significant for the whole population 
and for CD4+ iNKT cells, and borderline significant for the CD4- iNKT cell population 
(p<0.08) (figure 2e). In addition, a very small but distinct population of IL-10 producing 
iNKT cells appeared after stimulation with M312CD1d-DC (figure 2f). Stimulation with 
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M312CD1d-DC induced expression of the lymphoid homing receptor CD62L, known to be 
expressed on early effector CD8+ and central memory conventional T-cells, on a 
subpopulation of both CD4+ and CD4- iNKT cells (figure 2g). The increased expression of 
Granzyme B by M312CD1d-DC stimulated iNKT cells (figure 2 a) did not lead to enhanced 
killing of CD1d+ target cells: Jurkat (figure 2h), MOLT-4 and CD1d transfected Hela (not 
shown). Killing of CD1d- target cells (Daudi, HL60, Hela) was always low (<5%) and could 
not be enhanced by IL-12 (not shown).  
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Figure 2: Stimulation with M312CD1d-DC induces iNKT cell activation and increased IFNγ production. iNKT 
cells were expanded for 2-3 weeks using M3CD1d-DC followed by 5 days culture with either M3CD1d-DC 
(open bars F) or M312CD1d-DC (closed bars J). Phenotype of the resulting iNKT cell lines was determined 
by FACS analysis after gating on CD3+6B11+ iNKT cells. All iNKT cell lines were >90% pure. a) Mean 
fluorescence index (mean ±SD of 6-8 individual experiments) of activation markers (CD161, CD56, CTLA4, 
Granzyme B and CD25). Percentage of IFNγ and IL-4 producing cells (mean±SD of 8 individual experiments) 
among b) all iNKT cells, c) CD4 negative and d) CD4 positive iNKT cells. e) ratio of IFNγ and IL-4 producing 
iNKT cells (mean±SD of 8 individual experiments). f) stimulation with IL-12 induces a small increase in IL-10 
producing iNKT cells (mean±SD of 4 individual experiments). g) increase in number of iNKT cells expressing 
CD62L after stimulation with IL-12 (mean±SD of 6 individual experiments). P values are the result of a paired 
two-sided Student’s T-test.  h) No increase in αGC dependent killing of CD1d positive targets cells (Jurkat) by 
iNKT cells stimulated with IL-12 over-expressing DC.  
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Figure 3: IL-12 stimulated iNKT cells significantly enhance expansion of MART-1 specific CTL. a) iNKT cells 
and IL-12 stimulated iNKT cells (iNKTIL-12) were added (0.2%) to multiple bulk co-cultures (n=8) of isolated 
CD8β T-cells and autologous MoDC pulsed with MART1 peptide alone or with peptide and αGC. Percentage of 
Tm positive CD8+ T-cells is shown, horizontal lines represent the mean, p values are the result of a two sided 
student’s T-test. b) Induced CTL were functional and produced IFNγ in response to HLA-A2.1 positive, MART1 
peptide loaded, JY cells and the MART1 and HLA-A2.1 positive melanoma cell line (Mel-AKR), MART1 
negative JY and MART1 positive but HLA-A2.1 negative Mel-JKO cells are not recognized. Percentage of IFNγ 
positive Tm positive T-cells is shown. Results shown are from one representative donor out of 4 tested. c, d) 
Melanoma patient derived, IL-12 stimulated iNKT cells (iNKTIL-12) were added (0.2%) to multiple bulk co-
cultures of autologous isolated CD8β T-cells and allogeneic HLA-A2 matched MoDC pulsed with MART1 
peptide and αGC. The percentage of Tm positive CD8+ T-cells is shown, horizontal lines represent the median, 
p values are the result of a two sided Mann-Whitney U-test. e, f) Melanoma patient derived, IL-12 stimulated 
iNKT cells (iNKTIL-12) were added (0.2%) to multiple bulk co-cultures of healthy donor derived CD8β T-cells 
and MoDC pulsed with MART1 peptide αGC. The percentage of Tm positive CD8+ T-cells is shown, horizontal 
lines represent the median (e) or mean (f), p values are the result of a two sided Mann-Whitney U-test (e) or two-
sided Student’s T-test (f). 
 
 
IL-12 stimulated iNKT cells significantly enhance expansion of MART-1 specific CTL 
 To analyze the effects of iNKT cells on antigen specific CTL responses, isolated 
CD8β+ T-cells, depleted of iNKT cells, were co-cultured with autologous MoDC. Autologous 
iNKT cell lines were generated using αGC pulsed M3CD1d-DC (iNKT) and M312CD1d-DC 
(iNKTIL-12) as described above, and were added to CD8β+ and MoDC co-cultures. MoDC 
were pulsed with αGC to induce cytokine release by the added iNKT cells and/or MART1 
peptide to stimulate TAA specific CTL. Specific CTL frequencies were measured using 
tetramer (Tm) staining after two in vitro stimulations as described previously (35). Addition 
of iNKT or iNKTIL-12 lead to a significant increase in MART1 specific CTL (p<0.02 and 
p<0.0005 respectively; figure 3a). The iNKT cell effect was αGC dependent; addition of 
iNKT cells had no effect when MoDC were pulsed with peptide alone without αGC. The 
MART1 specific CTL were functionally active as demonstrated by specific IFNγ production 
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by Tm positive CD8+ T-cells in response to either peptide pulsed targets or endogenously 
MART1 expressing melanoma cells. However, addition of iNKTIL-12 did not increase the 
effector function of the induced MART specific CTL (figure 3b). Peptide titration assays 
revealed no difference in functional avidity (not shown). To study the clinical relevance of 
this finding, iNKTIL-12 were generated from four melanoma patients as described above. Since 
the amount of blood that could be obtained was not sufficient to generate sufficient numbers 
of autologous MoDC, CD8β T-cells from two HLA-A2+ patients were stimulated with 
allogeneic HLA-A2 matched MoDC in the absence or presence of iNKTIL-12 (figure 3c and d). 
The two other melanoma patients were HLA-A2 negative and therefore their iNKTIL-12 cells 
were added to co-cultures of CD8β and MoDC of HLA-A2+ healthy donors (figure 3e and f). 
As was observed with the healthy donor derived iNKT cells, addition of melanoma patient 
derived iNKTIL-12 cells lead to a significant increase in MART specific CTL in three out of 
the four donors tested (p<0.03, figure 3c, e and f). In one of the HLA-A2 positive donors a 
high proliferation of presumable alloresponsive CD8 T-cells was observed, which resulted in 
overall relatively low percentages of MART specific CTL. However, an increased, although 
not statistically significant, percentage of MART specific CTL was observed when iNKTIL-12 
cells were added (p=0.11, figure 3d).  
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Figure 4: iNKT cell mediated help is IFNγ 
dependent. a) Multiple bulk co-cultures (n=6 / 
condition) of isolated CD8β T-cells and autologous 
MoDC pulsed with MART1 peptide and αGC were 
set up in a trans-well system (-iNKT). IL-12 
stimulated iNKT cells were added either to the 
lower well (+iNKTlow), to the upper well alone 
(+iNKTup) or in the presence of αGC pulsed MoDC 
(+iNKTup +DCup). Percentage of Tm positive CD8+ 
T-cells is shown, horizontal lines represent the 
mean. Results shown are from one representative 
donor out of three tested, p values are the result of a 
two sided student’s T-test. b) Multiple bulk co-
cultures (n=4/condition) of isolated CD8β T-cells 
and autologous MoDC pulsed with MART1 peptide 
and αGC were set up in the presence or absence of 
IL-12 stimulated iNKT cells (iNKTIL-12) in the 
presence of blocking antibodies against IFNγ, IL-4, 
IL-10 or isotype controls. Percentage of Tm positive 
CD8+ T-cells is shown, horizontal lines represent the 
median. Results are from one donor out of two 
tested, p values are from a two-sided Mann-Whitney 
U-test. c) Multiple bulk co-cultures (n=6/condition) 
of isolated CD8β T-cells and autologous MoDC 
pulsed with MART1 peptide and αGC were set up 
(-), recombinant IFNγ or iNKTIL-12 cells were 
added. Percentage of Tm positive CD8+ T-cells is 
shown, horizontal lines represent the mean, results 
are from one donor out of three tested, p values are 
the result of a two sided Student’s T-test. 
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 iNKT cell mediated help is IFNγ dependent 
 To analyze whether the enhanced expansion of MART1 specific CTL in the presence 
of iNKTIL-12 cells was dependent on cell-cell contact or soluble factors, co-cultures were set 
up in trans-wells. Lower wells contained CD8β+ T-cells and peptide and αGC pulsed MoDC 
(-iNKT; figure 4a). iNKTIL-12 were added to the lower wells (+iNKTlow), the upper wells 
alone (+iNKTup) or together with αGC pulsed MoDC (+iNKTup+DCup). Similar CTL 
frequencies were obtained when iNKT cells were added to the lower wells and to the upper 
wells as long as αGC presenting DC were also present to trigger the iNKT cells, suggesting 
that soluble factors were responsible for the observed enhanced effects (figure 4a). Since 
iNKTIL-12 cells provoked the strongest effect and contained high numbers of IFNγ, IL-10 and 
IL-4 producing cells, MART1 CTL stimulation cultures were performed in the presence of 
iNKTIL-12 cells and IFNγ, IL-10 or IL-4 blocking antibodies. Blocking of IFNγ, IL-4 and IL-
10 had no effect on specific CTL frequencies in the absence of iNKT cells (figure 4b). 
However, the enhanced effect of iNKTIL-12 cells was completely blocked by anti-IFNγ, while 
anti-IL-4 antibodies did not have any effect. Interestingly, in the presence of anti-IL-10 
antibodies the CTL frequencies increased even further (figure 4b). Finally, to confirm that 
IFNγ can indeed enhance the MART1 specific CTL response, soluble recombinant IFNγ was 
added to co-cultures and had similar enhancing effects as iNKTIL-12 (figure 4c). 
 
αGC and MART1 double loaded IL-12 over-expressing MoDC induce activation of iNKT 
cells and increased MART1 specific CTL expansion   
In order to examine whether IL-12 stimulated iNKT cells in PBMC physiologically 
enhance CTL expansion, cultures were started from PBL and αGC/MART1 double loaded 
MoDC. Multiple bulk cultures of total monocyte depleted PBL were stimulated with 
autologous mature MoDC, transfected with MART1 minigene ubi(MART)4 mRNA or 
ubi(MART)4-2A-IL-12  mRNA (35), either loaded with vehicle or αGC. Bulk cultures 
stimulated with αGC loaded MoDC contained significantly higher numbers of iNKT cells, 
which were further increased when DCs were transfected with IL-12 mRNA (figure 5a). As 
expected and previously described by us (35), stimulation with IL-12 over-expressing MoDC 
leads to an increased MART1 specific CTL response (figure 5b). Pulsing with αGC without 
IL-12 over-expression had no significant effect, however IL-12 over-expressing DC pulsed 
with αGC induced significantly more MART specific CTL as compared to either IL-12 over-
expressing DC or αGC pulsed DC (figure 5b). 
 
 
Discussion 
Here we demonstrate that healthy donor derived, expanded iNKT cells, and IL-12 
stimulated iNKT cells in particular, enhance antigen specific CTL responses in vitro. This 
effect was dependent on αGC induced IFNγ production. We have previously demonstrated, 
that despite impaired numbers of iNKT cells in cancer patients, IFNγ production by the 
remaining iNKT cells was not affected (14). Furthermore, iNKT cells from cancer patients 
could be expanded and skewed to produce IFNγ in vitro, to similar levels as healthy donor 
derived iNKT cells (40). In line with these findings we demonstrate here that melanoma 
patient derived, in vitro expanded iNKT cells, enhanced melanoma antigen specific CTL as 
well, demonstrating their  potential for  the enhancement of  CTL responses. Apart from IFNγ,  
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IL-12 can also enhance IL-4 and IL-10 production by conventional T-cells (41,42). Indeed 
after  stimulation  with  IL-12  over-expressing  DC,  not  only  an  increased  number of IFNγ 
producing iNKT was detected, but a small increase in IL-10 producing iNKT cells was 
observed as well. The positive effect of iNKT cell derived IFNγ on CTL proliferation was not 
affected by concomitant IL-4 secretion; blocking of IL-10 however, further enhanced CTL 
expansion. Although only few iNKT cells produced IL-10 (see figure 2f), the amount of IL-10 
may have been sufficient for the inhibiting effect. Alternatively, MoDC derived IL-10 
induced by iNKT cell-MoDC interactions may inhibit CTL expansion. In contrast to our 
findings here, Osada and colleagues previously demonstrated an inhibition of MART1 
specific CTL responses by expanded CD4+ iNKT cells. This inhibition was type 2 cytokine 
(a.o. IL-4 and IL-10) mediated. In the present study the majority of the added iNKT cells was 
CD4+ (80-90%). However, there are several technical aspects which may explain the 
discrepancies. In healthy donors the frequency of circulating iNKT cells ranges from 
undetectable to 0.3% of circulating T-cells. In the present study iNKT cells were added to the 
co-cultures approximating physiological proportions, i.e. 0.2% (1000 iNKT were added to 
0.5x10E5 CD8β+ T-cells). The much higher dose of iNKT cells (i.e. 10%) used by Osada and 
co-workers may have had different effects on CTL responses. IFNγ effects may come 
apparent at lower doses, while inhibition by IL-4 may become effective at higher 
concentrations. Both Osada et al. and Ho et al. observed a decline in antigen specific CTL 
when free αGC and antigenic peptide were added to total PBMC and autologous DC co-
cultures (28,29). It was concluded that this was due to type 2 cytokine release by CD4+ iNKT 
cells and lysis of APC and/or activated T-cells by CD4-CD8αα+ iNKT cells respectively. 
Addition of free MART peptide and αGC enables peptide presentation by (MART specific) 
CTL as well as αGC presentation by activated T-cells expressing CD1d (28) facilitating 
fratricide and iNKT cell mediated killing of MART specific CTL respectively, which may 
lead to reduced MART specific CTL rather than increased frequencies. Here, lysis of 
Figure 5: αGC and MART1 double loaded 
IL-12 over-expressing MoDC induce 
activation of iNKT cells and increased 
MART1 specific CTL expansion. Multiple 
bulk cultures (n=8/condition) of monocyte 
depleted PBL were stimulated with 
autologous MoDC transfected with 
MART1minigene mRNA or MART1 
minigene-2A-IL-12 mRNA, pulsed with 
either vehicle or αGC. The percentage of 
a) iNKT cells and b) MART1 Tm positive 
T cells was determined in each bulk culture 
1 week after the second stimulation. 
Horizontal lines represent the mean, results 
are from one donor out of two tested, p 
values are the result of a two sided 
student’s T-test. 
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 activated MART1 specific CTL is less likely to occur because MART1 was either introduced 
by mRNA transfection or the peptide was loaded, as was αGC, on DC before addition to total 
PBL or isolated CD8β+ T-cells. In vivo, αGC loading specifically on DC also appears to be 
important, since in mice treatment with free αGC induced iNKT cell anergy in contrast to 
adoptive transfer with αGC pulsed DC, which induces prolonged iNKT cell responsiveness 
(43). Similarly, in humans free αGC induces immune activation only after the first injection 
without iNKT expansion (44), while adoptive transfer with mature αGC pulsed DC leads to a 
sustained expansion of iNKT cells (45). Addition of free αGC to total PBMC may lead to 
presentation by non-professional APC leading to iNKT cell unresponsiveness. Furthermore, 
to provide iNKT cell mediated help for  antigen specific CTL induction in vivo, the same DC 
had to present both the peptide and the glycolipid (7,8). This is in contrast to our transwell 
results, where iNKT cells activated by αGC pulsed DC in the upper well could enhance CTL 
responses induced by antigen loaded MoDC in the lower well. This is probably due to the 
experimental conditions: a confined environment of a small well where cytokine 
concentrations remain high and can easily reach all the cells versus the in vivo situation where 
cytokine levels rapidly diffuse, and the differentially loaded DC have a low chance of ending 
up in close proximity to each other in the secondary lymphoid organs. 
The cytokine neutralization experiments revealed that IFNγ is at least one soluble 
factor responsible for the enhanced proliferation of antigen specific CTL, this effect was αGC 
dependent. It is not yet clear how the iNKT cell derived IFNγ enhances CTL responses. It 
may act together with CD40 signaling provided by helper cells present in the co-cultures to 
enhance IL-12 production by MoDC, which is an essential third signal for the development of 
CTL responses. However, as we have previously demonstrated for help provided by irradiated 
PBL (35) or isolated NK cells (46), CTL expansion is even further enhanced by iNKT cells 
(figure 5b) when DC over-express IL-12. These results suggest that enhancing IL-12 secretion 
by DC is not the only mechanism at work here. Alternatively, IFNγ enhances CTL responses 
by positively affecting antigen presentation, at least in those experiments using MART1 
mRNA transfection for antigen loading of DC, through up-regulation of HLA class I 
expression and optimizing access of antigenic peptides to HLA class I (47) or by direct 
signaling through the IFNγR on CD8+ T-cells (48).  
MART1 presenting MoDC pulsed with αGC without IL-12 over-expression did not 
increase CTL expansion within PBL (figure 5b), in contrast to when expanded iNKT cells 
were added (figure 3a). This may be due to the type 1 skewing growth factor IL-15, which 
was added (next to IL-2 and IL-7) during the in vitro expansion of iNKT cells. This may 
generate iNKT cells more prone to produce IFNγ than the iNKT cells in the PBL experiments 
to which IL-2 and IL-7 but no IL-15 was added. This IL-15 mediated pre-activation may be 
necessary in the absence of IL-12 for sufficient iNKT cell derived IFNγ, while in the presence 
of IL-12, αGC does have an effect on CTL expansion. 
The opposing effects of iNKT cells, i.e. on enhancing anti-tumor immune responses 
on the one hand and inhibiting auto-immunity on the other hand have been explained by the 
existence of iNKT cell subsets, based on CD4 and CD8αα expression, secreting distinct 
cytokine profiles ex vivo (18,19). Here we show that upon culture of human blood derived 
iNKT cells the distinction based on CD4 expression becomes less clear. Both CD4- and CD4+ 
iNKT cells produced IFNγ as well as IL-4, and IFNγ production was enhanced by IL-12 in 
CD4- as well as CD4+ iNKT cells, demonstrating the plasticity of iNKT cell subsets. The ratio 
of CD4-/CD4+ iNKT cells also changed during in vitro culture. Human CD4+ and CD4- iNKT 
cells have differential homeostatic requirements, CD4- iNKT cells proliferate with a higher 
rate in response to IL-15, while CD4+ iNKT cells respond better to IL-7 in vitro (49). 
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Nevertheless, the CD4-/CD4+  ratio is reduced upon culture in vitro irrespective of the 
cytokine used, due to a higher proliferation rate of CD4+ iNKT cells (50), which may be due 
to the fact that CD4- iNKT cells have been through more cell divisions in vivo as illustrated 
by a decrease in TRECs in CD4- iNKT cells (49). IL-12 stimulation induced an overall 
increase in activation markers, but despite the increase in Granzyme B expression, cytolytic 
activity was not enhanced. This is probably due to the fact that the expression of NKG2D, 
which is thought to play an important role in cytolytic activity by conventional NK and T-
cells (51), is not modulated by IL-12 (not shown).  
  In conclusion, IFNγ production by iNKT cells can be increased, irrespective of CD4 
expression, by stimulating with IL-12 producing DC. These iNKT cells enhance antigen 
specific CTL expansion in an IFNγ dependent fashion. Phase I studies aiming at increasing 
iNKT cell numbers and activation by i.v. injection of αGC, αGC pulsed DC or in vitro 
expanded iNKT cells were shown to be safe (44,45,52). Both, vaccination with αGC pulsed 
mature DC and iNKT cell adoptive transfer, resulted in an increase in circulating iNKT cell 
numbers and IFNγ producing PBMC but no clinical responses were observed. Using the 
approach described here, the efficacy of both treatment modalities may be enhanced. In vitro 
expansion of iNKT cells using IL-12 over-expressing (allogeneic) DC will lead to an iNKT 
cell population for adoptive T-cell transfer which is superior in providing help for antigen 
specific CTL. However, additional treatment with αGC, presented by DC, may be needed to 
re-activate the iNKT cells in vivo. An even more effective form of iNKT cell mediated 
immunotherapy would be vaccination with antigen and αGC loaded, IL-12 over-expressing, 
DC. This approach is expected to lead to an increased anti-tumor immune response mediated 
by TAA specific CTL as well as IFNγ producing iNKT cells. 
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Chapter 4 
 
In vitro expanded human invariant Natural Killer T-cells promote 
functional activity of Natural Killer cells 
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 Abstract 
Invariant Natural Killer T (iNKT) cells play a pivotal role in cancer immunity through trans-
activation of effector cells via swift cytokine secretion. In mice, iNKT cell activation by α-
Galactosylceramide (α-GC) induces potent NK cell-mediated anti-tumour effects. Here we 
investigated whether human iNKT cells could enhance NK cell functional activity in vitro. 
iNKT cell activation by α-GC treatment of peripheral blood mononuclear cells (PBMC) was 
not sufficient to enhance NK cell effector functions. However, addition of in vitro expanded 
iNKT cells to PBMC enhanced NK cell-mediated cytotoxicity in an α-GC-dependent manner. 
NK cell activation by iNKT cells was primarily mediated by soluble factors, and could be 
enhanced by the NK cell activating cytokine IL-21. These results suggest that adoptive 
transfer of ex vivo expanded iNKT cells will enhance NK cell function and is expected to 
enhance the efficacy of cancer immunotherapy, particularly in combination with IL-21 and α-
GC. 
 
 
Keywords: human, invariant NKT cells, α-Galactosylceramide, NK cells, cytotoxicity, 
interferon-γ 
 
 
Abbreviations: α-GC: α-galactosylceramide; CTL: cytotoxic T lymphocytes; DC: dendritic 
cells; IFN-γ: interferon-γ; iNKT: invariant natural killer T-cells; moDC: monocyte derived 
dendritic cells; NK: natural killer cells; PBMC: peripheral blood mononuclear cells; TNF-α: 
tumour necrosis factor-α  
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Introduction  
Invariant Natural Killer T (iNKT) cells are T lymphocytes characterized by an 
invariant TCR α chain gene rearrangement (Vα24-Jα18 paired with Vβ11 in humans) and co-
expression of NK cell receptors (1). This invariant TCR recognizes glycolipid ligands, such as 
the putative endogenous ligand isoglobotrihexosylceramide (iGb3), bacterial glycosphyngo-
lipids or the artificial ligand α-Galactosylceramide (α-GC), in the context of the monomorphic 
CD1d antigen-presenting molecule (2-7). Upon stimulation, iNKT cells have the capacity to 
rapidly produce large amounts of cytokines e.g. IFN-γ and IL-4 (1), leading to the trans-
activation of other immune cells, such as dendritic cells (DC), natural killer (NK), T and B 
cells (8-11). In mice, iNKT cells play an important role in tumour immunosurveillance (8;12-
17). In vivo iNKT cell activation by α-GC or α-GC-loaded DC can induce potent anti-tumour 
immune responses in various tumour models by NK cell trans-activation (18-22). 
 In humans, we and others have demonstrated that cancer patients have reduced 
circulating iNKT cell numbers (23-27). In addition, we recently observed in a prospective 
study that a relatively large circulating iNKT cell pool predicts favourable clinical outcome in 
individuals with squamous cell carcinoma of the head and neck (28). These findings suggest 
that cancer patients might benefit from immunotherapy aimed at the expansion of their 
peripheral blood iNKT cell pool.  
 We have recently demonstrated that human iNKT cells can enhance tumour antigen 
specific cytotoxic T lymphocyte (CTL) responses (29). Next to CTL, human NK cells have a 
high cytolytic potential against tumour cells. NK cells discriminate between normal and 
tumour cells due to the loss of NK cell inhibiting MHC class I molecules (30). Since MHC 
class I loss renders tumour cells invisible to MHC class I restricted CTL (31), it is relevant to 
examine whether human iNKT cells not only enhance tumour antigen specific CTL responses 
but also induce NK cell functional activity. Here, we investigated the effect of human iNKT 
cell activation on phenotypic and functional NK cell activation.  
 
 
Materials and methods 
Cell lines and culture media 
IMDM (Cambrex, Verviers, Belgium) was supplemented with 10% Foetal Calf Serum 
(Perbio, Helsingborg, Sweden) for culture of peripheral blood mononuclear cells (PBMC), 
monocyte-derived DC (moDC) and the NK-sensitive K562 (ATCC, Manassas, VA, USA) cell 
line, or 8% human pooled serum (Sanquin, Amsterdam, The Netherlands) for the culture of 
iNKT cells. Both media were supplemented with 100 IU/ml sodium penicillin (Yamanouchi 
Pharma, Leiderdorp, The Netherlands), 100μg/ml streptomycin sulphate (Radiumfarma-
Fisiopharma, Naples, Italy) and 0.01 mM β-mercaptoethanol (Merck, Darmstadt, Germany). 
 
Isolation of peripheral blood mononuclear cells (PBMC), NK cell purification, iNKT cell 
expansion 
PBMC were isolated from buffycoats from healthy donors obtained from Sanquin 
Blood Bank (Amsterdam, The Netherlands) by density gradient centrifugation using 
Lymphoprep (Nycomed, Oslo, Norway). The number of cells was determined and PBMC 
were cryopreserved in separate batches until use. To generate moDC, 50x106 PBMC were 
allowed to adhere in a T75 flask for 60-90 min. Non-adherent cells were washed away by 
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 rinsing the flask with PBS. Adherent monocytes were then cultured in the presence of 1000 
IU/ml GM-CSF (Schering-Plough, Kenilworth, NJ, USA) and 10 ng/ml IL-4 (R&D Systems, 
Abingdon, UK) for 7 days. Maturation was induced by 48hs culture in the presence of 30% 
v/v monocyte conditioned medium (MCM) and 50 ng/ml TNF-α (Strathmann Biotech, 
Hanover, Germany) as described (32). 
Vα24+ Vβ11+ iNKT cells were enriched from PBMC by positive selection using the 
iNKT cell specific antibody 6B11 (BD Biosciences, San Jose, CA, USA) and anti-mouse Ig-
coated magnetic beads mAb (Milteny Biotec, Bergisch Gladbach, Germany) by MACS 
sorting. The non-selected PBMC (iNKT cell-depleted PBMC, containing < 0.00% iNKT cells 
among CD3+ lymphocytes) were cryopreserved until use. The selected iNKT cells were 
expanded by weekly stimulation with irradiated autologous PBMC at a 1:1 iNKT : PBMC 
ratio in the presence of 100ng/ml α-GC (KRN7000, kindly provided by Dr Shigeyuki 
Yamano, KIRIN Brewery, Gunma, Japan), 40 IU/ml recombinant human (rh) IL-2, 5 ng/ml 
rhIL-7 and 5 ng/ml rhIL-15 (all purchased from Strathmann Biotech, Hanover, Germany). 
NK cell enrichment was performed by negative selection using Easysep human NK 
cell enrichment kit (StemCell Technologies, Grenoble, France) according to manufacture’s 
recommendations. Achieved purity was higher than 99.5%. 
 
Evaluation of NK cell activation by iNKT cells 
 Donor PBMC (5x106 cells/ml) were cultured in the presence or absence of 100 ng/ml 
α-GC. In vitro expanded iNKT cells were added to iNKT cell-depleted PBMC at different 
percentages, as specified, and cultured for 5 days. In some experiments, IL-21 (25 ng/ml) was 
added to the cultures on day 2.  
 In order to analyse the involvement of soluble factors, 2x106 NK cells were co-
cultured with 2x105 iNKT cells, 2x105 α-GC-pulsed moDC or both in a trans-well system 
(0.4μm pore size, Corning Life Science, Schiphol-Rijk, The Netherlands) or in the presence 
of 400 IU/ml of IFN-γ (Biosource, Camarillo, CA, USA), or 4 μg/ml IFN-γ neutralizing 
antibody  (R&D Systems, Abingdon, UK), for 5 days. 
 
NK cell effector function analysis 
After 5 days of iNKT cell-mediated stimulation of either PBMC or NK cells, NK cell 
effector functions were analysed. Cytolytic activity of the NK cells to K562 cells was 
assessed using a standard chromium release assay. Briefly, 1x106 K562 target cells were 
labelled with 100 µCi of Na2[51Cr]O4 (Amersham, Bucks, U.K.) for 2h at 37°C and washed 
extensively. Effector PBMC were harvested, washed and added to 5x103 target cells at the 
indicated E:T ratios in triplicate wells of a round-bottom 96-well plate (Nunc). After 18h 
incubation at 37°C, 50 µl of the supernatant was harvested, and its radioactive content was 
measured. The percentage specific lysis was defined as follows: [(experimental release - 
spontaneous release) / (maximum release - spontaneous release)] x 100%.   
Alternatively, NK cell cytotoxic capacity was determined in a CD107a (LAMP1) 
translocation assay (33). NK cells (1x105 cells) were cultured in the presence of PE-labelled 
mouse anti-human CD107a (BD Biosciences, San Jose, CA, USA) and 4μM monensine in the 
absence (background translocation) or presence of K562 target cells (0.5x105 cells). After 5 
hours, cells were washed and counterstained with CD3 and CD56 for at least 30 min at 4ºC. 
Flow cytometry was performed on a FACSCALIBURTM apparatus and data were analysed 
using CellQuestTM software (BD Biosciences, San Jose, CA, USA). The percentage of 
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CD107a positive NK cells and the mean fluorescence index (MFI) of CD107a expression 
induced by K562 were calculated as follows:  
% CD107a+ = % CD107a+ upon K562 stimulation - % CD107a+ background 
MFI = mean fluorescence intensity upon K562 stimulation / background mean fluorescence 
intensity.  
 
Cytokine detection 
For determination of cytokine secretion, supernatants were harvested after 5 days of 
culture. Supernatants were analysed for IL-2, IFN-γ and TNF-α by ELISA using the 
appropriate PeliKine Compact human ELISA kit (Sanquin, Amsterdam, The Netherlands) 
according to the manufacturer’s recommendations. 
 
Surface marker expression on iNKT and NK cells 
FITC-, PE-, PerCP-Cy5- or APC-labelled isotype controls and mouse anti-human 
6B11, CD3, CD4, CD16, CD25, CD69 (BD Bioscience, San Jose, CA, USA), Vα24, Vβ11 
(Immunotech, Marseille, France) and CD56 (IQ products, Groningen, The Netherlands) were 
used to determine the phenotype of NK and iNKT cells by flow cytometry. Cells were 
incubated with the antibodies for at least 30 min at 4ºC. Flow cytometry was performed on a 
FACSCALIBURTM apparatus and data were analysed using CellQuestTM software (BD 
Biosciences, San Jose, CA, USA). 
 
IFN-γ and TNF-α intracellular cytokine staining (ICCS) 
Intracellular IFN-γ and TNF-α staining was performed using the BD cytofix/cytoperm 
plus kit (BD Bioscience, San Jose, CA, USA) according to the manufacturer’s instructions. 
After 5 days of iNKT cell-stimulation of NK cells, GolgiPlug was added to each well (0.1% 
v/v) for 5h. iNKT and NK cells were washed and stained with FITC-labelled 6B11 and 
PerCP-Cy5-labelled CD3, and APC-labelled CD56 respectively, followed by intracellular 
staining with PE-labelled anti-IFN-γ or PE-labelled anti-TNF-α (both from BD Bioscience, 
San Jose, CA, USA). 
 
Statistics 
Normality of distribution of the data was analysed with Kolmogorov-Smirnov test and 
Q-Q plots. The non-parametric Wilcoxon Signed Ranks test was used to analyse increase in 
cytokine (IFN-γ and TNF-α) production. Otherwise, a parametric paired Student’s T-test was 
used to analyse the differences between groups. Non-parametric correlation Spearman’s test 
was performed to investigate the relation between cytokine secretion and up-regulation of 
activation markers. P < 0.05 was considered significant. All data were analysed using SPSS 
14.0 software. 
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 Results 
iNKT cell activation with α-GC is not sufficient to  augment NK cell activity 
In vitro stimulation of PBMC, containing various numbers of iNKT cells (range 0.01-
0.19% iNKT cells among CD3+ lymphocytes), with α-GC for up to 5 days induced iNKT cell 
activation, as demonstrated by an increased proportion of iNKT cells expressing CD69 and 
CD25 (p<0.001 and p=0.017, respectively) (figures 1a and b). A limited, but statistically 
significant NK cell activation was observed as well (p=0.024 and 0.027, respectively) (figures 
1c and d). However, this limited phenotypic NK cell activation may not be biologically 
significant since no enhanced NK cell-mediated cytotoxicity against K562 was observed 
(figure 1e). Moreover, IFN-γ, as well as TNF- α, secretion was only modestly increased 
following α-GC treatment of total PBMC [Mean (range) 53 (0-194) vs 185 (0-768) pg/ml 
IFN-γ, and 11 (0-30) vs 25 (5-62) pg/ml TNF-α, in supernatants of unstimulated vs α-GC-
stimulated PBMC, p>0.05]. Of note, no increase in IL-2 secretion could be detected. Thus, 
while addition of α-GC to total PBMC was sufficient to induce phenotypic activation of iNKT 
cells accompanied with a modest increase in cytokine production, this activation was 
insufficient to establish enhanced NK cell lytic activity. 
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Figure 1: Invariant NKT cell activation by PBMC stimulation with α-GC. PBMC were stimulated with 
100ng/ml α-GC. Activation status of a, b) iNKT cells (defined as CD3+ 6B11+ cells) and c, d) NK cells (defined 
as CD3- CD56+ cells) after 5-days culture. a, c) Example dot-plots of CD69 and CD25 expression on iNKT and 
NK cells after 5 days without and with α-GC. The numbers in the right upper quadrant represent the % of 
positive cells. b, d) The graphs show the mean ± SEM of CD69 and CD25 expression of 5 independent 
experiments performed with individual donors, in the absence (open bars) or presence (solid bars) of α-GC. 
Paired Student’s T-test: *p<0.05. e) NK cell effector function was assessed by K562 cytotoxic assays. Results 
from one representative experiment out of 7 performed are shown. 
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Addition of expanded iNKT cells to iNKT-depleted PBMCs enhances NK cell cytotoxicity in 
an α-GC-dependent manner  
 We have previously developed a method to generate high purity pro-inflammatory 
iNKT cell lines from healthy donors in vitro (34). Using an adapted version of this method, 
we expanded iNKT cells from healthy donor PBMC to investigate their capacity to activate 
NK cells. After 2 expansion rounds, purity of iNKT cells was more than 90%, and the cells 
exhibited an activated phenotype, demonstrated by CD69 expression (median 7%, range 1-
34%, n=5) and an increased CD25 expression (median 46%, range 32-66%, n=5), compared 
to resting iNKT cells (figure 1b, open bars). Expression of both activation markers could be 
further increased by antigen stimulation (data not shown).  
 To test the capacity of these pre-activated iNKT cells to activate NK cells, iNKT-
depleted PBMC were co-cultured with increasing percentages (within the physiological range, 
i.e. 0.02%, 0.10% and 0.50%) of in vitro expanded iNKT cells (>90% pure) for 5 days. 
Addition of iNKT cells resulted in an iNKT cell dose-dependent increase in IFN-γ (figure 2a) 
and TNF-α (data not shown) secretion. Higher cytokine levels were detected in cultures 
containing α-GC, although there was a large variation between donors. Ex vivo stimulation of 
total PBMC with α-GC leads to much lower levels of IFN-γ (see previous paragraph; 185 (0-
768) pg/ml), which is indicative for enhanced cytokine secretion by expanded iNKT cells 
compared to ex vivo stimulated iNKT cells. Addition of pre-activated iNKT cells did not 
modify percentage of NK cells but enhanced CD25 and CD69 expression on NK cells to a 
similar extend as adding α-GC to total PBMC (data not shown). Of note, after 5 days the 
proportion of iNKT cells in culture remained also unchanged. However, in addition to this 
phenotypic activation, NK cell functional activity was enhanced as well. Despite some 
variation in K562 lysis (5.4 - 19.9%) due to differences in NK cell frequencies between 
donors, the enhanced effect of the iNKT cells was observed in all donors (1.2 - 3.3 fold-
increase in cytotoxicity at E:T=12.5:1). In the absence of α-GC, the addition of expanded 
iNKT cells to PBMC had a limited effect on NK cell cytotoxicity (figure 2b). On the other 
hand, NK cell ability to kill K562 was substantially augmented when PBMC were co-cultured 
with in vitro expanded iNKT cells in the presence of α-GC, in an iNKT cell dose-dependent 
manner (figure 2c). This effect is not mediated directly by iNKT cells, as they have been 
shown to be unable to kill K562 (25;35).  
*
*
*
0.00% 0.02% 0.10% 0.50%
0
2500
5000
7500
10000
12500
without α-GC
with α-GC
iNKT cells
IF
N
- γ 
se
cr
et
io
n 
(p
g/
m
l)
CB
12.5:1 25:1
0
10
20
30
40
50
60
without α-GC
E:T ratio
%
 c
yt
ot
ox
ic
ity
0.00% iNKTs
0.02% iNKTs
0.10% iNKTs
0.50% iNKTs
A
12.5:1 25:1
0
10
20
30
40
50
60
with α-GC
E:T ratio
%
 c
yt
ot
ox
ic
ity
 
Figure 2: α-GC-dependent NK 
cell activation by expanded 
iNKT cells. iNKT-depleted 
PBMC were co-cultured with 
0.02, 0.10 and 0.50% in vitro 
expanded iNKT cells, in the 
absence or presence of iNKT 
cell ligand. After 5 days, a) 
IFN-γ secretion in supernatants 
was determined by ELISA. 
Wilcoxon Signed Ranks test: 
*p<0.05. b, c) NK cell effector 
function was assessed by K562 
cytotoxic assays. Results from 
one representative experiment 
out of 5 performed are shown. 
iNKT-depleted PBMC (open 
squares) were co-cultured with 
0.02, 0.10 and 0.50% in vitro 
expanded iNKT cells (solid 
symbols) b) in the absence or c) 
presence of α-GC.  
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 IL-21 is a strong NK cell activating cytokine. Indeed, in vivo activation of murine 
iNKT cells by α-GC injection, followed by IL-21 administration, enhanced NK cell activity 
(13). Therefore, we analysed whether sequential activation of human iNKT (with α-GC) and 
NK cells (with IL-21) could further enhance NK cell-mediated cytotoxicity. Invariant NKT-
depleted PBMC were co-cultured with 0.20% in vitro expanded iNKT cells (>90% pure), in 
the presence or absence of α-GC for 5 days. At day 2, IL-21 was added to the co-cultures. The 
proportions of iNKT and NK cells remained unaltered. The percentage in NK cell-mediated 
K562 killing varied between 2.2  and 6.7%, which was modestly increased when PBMC were 
stimulated with in vitro expanded iNKT cells followed by IL-21 in the absence of α-GC in all 
donors tested (1.3 – 3.9 fold increase at E:T=12.5:1) (figure 3a). In the presence of α-GC, 
combination of both treatments induced a strong increase in NK cell cytolytic activity (5.5 - 
10.3 fold increase) (figure 3b). These data show that NK cell cytotoxic function can be 
enhanced by sequential activation of human iNKT (with α-GC) and NK cells (with IL-21).  
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IFN-γ is sufficient but not necessary for iNKT mediated NK cell activation. 
To analyse whether the enhanced activation of NK cells by iNKT cells is dependent on 
cell-cell contact, soluble factors or both, co-cultures were set up in trans-wells. Lower wells 
contained purified NK cells alone (-iNKT). Autologous in vitro expanded iNKT cells were 
added to the lower wells (+iNKTlow) or to the upper wells (+iNKTup) alone or together with α-
GC-pulsed moDC (+iNKTlow+DClow and +iNKTup+DCup, respectively). Appropriate moDC 
controls were included (+DClow and +DCup). Analysis of the culture supernatants showed a 
significant increase in IFN-γ (Wilcoxon Signed Ranks test, p=0.018) (figure 4a), and to a 
lesser extent TNF-α (Wilcoxon Signed Ranks test, p=0.018) (data not shown), secretion in 
wells containing both iNKT cells and α-GC-pulsed moDC, compared to NK cells alone. 
Intracellular cytokine analysis revealed that both cytokines were produced by iNKT cells and 
not by NK cells (data not shown). Interestingly, IL-2 levels in supernatants dropped under 
these conditions (data not shown), suggesting IL-2 consumption by NK cells, iNKT cells or 
both. In parallel with IFN-γ secretion, NK cell activation status (figures 4b and 4c), 
particularly CD69 expression, was augmented when NK cells were cultured with iNKT cells 
in the presence of α-GC-pulsed moDC. Likewise, NK cell lytic capacity against K562 
Figure 3: Effect of α-GC-stimulated 
iNKT cells and IL-21 combination 
on NK cell activation. K562 
cytolysis performed with a) 
unstimulated and b) α-GC-
stimulated iNKT-depleted PBMC 
without (open squares) or with 
(solid triangles) 0.20% in vitro 
expanded iNKT cells, in the absence 
(solid lines) or presence (dashed 
lines) of IL-21. Results shown are 
from one representative experiment 
out of 3 performed.  
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induced by iNKT cells, determined by CD107a translocation, was also enhanced under these 
conditions. This was illustrated by an increase both in the percentage of NK cells that 
translocated CD107a (1.3–3.9 fold increase) (figure 4d) and in the amount of degranulation 
on a single cell level (1.4–2.5 fold increase in CD107a surface expression level) (figure 4e). 
NK cell activation could likely be attributed to the iNKT cells because addition of α-GC-
pulsed moDC alone, either in the lower or in the upper wells, had no effect on NK cell 
activation.  
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Figure 4: NK cell activation by expanded human iNKT cells is mediated by soluble factors, the production of 
which is dependent on iNKT cell - α-GC-loaded moDC contact. Trans-well experiments were performed by 
culturing purified NK in the lower wells (-iNKT).  Autologous in vitro expanded iNKT cells were added to the 
lower wells (+iNKTlow) or to the upper wells (+iNKTup) alone or together with α-GC-pulsed moDCs 
(+iNKTlow+DClow and +iNKTup+DCup, respectively). Appropriate moDC controls were included (+DClow and 
+DCup). After 5 days, a) IFN-γ secretion in supernatants was assessed by ELISA (mean ± SEM of 7 individual 
experiments). Wilcoxon Signed Ranks test: *p<0.05. NK cell activation was determined as up-regulation of b) 
CD69 and c) CD25 expression (mean ± SEM of 5 individual experiments). Paired Student’s T-test: *p<0.05. NK 
cell lytic capacity against K562 was determined as d) percentage of CD107a positive cells and e) CD107a MFI 
within NK cell population (mean ± SEM of 3 individual experiments). 
 
These data suggest a role for soluble factors in iNKT cell-mediated NK cell activation. 
Indeed, correlation analysis showed a significant correlation between increase in IFN-γ 
secretion and up-regulation of CD69 expression (p<0.001) (figure 5a), as well as CD107a 
translocation by NK cells (p<0.001) (figure 5b). Correlation was also observed for TNF-α 
(p=0.003 and <0.001, respectively) (data not shown). To confirm that IFN-γ can indeed 
enhance the NK cell response, soluble recombinant IFN-γ was added to NK cell cultures. 
Indeed, addition of IFN-γ had similar enhancing effect as iNKT cells: up-regulation of CD69 
and increase in lytic function in both donors tested (figures 6a and 6b). However, the 
enhanced effect of iNKT cells was not blocked by an IFN-γ neutralizing antibody in either of 
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 the two donors tested (figures 6c and 6d), while IFN-γ secretion was completely inhibited 
(data not shown). These results suggest that beside IFN-γ, other soluble factors, such as TNF-
α or IL-2, can play a role in NK cell activation.  
Interestingly, higher cytokine levels, which were associated with the stronger NK cell 
activation, were induced when NK cells were cultured in contact with both iNKT cells and α-
GC-loaded moDC compared to NK cells cultured with iNKT cells and α-GC-loaded moDC in 
the trans-well, indicating a role for cell-cell contact between NK and iNKT cells next to 
soluble factors. This is also suggested by the observation of slight, although not significant, 
increase in cytokine secretion, and NK cell activation, after co-culture of NK cells in contact 
with iNKT cells alone (+iNKTlow) in some of the donors (figure 4).  
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Discussion 
We investigated whether human iNKT cells activated by α-GC could promote NK cell 
activation, in the context of improving NK cell-mediated tumour immunotherapies. In murine 
models, resident iNKT cells can augment anti-tumour responses upon systemic treatment with 
α-GC or α-GC-loaded DC, as a result of NK cell trans-activation by iNKT cells (13;19;22). 
Circulating iNKT cells of patients with cancer are significantly reduced compared to healthy 
controls (23-27). Nonetheless, the iNKT cells in these patients still possess the capacity to 
proliferate and to secrete IFN-γ when properly stimulated in vitro (28). This suggests that 
iNKT cells of cancer patients, though reduced in number, may still be capable of enhancing 
anti-tumour responses in a physiological setting or after therapies aiming at their increase and 
activation. One approach to achieve the latter could be by systemic α-GC treatment. Here we 
demonstrate that stimulation of total PBMC with α-GC strongly promotes phenotypic 
activation of iNKT cells as evidenced by a highly increased expression of CD69 and CD25. 
However, α-GC induced only a modest increase in IFN-γ production. Although NK cells 
became phenotypically activated, functional activity of NK cells was not enhanced by this 
approach. In vivo, systemic treatment with free α-GC in mice induces iNKT cell anergy, 
rendering iNKT cells unresponsive to subsequent α-GC treatment (11). Similarly, 
administration of free α-GC in humans induces a transient and limited increase of cytokines 
(IFN-γ, TNF-α, IL-12 and GM-CSF) without enhancing NK cell cytolytic activity. 
Figure 5: Human iNKT cell-mediated NK cell activation correlates with IFN-γ cytokine secretion. Spearman’s 
correlation between increase in IFN-γ secretion and a) CD69 up-regulation on NK cells and b) enhanced NK 
cell lytic capacity against K562.  
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Furthermore, the transient cytokine increase was only observed in patients with normal pre-
treatment iNKT cell numbers (36). These results combined with the data we present here 
where stimulation with free α-GC, even of PBMC derived from healthy donors with relatively 
high numbers of iNKT cells, is not sufficient to enhance iNKT cell numbers and NK cell-
mediated cytolytic activity, exemplify that alternative treatments to expand and activate iNKT 
cells in vivo are warranted. This can be achieved either by vaccination with α-GC-pulsed 
mature moDC or by adoptive transfer of in vitro expanded iNKT cells. In this study we 
demonstrate an enhanced, α-GC-dependent, NK cell activation status and cytotoxic effector 
function upon addition of expanded and pre-activated iNKT cells. Furthermore, we 
demonstrate that sequential activation of in vitro expanded human iNKT cells with α-GC, 
followed by IL-21 treatment to mature the iNKT cell-activated NK cells into highly cytotoxic 
effector cells, strongly enhanced NK cell cytotoxicity. Previously, Lin et al. (37) showed up-
regulated CD69 expression on NK cells early after addition of in vitro expanded iNKT cells 
to PBMC, but CD25 expression was not affected. Here we show that in vitro expanded human 
iNKT cells not only promote phenotypic activation of NK cells, but induce functional NK cell 
activation as well. Both effects were dependent on α-GC. Transwell experiments showed that 
iNKT cell-mediated NK cell activation is mainly mediated by soluble factors, and correlates 
with cytokine (IFN-γ and TNF-α) production. Recombinant IFN-γ induced a similar level of 
NK cell activation as addition of iNKT cells. However, human iNKT cell-mediated NK cell 
activation was not solely dependent on IFN-γ, as neutralization of IFN-γ did not abrogate the 
effects of iNKT cells (figures 6c and b). Interestingly, when NK cells were co-cultured with 
iNKT cells in the presence of α-GC-loaded moDC, IL-2 completely disappeared from 
supernatants (data not shown), most likely due to consumption during NK cell activation. 
Thus other factors such as TNF-α or IL-2 may be sufficient to induce NK cell activation. A 
role for IL-2 was indeed demonstrated by Metelitsa et al., who showed that the iNKT cell-
mediated enhancement of NK cell activity was primarily mediated by IL-2, an effect which 
was enhanced by IFN-γ (38). However in contrast to our findings these authors demonstrated 
a small but significant effect of IFN-γ neutralization while the addition of recombinant IFN-γ 
had only an effect when added in combination with IL-2. These differences may be explained 
by different dosages of recombinant IFN-γ added and the experimental conditions: i.e. the 
addition of iNKT cell culture supernatants versus the addition of iNKT cells in trans-wells. 
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Figure 6: IFN-γ is sufficient but not 
necessary for iNKT mediated NK cell 
activation. 2x106 NK cells were co-cultured 
with 2x105 α-GC-loaded moDC. 400IU/ml 
soluble recombinant IFN-γ or 2x105 in vitro 
expanded iNKT cells were added. a) 
Percentage of CD69+ cells within NK cell 
population is shown. b) NK cell lytic 
capacity against K562 was determined as 
CD107a MFI. NK cell cells were cultured 
alone or with in vitro expanded iNKT cells in 
the presence or absence of α-GC-loaded 
moDC in a trans-well system, in the presence 
of 4μg/ml blocking antibodies against IFN-γ 
(solid bars) or isotype control (open bars). c) 
Percentage of CD69+ cells within NK cell 
population is shown. d) NK cell lytic 
capacity against K562 was determined as 
CD107a MFI. The graphs show the results of 
one experiment out of two performed. 
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 In addition to soluble factors, direct contact-mediated interactions between NK and 
iNKT cells appear to play a role as well in iNKT cell-mediated NK cell activation. It is not 
yet clear which molecules are involved in iNKT cell-NK cell interactions, and whether TCR 
ligation is required. While endogenous glycolipid antigens, such as iGb3 (6), could act as 
iNKT cell ligand, CD1d expression on NK cells has not been demonstrated. Other co-
stimulatory interactions may play a role. Of interest in this respect is the APC like properties 
of activated NK cells, expressing co-stimulatory molecules such as CD80, CD86 and OX40 
ligand as well as MHC class II (39).   
We have recently shown that human iNKT cells enhance antigen specific CTL 
responses as well. This effect was only dependent on soluble factors and was completely 
blocked after IFN-γ neutralization (29). These results suggest that the regulation of NK cell 
activity and antigen specific CTL responses by iNKT cells is mediated by different 
mechanisms. 
Recently it has been demonstrated that adoptive transfer with PBMC enriched for 
iNKT cells, is well tolerated and resulted in a transient increase in circulating iNKT cells and 
direct ex vivo IFN-γ production in response to α-GC in an ELISPOT assay (40). Our results 
provide further evidence that in vitro expanded human iNKT cells can activate NK cells, an 
effect which depends on α-GC and which is strongly enhanced by IL-21. It may therefore be 
necessary to combine adoptive iNKT cell therapy with additional IL-21 or α-GC (pulsed DC) 
treatment to achieve clinical effects in vivo. 
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AbstractThe huHMFG-1 (AS1402) antibody is a humanised IgG1 directed against MUC1 and is currently in clinical trials for
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coprotein that is expressed on the ductal cell su
of normal glandular epithelia and is over-expr
in a variety of epithelial cancers [5]. In cancer
MUC1 is not only over-expressed but also
ciently glycosylated, exposing a variable numb
immuno-dominant domains on the MUC1 pe
core, which makes it a good target for immuno
apy [6]. We and others have demonstrated anti
responses to MUC1 in breast, ovarian, colon,
and pancreatic cancer patients and in he
women [7–10]. This natural humoral imm
response is a favourable prognostic factor [11
Naturally occurring anti-MUC1 antibodies c
lead to a capping or clustering of MUC1 on th
surface, unmasking cell surface molecules invo
in cell adhesion and limiting tumour invasio
redistribution of MUC1 could also be instrum
in exposing cell surface receptors involve
immune recognition processes. This would en
recognition and destruction of the tumour ce
antigen speciﬁc T-cells and/or NK-cells.
The humanised MUC1 speciﬁc monoclonal
body huHMFG-1 (AS1402) [15] can me
in vitro tumour cell killing and is currently evalu
in clinical trials as a potential immunotherap
breast cancer [16]. MUC1 serum levels correlate
tumour load and progression [17] and could a
huHMFG-1 mediated tumour cell killing. Her
have analysed the eﬀect of MUC1 present in se
cancer patients, as well as PBMC characteristic
in vitro huHMFG-1- mediated ADCC. Approa
to increase the eﬃcacy of huHMFG-1 treatm
such as addition of cytokines and eﬀect of anti
concentration, are investigated and discussed.
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2.2. Isolation of peripheral blood mononuclear cells
(PBMCs) and natural killer (NK) cell puriﬁcation
Peripheral blood mononuclear cells (PBMCs) fro
diﬀerent healthy donors were isolated from buﬀy
obtained from Sanquin Blood Bank (Amsterdam
Netherlands) by density gradient centrifugation
Lymphoprep (Nycomed, Oslo, Norway). The numb
cells was determined and PBMCs were cryopreserv
separate batches until use. NK cell enrichment wa
formed by negative depletion using the NK cell Iso
Kit II (Miltenyi Biotec, Bergisch Gladbach, Germ
according to manufacture’s recommendations.
2.3. ADCC assay
HuHMFG-1, a humanised IgG1-type MUC1
was provided by Antisoma plc, London, UK. Highly
ﬁed human IgG (Pelicluster-Sanquin, Amsterdam
Netherlands) was used as control antibody. The b
tumour cell line ZR-75-1 [21] that over-expresses M
was cultured in IMDM plus 10% FCS and was used a
get cell line.Donor PBMCswere thawed and cultured
night in Iscove’s modiﬁed Dulbecco’s medium (IM
(Gibco, Paisley, Scotland) supplemented with 10%
calf serum (FCS) (Gibco, Paisley, Scotland). In
experiments, IL-2 (100 IU/ml), IL-21 (25 ng/ml),
(10 ng/ml) or IFN-c (400 IU/ml) were added to th
tures. PBMCs were re-suspended in medium at a co
tration of 107 cells/ml. Target cells (1 · 106 ZR-
were labelled with 100 lCi (3.7 MBq) 51Cr (Amers
Buckinghamshire, UK) for 2 h at 37 C. Cells were w
twice with 10 ml medium and re-suspended in medium
concentration of 105 cells/ml. Fifty microlitres of the
cells was seeded inU-bottom 96-well culture plates (C
Cambridge, MA, USA). Cells were then incubated
MUC1 mAb or control antibody at a ﬁnal concentr
of 5 lg/ml (unless otherwise speciﬁed). Alternat
serum samples were added. After 30 min incubati
37 C, 50 ll of the PBMC were seeded into the cu
plates at eﬀector:target cell (E:T) ratios 25:1, 50:1
100:1, and the plates were incubated for another 18
37 C. The release of 51Cr in the supernatant was
mined in an automatic gamma counter. Eachmeasure
was carried out in triplicate. Spontaneous and ma
51Cr release was determined in sixfold. The percenta
51-Cr release and speciﬁc release is deﬁned as:
%51Cr release ¼
51Cr release 51Cr spontaneous re
51Cr maximal release 51Cr sponta
 10079
%51Cr specific release ¼ %51Cr release with Ab
%51Cr release without Ab
CD4
mediated ADCC was performed using the human breast
cancer cell line ZR-75-1 as target cells and human periph-
eral blood mononuclear cells as eﬀector cells. Humanised
HMFG-1 showed a dose-dependent killing of ZR-75-1
nging
sence
aried
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FITC- or PE- labelled mouse anti-human CD3,
CD8, CD14, CD16 (clone CLB-Fc-gran/1), CD19
anti
ther
3G8
SA
arke
wa
d fo
ients
tems
rab
lost
wa
R&D
PE
ulin
bated
using
ELL
).
oclo
and
ntro
, San
incu
l) and
ody
rmed
Pear-
se the
g and
CC.
ce of
value
ana-
ine
ether
G-1-
onors
nder
con-
not
BMC
medi-
posi-
cells
ween
elper
lls or
D16)
III is
were
odel.
ector
ainst
cRII)
onent
l kill-
high
rs of
iched
c kill-
spon-
esults
and
0
10
20
30
40
25:1 50:1 100:1
E:T ratio
%
 s
pe
ci
fic
 c
yt
ot
ox
ic
ity
 1
 2
PBMC 3
PBMC 4
PBMC 5
PBMC 6
PBMC 7
PBMC 8
PBMC 9
PBMC 10
PBMC 11
PBMC 12
PBMC 13
Fig. 1. Diﬀerential huHMFG-1-dependent ADCC mediated by
PBMC from 13 healthy donors using 5 lg/ml of huHMFG-1.CD56 and the corresponding murine IgG control
bodies (Pelicluster-Sanquin, Amsterdam, The Ne
lands) as well as mouse anti-human CD16 (clone
Pharmingen, Becton–Dickinson, San Jose, CA, U
were used for the determination of PBMC surface m
expression by ﬂow cytometry. Expression of NKG2D
analysed on NK cells from healthy donors culture
18 h in complete medium with or without 30% pat
sera with puriﬁed anti-NKG2D MAB139 (R&D Sys
Minneapolis, MN, USA), followed by FITC-labelled
bit anti-mouse immunoglobulins F(ab 0)2 (Dako, G
rup, Denmark). MICA expression on ZR-75-1
analysed with anti-human MICA (clone AMO1;
Systems, Minneapolis, MN, USA), followed by
labelled polyclonal goat anti-mouse immunoglob
F(ab 0)2 (Dako, Glostrup, Denmark). Cells were incu
with the antibodies for 30 min at 4 C and analysed
a FACScan; data analysis was performed using C
Quest software (BD Bioscience, San Jose, CA, USA
2.5. Fcc receptor (FccR) and NKG2D blocking
Eﬀector cells were pre-treated overnight with mon
nal antibodies against CD16 (clone CLB-Fc-gran/1
3G8), CD32 (clone FLI8.26), CD64 (clone 10.1) or co
mouse IgG (all from Pharmingen, Becton–Dickinson
Jose, CA,USA). ForNKG2D blocking PBMCswere
batedovernightwith theantibody (MAB139, 10 lg/m
the ADCC was performed in the presence of the antib
2.6. Statistics
Normality of distribution of the data was conﬁ
with the Kolmogorov–Smirnov test and Q–Q plots.
son correlation and v2 test were performed to analy
relation between cell numbers and tumour cell killin
to analyse the inﬂuence of MUC1 serum levels on AD
A signed-rank test was used to investigate the inﬂuen
diﬀerent cytokines on ability to mediate ADCC. A
of p < 0.05 was considered signiﬁcant. All data were
lysed using the SPSS 9.0 software.
3. Results
3.1. NK cell numbers and CD16 polymorphism determ
the level of ADCC
Based on the developed in vitro assay to study wh
MUC1 antibodies can mediate ADCC [16], huHMF80,
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cells, with maximal killing at concentrations ra
between 2.5 and 25 lg/ml (not shown). In the pre
of 5 lg/ml of huHMFG-1, tumour cell killing v
widely, from 43% to 1%, between the 13 healthy d
tested (Fig. 1). Tumour cell killing by low respo
donor PBMCs was not improved by increasing the
centration of huHMFG-1 (up to 500 lg/ml, data
shown). The percentage of CD56+ NK cells within P
correlated with the ability to mediate huHMFG-1-
ated ADCC (p = 0.023, Table 1). There was also a
tive correlation with FccRIII (CD16) positive
(p = 0.049, Table 1). No correlation was found bet
tumour cell killing and the percentage of CD4+ T h
cells, CD8+ cytotoxic T lymphocytes, CD19+ B ce
CD14+ monocytes (not shown).
ADCC is mediated primarily through FccRIII (C
[22]. Snijdewint et al. [16] have shown that FcRcR
involved in huHMFG-1 ADCC. Blocking assays
carried out to conﬁrm this mechanism in our m
Indeed ADCC was blocked after pre-treatment of eﬀ
cells with two diﬀerent monoclonal antibodies ag
CD16 but not with antibodies against CD32 (Fc
or CD64 (FccRI) (Fig. 2).
The proportion of NK cells is not the only comp
contributing to the observed diﬀerence in tumour cel
ing by PBMC from diﬀerent donors. PBMC from
and low responders were enriched to equal numbe
NK cells and analysed in an ADCC assay. Enr
NK cells from a high responder induced 60% speciﬁ
ing (Fig. 3a), while enriched NK cells from a low re
der induced 25% speciﬁc killing (Fig. 3b). These r
suggest that the observed diﬀerence between high
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low responders may also be due to intrinsic characteristic
of the NK cells rather than just the number of NK cells
To elucidate this, expression levels of the FccRII
(CD16) were investigated (Figs. 3c and d). Two diﬀeren
with
omo
3,24]
ound
pres
with
the capacity to mediate ADCC (p < 0.01, Table 1), sug-
gesting a role for the FccRIIIa 158-Val polymorphism
in huHMFG-1-mediated ADCC.
Next it was investigated whether the addition of the
FG-1
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Table 1
huHMFG-1-mediated ADCC correlation with PBMC characteristics
% Speciﬁc killing
(E:T = 100:1)
% CD56+ cells % CD16+ cells
CLB-Fc-gran/1
MFI 3G8 MFI
CLB-Fc-gran/1
PBMC 1 42.3 16.0 21.9 1317 270
PBMC 2 40.7 13.8 28.6 1823 102
PBMC 3 32.8 7.8 23.8 1717 194
PBMC 4 16.9 10.2 23.5 1233 158
PBMC 5 12.5 11.1 21.9 811 200
PBMC 6 11.9 6.3 22.2 961 213
PBMC 7 11.2 7.6 20.3 802 94
PBMC 8 10.5 15.2 21.1 952 231
PBMC 9 9.0 10.1 18.3 823 160
PBMC 10 4.1 8.6 25.6 766 194
PBMC 11 2.4 4.1 3.2 445 126
PBMC 12 1.2 6.4 4.5 295 nd
PBMC 13 0.4 8.0 19.2 690 140
N 13 13 13 12
p-value 0.023 0.049 <0.001 0.473
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Fig. 2. HuHMFG-1-mediated ADCC depends on the FccRIII.
Antibodies against diﬀerent FccRs: FccRIII (CD16, clone 3G
and clone CLB-Fc-gran/1), FccRII (CD32) and FccRI (CD64
were used to block huHMFG-1 mediated ADCC. Eﬀector cell
were incubated overnight with 0.5 lg/ml of the mAbs against th
Fc receptors, and ADCC was performed using 5 lg/ml o
huHMFG-1.
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a higher aﬃnity to cells from individuals who are h
zygous for the FccRIIIa 158-Val polymorphism [2
While there was no diﬀerence in CD16 expression f
with clone CLB-Fc-gran/1 (p = 0.473, Table 1), ex
sion levels determined with clone 3G8 correlatedNK cell activating cytokines could enhance huHM
ADCC mediated by low, and also by high, respon
Previously we demonstrate an increase in ADCC b
addition of IL-2 and IFN-c [16]. To conﬁrm and e
on these ﬁndings, we studied the eﬀect of these cyto
as well as IL-15 and IL-21 on huHMFG-1-med
ADCC. A 2- to 5-fold enhancement of tumour cell k
was observed when PBMC were pre-treated with IL-
21 and IL-15, while IFN-c had diﬀerential eﬀects (F
3.2. High MUC1 antigen serum levels inhibit
huHMFG-1-ADCCs
.
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huHMFG-1-mediated ADCC [16]. MUC1 is frequ
elevated in serum of patients with breast and ovarian
cer. As huHMFG-1 is being tested as a tumour imm
therapeutic agent, we analysed the eﬀect of serum M
antigen levels on huHMFG-1-dependent ADCC
high responder PBMC 1 (see Fig. 1). Killing of the
75-1 cell line without antibody was always low (
and was not aﬀected by addition of MUC1 conta
patient sera, indicating that natural anti-MUC1 antib
that may be present in serum were not suﬃcient to me
in vitro ADCC. HuHMFG-1 mediated ADDC was
ever strongly inhibited in the presence of serum conta
1949 U/ml MUC1 (from 40.3% to 8.0% speciﬁc
However, addition of serum containing low leve
MUC1 (9 U/ml) had no eﬀect on tumour cell k
(40.3% versus 39.2% speciﬁc lysis, Fig. 5a). In 15 o
20 (75%) serum samples with MUC1 levels below
8
)
s
e
f81
upper limit of normal (30 U/ml) huHMFG-1-dependen
ADCC inhibition was less than 20% (Fig. 5b). Inhibition
of cytotoxicity was higher than 20% in 22 out of 26
(85%) serum samples with MUC1 levels above 30 U/m
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olved
5d)
illing
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10 lg/ml; 23% killing vs 3% killing in the presence of
MUC1). However, in the presence of increasing
huHMFG-1 concentrations, inhibition of target cell killing
by MUC1 antigen decreased (25 lg/ml) or was completely
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Fig. 4. IL-2, IL-21 and IL-15 but not IFN-c can enhance
huHMFG-1-mediated ADCC. PBMC from four diﬀerent donors
(2 low responders and 2 high responses were cultured for 5 days in
the presence of IFN-c, IL-2, IL-21 or IL-15 prior to performing
ADCC. The increase in cytotoxicity due to cytokine treatment
[cytotoxicity ratio (cytokine treated/untreated)] was calculated as
follows: % tumour cell lysis by cytokine treated PBMCs (at
E:T = 25:1) / % tumour cell lysis by un-treated PBMCs (at
E:T = 25:1). A ratio >1 indicates that tumour cell killing is higher
in cytokine-treated PBMCs than in untreated PBMCs.
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Fig. 3. The level of ADCC depends partly on the proportion o
NK cells in PBMC and CD16 expression. ADCC was performed
using 5 lg/ml of huHMFG-1 with donor PBMC from a high (a
PBMC 3) and a low (b, PBMC 5) responder and the corre
sponding enriched NK cells obtained by negative selection. On
representative experiment of four performed is shown. CD1
expression on PBMC 3 (c) and PBMC 5 (d) was analysed by ﬂow
cytometry with two mAbs, clone 3G8 and cloneCLB-Fc-gran/1
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María Moreno Jauge(v2 two-tailed p < 0.001, Fig. 5b). Inhibition of tumou
killing by high levels of serum MUC1 could be over
with increasing serum dilutions and, thus, decre
MUC1 concentrations (Fig. 5c). However, other po
inhibiting factors would also be diluted. Therefo
was investigated whether the inhibiting eﬀect of s
containing high levels of MUC1 could also be res
by adding increasing levels of huHMFG-1 (Fig.
MUC1 antigen completely blocked tumour cell k
mediated by low concentrations of huHMFG-1 (182t
l
l
e
e
t
.
abrogated (100 lg/ml).
4. Discussion
Clinical successes of monoclonal antibodies
ciﬁcally targeting tumour cells have created
interest in antibody-based immunotherapy. T
uzumab is a monoclonal antibody targeting
extracellular domain of the HER2/neu pro
Results of trials that compared adjuvant chemo
apy alone or in combination with trastuzuma
women with surgically removed HER2-po
breast cancer showed a beneﬁt in disease free
vival and overall survival in trastuzumab tre
patients [25]. Contrary to HER2/neu, whic
expressed only in 30% of breast cancers, MUC
over-expressed in virtually all breast adenocar
mas. Due to its tandemly repeated extracel
sequence, MUC1 presents multiple anti
regions per molecule, ensuring antibody bin
even in low expressing tumours. The MUC1 sp
antibody huHMFG-1 could therefore be a
widely applicable therapeutic agent
HuHMFG-1 leads to a capping or clusterin
MUC1 on the surface of the tumour cell, expo
cell surface receptors involved in immune reco
tion processes. This would enable recognition
f
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destruction of the tumour cell by antigen speciﬁc T-
cells and/or NK-cells. Indeed, we have previously
shown that huHMFG-1 mediates ADCC of
MUC1 positive cell lines [16].
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Fig. 5. High MUC1 serum levels inhibit huHMFG-1-mediated ADCC, which can be overcome by adding increasing concentrations of the
antibody. (a) Example of ADCC of ZR-75-1 by PBMC 1 in the presence of serum with low (9 U/ml) or high (1949 U/ml) levels of MUC1.
(b) Correlation between MUC1 levels and percentage of inhibition of huHMFG-1 mediated tumour cell killing (p = 0.028). The graph is
divided in four quadrants: lower left, normal MUC1 levels (630 U/ml) and less than 20% inhibition (N = 15); upper left: normal MUC1
levels and more than 20% inhibition (N = 5); lower right: MUC1 above normal levels (>30 U/ml) and less than 20% inhibition (N = 4);
upper right: MUC1 above normal levels and more than 20% inhibition (N = 22). Closed symbols correspond to serum samples with
various MUC1 levels taken at diﬀerent time points from four patients with breast cancer (, d,m,j), and one patient with ovarian cancer
(*). Open circles correspond to single samples from individual patients with breast or ovarian cancer. All ADCC assays were performed
using 5 lg/ml of huHMFG-1 and high responder PBMC 1 as eﬀector cells. (c) A high MUC1 serum sample (6054 U/ml) obtained from a
patient with breast cancer was serially diluted to a MUC1 level of 1 U/ml. Each dilution was tested in an ADCC assay performed using
5 lg/ml of huHMFG-1. One representative experiment of three performed is shown. (d) MUC1 ADCC inhibition can be overcome with
increasing concentrations of huHMFG-1. White bars depict huHMFG-1 mediated tumour cell killing in the absence of serum. HuHMFG-
1-mediated killing is optimal with mAb concentrations of 1 or 25 lg/ml. Black bars depict tumour cell killing in the presence of a serum
sample with high MUC1 levels (6054 U/ml) obtained from a patient with breast cancer. One representative experiment of three performed
is shown.
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in mediating huHMFG-1-dependent tumour
killing. Two diﬀerent allotypes of the FccRIIIa
been described (FccRIIIa-158V and FccR
158F) and this polymorphism has been report
aﬀect IgG1 binding [27]. Donors positive fo
FccRIIIa-158V polymorphism had a better cli
response to treatment with rituximab [28].l
e
-
l
s
speciﬁc clone 3G8 displays a stronger bindin
PBMC from individuals homozygous for
FccRIIIa 158-Val polymorphism [23,24]. Her
show a correlation between high FccRIIIa ex
sion using the 3G8 antibody and huHMFG-1
iated ADCC. This correlation was not obse
with the CLB-Fcgran/1 antibody, which b
equally strong to both FccRIIIa allotypes. T83
data strongly suggest that the FccRIIIa polymor-
phism may also inﬂuence huHMFG-1-mediated
ADCC. DNA typed analysis should be carried out
to conﬁrm this observation.
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María Moreno JaugeThere are currently numerous eﬀorts ong
to improve the eﬃcacy of therapeutic IgG1
bodies. In vitro molecular engineering of th
region is one possibility to improve the aﬃ
of mAbs for the FccRIIIa and thereby to enh
ADCC [30]. Furthermore, combination ther
with NK cell activating cytokines may inc
ADCC. It has previously been shown that
IL-15 and IL-21 can augment ADCC [31
Indeed in our system, stimulation of PBMCs
IL-2, IL-21 and IL-15, but not with IF
increased huHMFG-1-mediated ADCC. M
over, it has been demonstrated that patients
ted with antibodies in combination with
exhibit an increased in vitro ADCC [32,35]. G
et al. showed that the addition of IL-2 to r
imab therapy for the treatment of B-cell
Hodgkin’s lymphomas results in NK cell ex
sion that correlates with clinical response.
also observed that ADCC activity was incre
or maintained in responding and stable di
patients [36]. However, the in vivo relevanc
in vitro results needs further conﬁrmation.
Using diﬀerent serum samples with var
MUC1 levels, we demonstrated that MUC1
inhibit huHMFG-1-mediated ADCC. M
serum levels above the upper limit of no
(30 U/ml) inhibited huHMFG-1-mediated AD
(85%, 22/26 serum samples) and as these l
diﬀer among cancer patients, they have to be
sidered to deﬁne the therapeutic dose
huHMFG-1. One way to conﬁrm the inhib
eﬀect of MUC1 would be to perform ADCC
removing MUC1 from the sera. Unfortunate
was not possible to remove MUC1 from pa
sera without diluting the sera. However, tum
cell killing could be restored with h
huHMFG-1 concentrations. Antibody conce
tions between 25 and 100 lg/ml could overc
in vitro inhibition of tumour cell killing by e
mely high MUC1 levels (6054 U/ml), strongly
gesting that MUC1 is indeed inhibiting huHM
1-mediated ADCC. These concentrations coul
achieved in serum with administration
huHMFG-1 dose levels P3 mg/kg in vivo.
concentration lies well within the tolerable
considering that the MTD exceeded 16 m
[26]. Nevertheless, care is needed in extrapol84-
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ADCC even though the levels of MUC1 were b
the normal limit. Another possible inhibitory f
could be the soluble form of the stress-indu
MHC class I-related chain A (MICA) which
ligand of the NK cell receptor NKG2D [37]. So
MICA is released from tumour cells and inh
cell-surface NKG2D expression and NKG2D-
iated eﬀector functions of immune cells in pat
with progressive malignant tumours [38–41]. M
was expressed on the target cell we used in
ADCC assays and blocking of NKG2D inhi
killing, suggesting that NKG2D co-stimula
plays a role in huHMFG-1-mediated ADCC. H
ever, we could not demonstrate impairmen
NKG2D expression on NK cells after incuba
with serum samples (with low MUC1) that inhi
ADCC, suggesting that in these cases so
NKG2D ligands did not play a role in ADCC
bition (data not shown).
In conclusion, our in vitro results indicate
the number of NK cells, NK cell activating
kines, the FccRIIIa-158 polymorphism and
MUC1 serum levels inﬂuence huHMFG-1-med
ADCC. The use of higher concentration
huHMFG-1, which lie within the well-tole
doses recently tested in a phase I clinical trial
compensate for the elevated MUC1 serum le
Optimal eﬀects of huHMFG-1 treatment migh
seen when the serum MUC1 levels are lower,
as in early stage patients, in contrast to
advanced disease patients. Screening for pat
with high levels of NK cells bearing the FccR
158V polymorphism, adjusting the dosage to c
lating levels of MUC1 and co-administration of
cell activating cytokines may increase the eﬃca
huHMFG-1 treatment.
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Chapter 5b 
 
Toll-like receptor agonists and invariant Natural Killer T-cells 
enhance antibody-dependent cell-mediated cytotoxicity (ADCC) 
 
 
María Moreno, Berber M. Mol, Silvia von Mensdorff-Pouilly, René H.M. Verheijen,  
B. Mary E. von Blomberg, Alfons J.M. van den Eertwegh, Rik J. Scheper, Hetty J. Bontkes 
Cancer Letters: In press 
 Abstract  
huHMFG-1 (AS1402) is a humanised IgG1 against MUC1, which exerts tumour cell killing 
through antibody-dependent cellular cytotoxicity (ADCC) mediated by Natural Killer (NK) 
cells. Here we explored the capacity of invariant NK T (iNKT) cells, which are known to 
activate NK cells, and Toll-like Receptor (TLR) ligands which activate both iNKT and NK 
cells, to enhance huHMFG-1-ADCC. Addition of iNKT cells, as well as TLR2/6, 7, 8 and 9 
agonists to PBMC improved the efficacy of huHMFG-1. These results suggest that transfer of 
ex vivo expanded iNKT cells or TLR agonist treatment may improve the efficacy of NK cell-
mediated antibody-based tumour immunotherapies. 
 
 
Key words: human, invariant NKT cells, Toll-like receptor, NK cells, ADCC 
 
 
Abbreviations: -GC: -galactosylceramide; ADCC: antibody-dependent cell-mediated 
cytotoxicity; DC: dendritic cells; huHMFG-1: humanized Human Milk Fat Globulin-1; iNKT: 
invariant natural killer T-cells; LPS: lipopolysaccharide; mAb: monoclonal antibodies; NK 
cells: Natural Killer cells; PBMC: peripheral blood mononuclear cells; PGN: peptidoglycan; 
Poly (I:C): polyionosinic-polycytidylic acid; T-cell receptor (TCR); TLR: Toll-like receptor 
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Introduction 
MUC1, also known as CA15-3 antigen, is a high-molecular-weight transmembrane 
glycoprotein that is expressed on the ductal cell surface of normal glandular epithelia and is 
over-expressed in a variety of epithelial cancers [1]. In cancer cells MUC1 is not only over-
expressed but also deficiently glycosylated, exposing a variable number of immuno-dominant 
domains on the MUC1 peptide core, which makes it a good target for immunotherapy [2]. In 
this context, a humanised MUC1 specific monoclonal antibody (mAb), huHMFG-1 
(humanized Human Milk Fat Globulin-1, AS1402), has been developed [3] and is currently 
being evaluated in clinical trials as a potential immunotherapy for breast cancer. Humanised 
HMFG-1 can mediate in vitro tumour cell killing by antibody-dependent cell-mediated 
cytotoxicity (ADCC) [4] through Natural Killer (NK) cells [5], though with limited efficacy. 
A therapy aiming at activation of NK cells could be of value for huHMFG-1 treatment. In this 
context, pre-treatment of peripheral blood mononuclear cells (PBMC) with NK cell activating 
cytokines, such as IL-2, IL-21 and IL-15, promotes an improvement of huHMFG-1-mediated 
tumour cell killing in vitro [5]. However, cytokine therapies are often highly toxic, limiting 
their in vivo use. Therefore, alternative strategies should be explored. 
CD1d-restricted invariant Natural Killer T (iNKT) cells are T lymphocytes, 
characterized by an invariant T-cell receptor (TCR)  chain gene rearrangement (V24-J18 
paired with V11 in humans) and co-expression of NK cell receptors [6]. The invariant TCR 
recognizes glycolipid ligands, such as the artificial ligand Galactosylceramide (-GC), in 
the context of the monomorphic CD1d antigen-presenting molecule. Upon activation, iNKT 
cells rapidly secrete cytokines, such as IL-2, IFN-, TNF- and IL-4, leading to the activation 
of other immune cells, such as dendritic cells (DC) and NK, T and B cells (reviewed in [7]). 
We have recently demonstrated that in vitro expanded human iNKT cells can enhance 
antibody-independent NK cell cytotoxicity through the production of cytokines [8]. 
Therefore, iNKT cells could be exploited as cytokine producing cells to activate NK cells, 
hence improving huHMFG-1 efficacy in vivo.  
Toll-like receptors (TLR) recognize different pathogen-associated molecular patterns 
(PAMPs) and trigger innate and adaptive immune responses. The TLR-family consists of at 
least 11 members, although the function of TLR10 is not yet clear and TLR11 appears not to 
be functional in humans. Bacterial components are mainly recognized by cell surface TLR; 
for example, bacteria lipopeptides are recognized by the heterodimers TLR1/2 and TLR2/6, 
lipopolysaccharide (LPS) by TLR4, and flagellin by TLR5. Endosomal-associated receptors 
are triggered by viral products, i.e. TLR3 is triggered by dsRNA, TLR7 and 8 by ssRNA, and 
TLR9 by hypomethylated CpG DNA (reviewed in [9]). TLR are mainly expressed by antigen 
presenting cells, but also by NK cells and cells of the adaptive immune response, such as T 
and B lymphocytes [10]. NK cell activation by TLR agonists has been extensively reported 
[11-14]. In addition, we have recently found that PBMC treatment with TLR agonists leads to 
indirect iNKT cell activation (Moreno et al., submitted
1
). 
Based on these results, we investigated whether activated iNKT cells and TLR ligands 
can enhance the ability of NK cells to mediate huHMFG-1-dependent tumour cell killing in 
vitro.  
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 Materials and Methods 
Media and reagents 
IMDM (Cambrex, Verviers, Belgium) was supplemented with 10% Foetal Calf Serum 
(Perbio, Helsingborg, Sweden) for culture of PBMC, or 8% human pooled serum (Sanquin, 
Amsterdam, The Netherlands) for the culture of iNKT cells. Both media were supplemented 
with 100 IU/ml sodium penicillin (Yamanouchi Pharma, Leiderdorp, The Netherlands), 
100g/ml streptomycin sulphate (Radiumfarma-Fisiopharma, Naples, Italy) and 0.01 mM -
mercaptoethanol (Merck, Darmstadt, Germany). 
The following TLR agonists were used: peptidoglycan (PGN) from Staphylococcus 
aureus (10μg/ml), polyionosinic-polycytidylic acid [Poly (I:C), 25μg/ml] and LPS (1μg/ml) 
(Sigma-Aldrich, Buchs, Germany); flagellin from Salmonella thyphimurium (5μg/ml) and 
CL075 (0.72μg/ml) (InvivoGen, San Diego, CA, USA); and human specific stimulatory CpG 
ODN type A (ODN A 2216,  5μg/ml) (Coley Pharmaceuticals, Düsseldorf, Germany). 
 
Isolation of peripheral blood mononuclear cells (PBMC) and PBMC stimulation 
PBMC were isolated from buffycoats from healthy donors obtained from Sanquin Blood 
Bank (Amsterdam, The Netherlands) by density gradient centrifugation using Lymphoprep
 
(Nycomed, Oslo, Norway). The number of cells was determined and PBMC were 
cryopreserved in separate batches until use.  
PBMC cultures containing 4 x10
6
 cells/ml were stimulated with different TLR agonists 
or combination of those for 48h. PBMC were incubated in the absence of any stimulus (only 
medium) as negative control.  
 
Surface marker expression on iNKT and NK cells 
FITC-, PE-, PerCP-Cy5- or APC-labelled isotype controls and mouse anti-human 
6B11, CD3, CD4, CD16, CD69 (BD Bioscience, San Jose, CA, USA), V24, V11 
(Immunotech, Marseille, France) and CD56 (IQ products, Groningen, The Netherlands) were 
used to determine the phenotype of NK and iNKT cells by flow cytometry. Cells were 
incubated with the antibodies for at least 30 min at 4ºC. Flow cytometry was performed on a 
FACSCALIBUR
TM
 apparatus and data were analyzed using CellQuest
TM
 software (BD 
Biosciences, San Jose, CA, USA). 
 
iNKT cell expansion 
V24+ V11+ iNKT cells were enriched from PBMC by positive selection using the 
iNKT cell specific antibody 6B11 (BD Biosciences, San Jose, CA, USA) and anti-mouse Ig-
coated magnetic beads mAb (Milteny Biotec, Bergisch Gladbach, Germany) by MACS 
sorting. iNKT cells were expanded by weekly stimulation with  irradiated autologous PBMC 
at a 1:1 iNKT : PBMC ratio in the presence of 100ng/ml -GC (KRN7000, kindly provided 
by Dr Shigeyuki Yamano, KIRIN Brewery, Gunma, Japan), 40 IU/ml recombinant human 
(rh) IL-2, 5 ng/ml rhIL-7 and 5 ng/ml rhIL-15 (all purchased from Strathmann Biotech, 
Hanover, Germany). 
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Evaluation of NK cell activation by iNKT cells 
 Donor PBMC (5x10
6
 cells/ml) were cultured in the presence or absence of 100 ng/ml 
-GC. iNKT cell-depleted PBMC were co-cultured with or without 0.50% in vitro expanded 
iNKT cells, in the absence or presence of -GC and cultured for 5 days.  
 
NK cell effector function analysis 
Intracellular Granzyme B staining was performed after fixing the cells with 4% 
paraformaldehyde for 15 minutes at 4˚C. PBMC were stained with CD69-FITC, CD3-PerCP 
and CD56-APC. Subsequently cells were permeabilised using the BD cytofix/cytoperm plus 
kit (BD Bioscience, San Jose, CA, USA) according to the manufacturer’s instructions, and 
intracellular staining for Granzyme B was performed with PE-labelled anti-granzyme B 
(Sanquin, Amsterdam, The Netherlands). 
 
ADCC assay 
HuHMFG-1, a humanised IgG1-type MUC1 mAb, was provided by Antisoma plc, 
London, UK. Highly purified human IgG (Pelicluster-Sanquin, Amsterdam, The Netherlands) 
was used as control antibody. The breast tumour cell line ZR-75-1 that over-expresses MUC1 
was used as target cell line. NK cell tumour cell killing was analysed by huHMFG-1 ADCC 
assay, performed as previously described [5]. 
 
Statistics 
Normality of distribution of the data was confirmed with the Kolmogorov-Smirnov test 
and Q-Q plots. Student T-test for paired samples was performed to analyze the effect of TLR-
triggering on NK cells. Pearson correlation test were performed to investigate the relation 
between Granzyme B production and huHMFG-1 ADCC. A two-tailed p value of < 0.05 was 
considered significant. All data were analysed using the SPSS 14.0 software. 
 
 
Results 
Addition of in vitro expanded iNKT cells to iNKT-depleted PBMCs enhances huHMFG-1 
ADCC in an -GC dependent manner  
We have previously shown that in vitro PBMC stimulation with -GC, an iNKT cell 
ligand, induced iNKT cell activation and a limited NK cell activation without enhancing NK 
cell effector functions [8]. In line with this observation, no enhancement of NK cell mediated 
huHMFG-1 ADCC was observed when PBMC, containing various numbers of iNKT cells 
(range 0.01-0.19% iNKT cells among CD3
+
 lymphocytes), were pre-treated with -GC for 2 
to 5 days (Figure 1a). 
 However, in vitro expanded pre-activated human iNKT cells induce NK cell activation 
and concomitant enhancement of their lytic functions [8]. To test the capacity of these pre-
activated iNKT cells to also increase NK cell-mediated huHMFG-1 ADCC, iNKT-depleted 
PBMC were co-cultured with 0.5% (which is within the physiological proportions) of in vitro 
expanded iNKT cells (>90% pure). We previously observed a high variation in donor’s ability 
to mediate huHMFG-1 tumour cell killing [5]. To appreciate the effect of iNKT cells in the 
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 present study, this variability was therefore normalized by calculating the fold-increase (FI) in 
tumour cell killing. Results are presented as the ratio between tumour cell killing of -GC- 
and/or iNKT cell-stimulated and unstimulated PBMC for each donor. iNKT cells induced a 
mean increase of 73% in huHMFG-1 ADCC at a 25:1 E:T ratio, an increase which depended 
on -GC (Figure 1b, Paired Student’s T-test: p=0.029). 
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Figure 1: Increase in huHMFG-1-dependent tumour cell killing by -GC-stimulated iNKT cells. The effect of -
GC-stimulated iNKT cells on huHMFG-1-mediated tumour cell killing was studied. a) PBMC were stimulated 
with -GC and after 48hs NK cell ability to mediate huHMFG-1 ADCC was assessed. One representative 
experiment out of 7 performed is shown. b) iNKT-depleted PBMC (○) were co-cultured with 0.5% in vitro 
expanded iNKT cells, in the absence (▲) or presence (●) of iNKT cell ligand, -GC. After 5 days, NK cell 
ability to mediate huHMFG-1-dependent tumour cell killing was assessed. Results of all donors (N=5) 
represented as fold-increase of huHMFG-1-dependent tumour cell killing at 25:1 E:T ratio. The horizontal lines 
represent the mean. Paired Student’s T-test of percentage of tumour cell killing mediated by -GC and/or iNKT-
stimulated PBMC compared to unstimulated PBMC. p<0.05 for iNKT-depleted PBMC co-cultured with iNKT 
cells in the presence of -GC (●). 
 
 
PBMC stimulation with different TLR agonists (PGN, CL075 and ODN A) enhances 
huHMFG-1-dependent tumour cell killing 
TLR agonists can increase NK cell activity [11-14]. Moreover, we (Moreno et al., 
submitted
1
) and others [15;16] have shown that PGN (a ligand for TLR2/6), CL075 (TLR7 
and 8) and CpG (TLR9) promote iNKT cell activation. Since, iNKT cells can enhance NK 
cell cytotoxicity [8;17], we tested whether TLR-triggering can increase the efficacy of 
huHMFG-1. PBMC from 6 healthy donors were stimulated with different TLR agonists, Poly 
(I:C) (a ligand for TLR3), LPS (TLR4) and flagellin (TLR5), and PGN, CL075 and CpG 
ODN A. After 48h, effects of TLR triggering on NK cell numbers and activation state were 
analyzed. No significant changes were observed in the proportion of NK cells (8.0  4.5 % of 
CD3
-
 CD56
+
 cells among the lymphocyte population, Table I). NK cell activation occurred 
upon PBMC TLR-triggering. Interestingly, all TLR agonists dramatically induced an up-
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regulation of CD69 activation marker expression on NK cells compared to unstimulated 
PBMC (figure 2 and Table I). PGN, CL075 and ODN A, the same ligands that induced iNKT 
cell activation, were most effective in inducing CD69 expression (% CD69
+
 NK cells, paired 
samples t-test p ≤0.001).  
 
Table I. Summary of NK cell characteristics after TLR-stimulation of PBMC.  
TLR agonist TLR % NK cells
a,b
  % CD 69
+ b,c
  % Granzyme B
+ c,d
 % ADCC
 b,e
 
No stimulus  8.0 ± 4.5 
f
 22.8 ± 16.9 18.7 ± 17.2 10.1 ± 5.5% 
PGN 2/6 6.3 ± 3.6 74.4 ±17.5 * 45.7 ± 25.1 14.8 ± 8.1% * 
Poly (I:C) 3 7.5 ± 4.4 40.0 ± 27.6 * 23.1 ± 15.8 11.7 ± 6.2% 
LPS 4 7.0 ± 4.7 66.4 ± 26.1 * 25.2 ± 21.3 10.5 ± 6.8% 
Flagellin 5 8.0 ± 5.2 51.7 ± 25.7 * 24.1 ± 22.7 14.2 ± 8.3% 
CL075 7 and 8 7.5 ± 4.4 78.7 ± 22.5 * 50.2 ± 29.7 15.0 ± 7.6% * 
ODN A 9 7.2 ± 5.4 90.3 ± 6.5 * 31.6 ± 24.6 13.0 ± 6.4% * 
a 
among the lymphocytes, 
b 
N=6, 
c
 among the NK cells (CD3
-
 CD56
+
), 
d 
N=3, 
e 
E:T ratio 25:1, 
f
 Mean ± SD, * 
Paired Student’s T-test, p<0.05 
 
 
The capacity to enhance huHMFG-1-ADCC was also addressed. A significant increase 
in huHMFG-1-mediated tumour cell killing was observed when PBMC were stimulated with 
PGN, CL075 and ODN A (Figure 3a), the same ligands that induced iNKT cell activation and 
higher NK cell activation, compared to unstimulated PBMC (paired samples t-test p = 0.018, 
0.018 and 0.027, respectively) (Table I). PGN, CL075 and ODN A induced 67, 90 and 59% 
increase in huHMFG-1-mediated tumour cell killing, respectively. Of note, flagellin enhanced 
huHMFG-1-ADCC, though not statistical significant (p=0.052). Poly (I:C) and LPS had no 
statistically significant effect on huHMFG-1-ADCC (Figure 3b). Moreover, there is a 
consistent, though not statistical significant, increase in Granzyme B production by NK cells 
upon TLR stimulation, in particular with PGN, CL075 and ODN A (Table I). Granzyme B 
production by NK cells positively correlated with percentage of tumour cell killing mediated 
by huHMFG-1 (Pearson correlation test, p=0.02). 
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Figure 2: CD69 expression by NK cells 
upon PBMC stimulation with different 
TLR agonists. PBMC were cultured for 
48h in medium (no stimulus, □) or in the 
presence of PGN (a ligand for TLR2/6, 
▲), Poly (I:C) (TLR3, ∆), LPS (TLR4, 
), Flagellin (TLR5, ○), CL075 (TLR7 
and 8, ♦) or ODN A (TLR9, ●). Results 
of all donors (N=6) represented as 
percentage CD69
+
 cells among NK cells 
(defined as CD3
-
 CD56
+
 cells). 
Horizontal lines represent the mean. 
Paired Student’s T-test, p<0.05 for Poly 
(I:C) and p<0.001 for the rest of TLR. 
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 To test whether the combined TLR triggering had synergistic effects, PBMC were 
stimulated with combinations of the three ligands with strongest effect (i.e. PGN, CLO75 and 
ODNA). Neither synergistic, nor additive effects on NK cell mediated ADCC were observed 
(data not shown). 
 
 
Discussion 
There are currently numerous efforts ongoing to improve the efficacy of therapeutic 
IgG1 monoclonal antibodies (mAb). Combination with NK cell activating therapies may 
increase ADCC. In this context, we and others have previously shown that NK cell activating 
cytokines, such as IL-2, IL-15 and IL-21, can augment ADCC, and huHMFG-1-mediated 
ADCC in particular [5]. However, most cytokine therapies have been shown to be toxic. An 
alternative approach could be to exploit the cytokine producing ability of iNKT cells. 
Previously we observed that addition of free -GC to total PBMC did not lead to enhanced 
NK cell activation, while addition of in vitro expanded and pre-activated iNKT cells to 
PBMC or isolated NK cells enhanced NK cell activation and cytotoxic effector functions in 
an -GC-dependent manner [8]. Here we demonstrate that in vitro expanded human iNKT 
cells, which promote NK cell activation in vitro, can also enhance the efficacy of huHMFG-1-
dependent NK cell-mediated ADCC in an -GC dependent fashion.  
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Figure 3: NK cell ability to mediate huHMFG-1-dependent tumour cell killing upon PBMC stimulation with different TLR 
agonists. PBMC were cultured in medium (no stimulus, □) or in the presence of PGN (a ligand for TLR2/6, ▲), Poly (I:C) 
(TLR3, ∆), LPS (TLR4, ), Flagellin (TLR5, ○), CL075 (TLR7 and 8, ♦) or ODN A (TLR9, ●).  After 48h, NK cell ability to 
mediate huHMFG-1-ADCC was assessed. a) Results from one representative experiment out of 6 performed are shown.  b) 
Results of all donors (N=6) represented as fold-increase of huHMFG-1-dependent tumour cell killing mediated by TLR-
stimulated compared to unstimulated PBMC at 25:1 E:T ratio. Horizontal lines represent the mean. Paired Student’s T-test of 
percentage of tumour cell killing mediated by TLR-stimulated PBMC compared to unstimulated PBMC. p<0.05 for PGN, 
CL075 and ODN A (solid symbols). 
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Another approach to enhance NK cell-mediated cytotoxicity is by triggering TLR. 
Increase in NK cell lytic activity has been reported upon stimulation of purified NK cells with 
a broad panel of TLR agonists (in the concentrations used in this study), but co-stimulation by 
different cytokines was generally required [11;13;14]. TLR-triggering of PBMC by Poly 
(I:C), TLR7 and 8 agonists, and CpG have been shown to enhance NK cell cytotoxicity 
[12;18], and up to now, only CpG has been shown to enhance ADCC [18]. In this study, all 
TLR ligands tested have been shown to activate NK cells but only PGN, CL075 and ODN A 
had an appreciable effect on huHMFG-1-dependent ADCC. Interestingly, these three TLR 
agonists also induced the strongest iNKT cell activation (Moreno et al., submitted
1
). Based on 
these results and the finding that the increase in huHMFG-1 ADCC by TLR-triggering was 
comparable to that obtained by the addition of activated iNKT cells (approximately 1.5 fold-
increase), it is tempting to speculate that at least part of the TLR effect is achieved through 
iNKT cell activation. On the other hand, iNKT cell activation by the addition of -GC to 
PBMC had no effect. This may be explained by the fact that administration of free -GC can 
lead to iNKT cell unresponsiveness [19], due to presentation by non-professional APC, or that 
the iNKT cell activation by -GC and TLR ligands induce different cytokine secretion 
profiles, and therefore lead to a different outcome. 
TLR ligands are of great interest in the field of cancer immunotherapy. Their 
immunostimulatory properties have been exploited to increase the efficacy of various types of 
immunotherapy. Up to now, only CpG has been reported to modulate ADCC [18]. In animal 
models, CpG has potent anti-tumour effects when administered in vivo in combination with 
mAb [20]. Notably, van Ojik et al. have demonstrated that CpG treatment enhances anti-
HER2 mAb-dependent NK cell-mediated tumour regression in mice bearing experimental 
HER2-overexpressing tumours [21]. In the present study, it is demonstrated that next to ODN 
A, PGN and CL075 are promising in this respect as well, as they have been shown to activate 
iNKT cells and enhance huHMFG-1-mediated tumour cell killing in vitro. However, they 
have not yet been tested in humans. Another TLR 7/8 agonist, resiquimod, as well as TLR9 
agonists have been proven safe in humans, also in combination with mAb, such as rituximab 
[22;23].  
Although we observed an increase in huHMFG-1-mediated tumour cell killing, the 
effect was only moderate. It has been implied that huHMFG-1-mediated ADCC could be 
influenced by Fc receptor IIIa (FcRIIIa) polymorphism [5], which affects IgG1 binding. In 
the case of huHMFG1, next to the enhancement of NK cell activation by TLR and/or iNKT 
cells, improvement in antibody affinity is necessary. In vitro molecular engineering of the Fc 
region can improve the affinity of mAbs for the FcRIIIa, and thereby enhance ADCC [24].  
In conclusion, we showed that NK cell activation and subsequent enhanced ADCC can 
be achieved by iNKT cells and particular TLR ligands. The mechanism of TLR- triggering is 
not yet clear but may depend in part on iNKT cell activation. Therefore, our findings suggest 
that NK cell-mediated mAb-based tumour immunotherapies may benefit from autologous 
adoptive transfer of ex vivo expanded iNKT cells or administration of TLR agonists which 
induce iNKT and NK cell activation.  
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 Footnotes 
1
 Differential indirect activation of human invariant NKT cells by Toll-like receptor (TLR) 
agonists. María Moreno, Berber M. Mol, Silvia von Mensdorff-Pouilly, René H.M. Verheijen, 
Esther C. de Jong, B. Mary E. von Blomberg, Alfons J.M. van den Eertwegh, Rik J. Scheper, 
Hetty J. Bontkes. Submitted for publication. 
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AbstractInvariant Natural Killer T (iNKT) cells are CD1d restricted innate lymphoid cells with an invariant T cell receptor (TCR) α chain
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y andgene rearrangement (Vα24-Jα18 in human and Vα14-Jα18 in mouse). iNKTcells play a pivotal role in anti-tumor immune resp
via cytokine mediated transactivation of various cells which mediate innate and adaptive immune responses. Here we describe,
knowledge for the first time, the generation of long-term mouse spleen derived iNKT cell lines. We found that dendritic cells
derived from the D1 line, but not Mf4/4 macrophages, loaded with the artificial iNKT cell ligand α-Galactosylceramide (αG
could be employed to expand iNKT cells in vitro. Furthermore, exogenously added IL-7, but not IL-2 or IL-15 had a prono
additive effect on iNKT cell expansion. Using this method up to 108 iNKT cells could be obtained from one spleen within
14 weeks, and cell lines could be continued for up to 24 months. Importantly, the iNKT cell lines had retained the capacity to s
secrete substantial amounts of both T helper (Th) 1 and Th2 cytokines upon activation.
In conclusion we have generated iNKT cell lines with high yields that can be maintained for up to 24 months, by rep
stimulation using alpha-GalCer loaded D1.DC and IL-7. These in vitro expanded iNKT cells preserved the capacity to s
produce both Th1 and Th2 type cytokines and are currently being utilized in pre-clinical adoptive transfer models to identif
optimize the characteristics of therapeutically effective iNKT cells in an anti-tumor setting.
© 2007 Elsevier B.V. All rights reserved.
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Mattner et al., 2005; Wu et al., 2005; Kinjo et al., 2
Activation of iNKT cells induces a cytokine stor
which iNKTcells rapidly produce large amounts of
γ and IL-4 (Godfrey et al., 2000). These results i
transactivation of other immune cells (e.g. NK,
cells and DC) (Kitamura et al., 2000; Hermans e
2003; Fujii et al., 2003; Smyth et al., 2005). Via
mechanism iNKT cells have been proposed t
naturally required for efficient tumor immune su
lance (Brutkiewicz and Sriram, 2002; Chamoto e
2004; Crowe et al., 2002; Smyth et al., 2000, 2
Takeda et al., 2000; Taniguchi et al., 2003). Therap
activation of iNKT cells e.g. by treatment of mice
αGalCer induces potent anti-tumor immune respo
in various tumor models (Nakui et al., 2000, 1
Nakagawa et al., 2001; Kawano et al., 1998). Addit
work revealed that cancer patients have a num
deficiency in circulating iNKT cells compared to
and gender matched healthy individuals. Wh
residual iNKT cells of cancer patients are still funct
is a matter of debate; while we and others have rep
a preserved capacity of direct ex vivo IFN-γ secr
upon antigenic triggering by residual circulating i
cells in patients with breast cancer, colon cance
lung cancer while others found a reduction in I
secretion in e.g. prostate cancer and certain hemat
ical malignancies (Molling et al., 2005; Dhod
et al., 2003; Giaccone et al., 2002; Motohashi e
2002; Tahir et al., 2001).
In a prospective study we recently observed t
relatively large circulating iNKT cell pool pre
favorable clinical outcome in individuals with squa
cell carcinoma of the head and neck [Molling e
J Clin Oncol 2007]. Therefore, we hypothesize
cancer patients might benefit from immunothe
aimed at increasing functionally competent perip
iNKT cell numbers, e.g. by adoptive transfer of in
expanded autologous iNKT cells.
To gain more insight in the in vivo effec
adoptively transferred iNKT cells we developed a r
method for the generation of mouse iNKT cell line
are currently being utilized in pre-clinical tra
models. Mouse cell lines such as Mf4/4 macroph
and D1 derived DC can efficiently present pe
antigens to T cells (Desmedt et al., 1998; Winzler
1997). Here, spleen iNKT cells were co-cultured
αGalCer loaded, CD1d expressing D1 derived DC
Mf4/4 macrophages as antigen presenting cells (A
based on human iNKT expansion protocols (van 
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obtained iNKT cells were characterized with rega
cytokine secretion and surface receptor profiles.
2. Materials and methods
2.1. Cell lines and culture media
The following culture media (Cambrex Bio Sci
Verviers, Belgium) were used. IMDM, RPMI 1640
DMEM were supplemented with 10% Foetal
Serum (Hyclone, Logan, UT, USA), 0.01 mM 2
and 50 units/ml penicillin–streptomycin and, in the
of DMEM 1% Non-Essential Amino Acids (Invitr
Carlsbad, CA, USA) (IMDMc, RPMIc and DM
respectively). D1, an immature DC line was cultur
described in IMDMc, supplemented with superna
from the GM-CSF transfected cell line R1 (Foti e
1999). J558-CD40L, a CD40L-transfected J558 cel
(gift of Dr. P. Lane, University of Birming
Birmingham, UK) and the CD1d-transfected Hela
line (Brossay et al., 1998) were cultured in IMD
Mf4/4, a macrophage cell line (Desmedt et al., 1
was cultured in RPMI. DN32.D3, a murine iNKT
hybridoma line was cultured in DMEMc.
2.2. Generation of APC
Mf4/4 macrophages were cultured for 24 h i
presence of LPS (1 μg/ml; Sigma-Aldrich, Zwijndr
The Netherlands) and IFN-γ (400 IU/ml; R&D sys
Minneapolis, MN, USA). Immature D1 DC
cultured for 4 or 48 h in the presence of LPS (10
ml), and IFN-γ or LPS and PGE2 (10
−7 M; Si
Aldrich) to generate D1.DC1 or D1.DC2 respect
These maturation procedures were performed in
presence of αGalCer (100 ng/ml) or vehicle co
(Kalinski et al., 1999; Langenkamp et al., 2000; va
Vliet et al., 2003). APC cytokine profiles were ana
after a 48 h stimulation of 4×104 APC with 8
J558-CD40L in 200 μl IMDMc in 96 well round bo
plates (Nunc, Wiesbaden, Germany). Supernatants
analyzed for TNF-α, IL-6, IL-10 and IL-12p70
flow cytometry beads (BD Biosciences, San Diego
USA). In other experiments 1×104 APC were us
activate 5×104 DN32.D3 in 200 μl IMDM 18 h
well round bottom plates. The level of αGalCer sp
DN32.D3 activation was determined by IL-2 produ
quantified by IL-2 ELISA (BD Biosciences). A
presentation of αGalCer by DN32.D3 was prevente101
the following approach: first, the maximum density of
DN32.D3 to prevent IL-2 secretion due to auto-
presentation was determined in pilot experiments (not
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and/or mIL-15 (10 ng/ml) (R&D Systems) were added
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María Moreno Jaugeshown); second, all APC were pulsed with vehic
αGalCer during maturation and next extens
washed before co-culturing with DN32.D3. Sp
IL-2 production was calculated by subtracting
levels from DN32.D3 stimulated with vehicle tr
APC from IL-2 levels obtained with DN32.D3
αGalCer loaded APC. Mature APC, J558-CD40L
DN32.D3 were irradiated at 5000 Rad before al
culture experiments.
2.3. Mice
Donor mice used were 6–10 week old female C
6 (Harlan Netherlands B.V., Horst, The Netherla
Mouse care was in line with the guidelines provid
the VU Animal Ethical Committee, who approve
study.
2.4. T lymphocyte isolation from mouse spleen
Single cell suspensions were obtained by g
pressing mouse spleens through 100 μm filters.
were then centrifuged at 600 ×g and cells wer
suspended with PBS/0.1 M EDTA/0.2 M NH4Cl/0.
KHCO3. Cells were left on ice for 5 min allowing
of erythrocytes and then centrifuged at 240 ×g. N
cells were labeled with a mixture of rat monoc
antibodies directed against F4/80, B220, MHC cl
and CD11b (hybridoma derived clones F4/80, 6B2
114 and Mac-1 respectively; kindly provided b
Janneke N Samsom, Erasmus MC, Rotterdam)
subsequently labeled with magnetic goat-anti-rat
beads (Miltenyi Biotec, Bergisch-Gladbach, Germ
T lymphocytes were then obtained by negative sele
using the MiniMACS system (Miltenyi Biotec). In
individual expansion experiment (e.g. comparin
effects of different APC or of different cytokine
iNKT cell expansion) paired data were obtaine
using T cells isolated from one spleen (depicted as s
donor T cells).
2.5. Expansion of iNKT cells
For evaluation of iNKT cell expansion, 4×1
lymphocytes were co-cultured with 4×104 irrad
APC (5000 Rad) per well for 7 days in 48 well pla
IMDMc. Cultures were weekly re-stimulated with
APC in a T cell/APC ratio of 5 to 1. During the
week no cytokines were added, to reduce growth of102r
-
/
.
s
-
s
l
I
/
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.
t
-
as indicated. In some experiments, dose related e
of these cytokines were evaluated as indicated. i
cell purity was analyzed by detection of TCR med
binding to αGalCer loaded CD1d:IgG dimers
Biosciences) by flow cytometry.
2.6. Evaluation of iNKT cell cytokine production
The intracellular cytokine profile of iNKT line
determined when purity was above 95%, using
Cytofix/Cytoperm™ kit (BD Biosciences). iNKT
were harvested, washed and 1×105 cells were stimu
4 h with 1×105 Hela-CD1d in the presence of 0.66
monensin (BD Biosciences) and 100 ng/ml αGalC
vehicle in 96 well round bottom plates (total vo
200 μl). The following antibodies were used:
labeled hamster-anti-mouse TCR-β-chain (clone
597), FITC-labeled rat-anti-mouse IFN-γ (c
25723.11), APC-labeled rat-anti-mouse IL-4 (
3010.211) or FITC and APC-labeled rat IgG1 (
A110-1) and Cy5 labeled hamster IgG2 (clone H
isotype control. For determination of cytokine secr
supernatants were harvested after a 24 h co-cultu
1×105 iNKT cells and 1×105 Hela-CD1d cells i
presence of 100 ng/ml αGalCer or vehicle in 96
round bottom plates (total volume 200 μl). Superna
were analyzed for IL-1α, IL-2, IL-4, IL-5, IL-6, I
IL-17, GM-CSF, IFN-γ and TNF-α using flow
metry beads (Bender Medsystems, Vienna, Austria
analyzed for IL-21 by ELISA (R&D systems).
2.7. Surface marker expression on APC and iNKT
For evaluation of APC surface receptors, the
lowingmonoclonal antibodies were used: rat-anti-m
CD40 or CD86 (clones 3/23 and GL-1 respect
provided by Dr. Janneke N Samsom), followed by
labeled donkey-anti-rat IgG (Jackson ImmunoRese
West Grove, PA, US). FITC-labeled anti-mouse C
(clone 1B1) (BD Biosciences), PE-labeled anti-m
CD80 (clone 1G10) (Southern Biotech, Birming
AL, US), PE-labeled anti-mouse MHC class II (
M5/114.15.2) (eBioscience, San Diego, CA, US
FITC or PE-labeled rat IgG2b isotype control (
A95-1) (BD Biosciences).
For evaluation of iNKT cell purity, cells
incubated for 10 min at 37 °C with αGalCer or ve
loaded CD1d:IgG dimers, washed twice and s
quently stained with PE-labeled rat-anti-mouse
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(clone A85-1) and APC-labeled anti-CD3ε (clone 145-
2C11) or Armenian hamster IgG1 isotype control (clone
A19-3) (BD Biosciences).
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Student's T test, Wilcoxon signed ranks test or variance
analysis (ANOVA and Tukey–Kramer). P values below
0.05 were considered significant.
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For evaluation of the expression of other su
markers the following reagents were used: biotin
jugated rat-anti-mouse TCR-Vβ2, Vβ7 and V
(clones B20.6, TR310 and MR5-2 respectively)
Biosciences) combined with FITC-labeled strepta
(Dako Cytomation, Glostrup, DK), polyclonal goat
mouse IL-15Rα (R&D) combined with FITC-la
polyclonal rabbit-anti-goat Ig (Dako), FITC-labele
anti-mouse Ly-49A, Ly-49C+I, Ly-49D and Ly4
(clones A1, 5E6, 4E5, 4D11 respectively), FITC-la
rat-anti-mouse CD4 (clone GK1.5), PE-labeled m
anti-mouse NK1.1 (clone PK136), rat-anti-mouse C
(clone H35-17.2), CD49b (clone DX5), CD127
7Rα) (clone SB/199), APC-labeled rat-anti-m
CD25 (IL-2Rα) (clone 11B11) and rat-anti-m
CD44 (clone IM7) (BDBiosciences) and the approp
isotype controls. Expression levels were determine
Mean Fluorescence Index (MFIndex=mean flu
cence marker/mean fluorescence isotype). Propi
iodide was added prior to analysis to exclude dead
and flow cytometry was performed on a FACSC
BUR apparatus (BD Biosciences).
2.8. Statistical analyses
Depending on whether variables fitted a Gau
distribution or not, statistical analyses performedFig. 1. Surface receptor expression on the different APC. (A) D1.DC
CD80, CD86 andMHC class II (open histograms). The grey histogram
Mean Fluorescence Index (MFI) values (MFI=mean fluorescence
representative of four. 
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3. Results
3.1. Characterization of APC
In order to obtain insight in their potential to stim
the expansion of iNKTcells, the different APC were
characterized with regard to surface expression of C
co-stimulatory molecules, MHC class II and their c
ity to secrete inflammatory mediators.
We found that CD1d expression was most prom
on D1.DC2 and low to undetectable on D1.DC1
MF4/4. Expression of MHC class II and the co-s
latory molecules CD40, CD80 and CD86 wer
highest on D1.DC2 (Fig. 1). The secretion of inflam
tory mediators was determined after 48 h of stimul
with CD40-L transfected J558 cells. Overall Mf4/4
DC1 and D1.DC2 did not significantly differ i
secreted amounts of TNF-α (mean±SEM=7207±4
3100 ±1102 and 3431 ± 972 pg/ml respecti
p=0.3794, repeated measures ANOVA), IL-6 (m
SEM=2949±2126, 3785±976 and 7782±3607 p
respectively) (p=0.1012, repeated measures ANO
and IL-10 (mean±SEM=12785±8444, 7705±499
18246±15641 pg/ml respectively; p=0.4805, rep
measures ANOVA). IL-12p70 was not detected in a
the samples.1, D1.DC2 and MF4/4 were analyzed for surface expression of CD1d, CD40,
s represent the isotype controls. The data in the upper right corners indicate the
marker/mean fluorescence isotype control). Data are from one experiment
103
Finally we determined whether all APC were able to
present αGalCer to the iNKT cell hybridoma DN32.D3,
which secretes IL-2 upon TCR triggering (Brutkiewicz
Fig. 2. D1.DC1 are more potent than D1.DC2 in mediating iNKT cel
expansion. iNKT cell expansion and purity was assessed after thre
weekly stimulations with αGalCer loaded D1.DC1 (n=24), D1.DC
(n=24) or Mf4/4 (n=8) in the presence of different combinations o
IL-2, IL-7 and/or IL-15. (A) Fold expansion of αGalCerCD1d dimer
iNKT cells (pb0.0001 Kruskal–Wallis); (B) Percentage of iNKT cell
of total cells in culture (pb0.0001 Kruskal–Wallis). Dots represen
individual cultures, bold lines represent medians.
Fig. 3. Different effects of IL-2, IL-7 and IL-15 on iNKT ce
expansion. iNKT cells were expanded by co-culturing with D1.DC1 i
medium supplemented with IL2, IL7 and/or IL15. After three weekl
stimulation rounds, cells were analyzed by FACS (CD3+/αGalCer
CD1d dimer+) and counted. (A) Fold expansion of iNKT cells usin
IL-7 and IL-15, IL-2 and IL-15, IL-2 and IL-7 (white, grey or black ba
respectively) or all three combined (hatched bar) in paired experi
ments. Bars represent means, error bars represent SEM (n=5)
(B) Fold expansion of iNKT cells using escalating doses of IL-
and/or IL-7. Markers represent means, error bars represent SEM
(n=3). Data are from three donors in one experiment, representative o
three. (C) Several iNKT lines were cultured for a prolonged period
Lines indicate growth kinetics of the individual iNKT lines
percentages indicate iNKT cell purity determined by CD3/αGal
CerCD1d dimer staining at the time of last analysis. ⁎: maintained i
culture for up to 24 months.
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et al., 1995). D1.DC1 and D1.DC2 were significantly
more potent in inducing αGalCer specific IL-2 release
by DN32.D3 than Mf4/4 (mean±SEM=25867±12878,
1 re
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edian
s 1.7
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f4/4
(median expansion [IQR]=24 [11–51], 1 [0–5] and
0 [0–0.05] fold respectively, pb0.0001 Kruskal–
Wallis) (median purity [IQR]=50 [27–66], 6 [1–28]
skal–
d D1.
tures,
ed in
unds
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iNKT
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25707±12568 and 11721±9454 pg/ml, pb0.00
peated measures ANOVA; n=5). These findings
cate that, despite the low level of expression of C
all APC could functionally present αGalCer to i
cells and that the intensity of CD1d expression wa
predictive of DN32.D3 activation.
3.2. D1.DC but not Mf4/4 can induce iNKTcell expa
Next, we evaluated whether D1.DC1, D1.DC2
Mf4/4 were able to induce the in vitro expansio
iNKTcells. Spleen T cells (∼95% pure) were week
stimulated using αGalCer loaded Mf4/4, D1.DC1 o
DC2 in the presence of matched combinations of
IL-7 and IL-15. At the start of culture the m
[inter quartile range (IQR)] iNKT cell purity wa
[1.3–1.9] % and after three stimulation round
cultures consisted solely of T cells (not shown). A
point iNKT cell expansion and purity were most
nounced using D1.DC1 compared to D1.DC2, wh
no iNKTcell expansion was observed when usingMFig. 4. CD1d dimer staining and intracellular staining for IFN-γ and I
and used for further characterization (depicted above plots). A) Histo
histograms) loaded CD1d:IgG dimers. Numbers in upper right indi
intracellular staining for IFN-γ and IL-4 after 4 h stimulation with Hel
plots). Numbers in upper right indicate percentage of cells in the cor 
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-
,
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and 0.1 [0–0.3] % respectively, pb0.0001 Kru
Wallis) (Fig. 2). Of note, although both D1.DC1 an
DC2 could be applied to generate iNKT bulk cul
repeated in vitro stimulation with D1.DC2 result
overall cell death after 4 to 5 total re-stimulation ro
(not shown). These data indicate that, of the three
that we compared, D1.DC1 provide the best too
expanding iNKT cells from mouse spleen T cells.
3.3. IL-2, IL-7 and IL-15 have different effects on
cell expansion
Next we investigated the influence of IL-2, IL-7
IL-15 on the in vitro iNKT cell expansion from s
donor Tcells after three stimulation rounds with D1
(n=5). Combining equal units of IL-7 and IL-15 res
in amean±SEM=21±8 fold expansion (Fig. 3A).W
IL-7 was replaced by IL-2, no remarkable differenc
observed (mean±SEM=17±9 fold). However,
IL-2 and IL-7 were combined a striking increase in i
cell expansion occurred (mean±SEM=46±21L-4 production. Four iNKT lines were selected on the basis of their high purity
gram plots indicate staining with vehicle (grey histograms) or αGalCer (open
cate percentage of αGalCerCD1d dimer positive cells. B) Dot plots indicate
a-CD1d in the presence of vehicle (upper plots) or αGalCer (100 ng/ml) (lower
responding quadrants.
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These findings indicate that IL-2 and IL-7 can col-
lectively support iNKT cell expansion, whereas IL-15
hampers the effects of the former two. This was
cel
dded
ntrib
e, the
ssay
dose
d by
IL-2
stem
tha
cel
pered
s o
using
s and
were maintained by weekly re-stimulation with exoge-
nously added D1.DC1 and IL-7.
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María Moreno Jaugeunderlined by the fact that the mean±SEM iNKT
expansion returned to 22±8 fold when IL-15 was a
to the combination of IL-2 and IL-7.
To further elucidate whether IL-2 and IL-7 co
uted synergistically or cumulatively to the mixtur
two cytokines were combined in a dose response a
Addition of IL-2 did not clearly affect the strong
dependent increase in iNKT cell expansion cause
IL-7 (n=3). Furthermore, in the dose range tested
alone did not support iNKT cell expansion in our sy
(Fig. 3B). Altogether the above data demonstrate
IL-7 was most effective in supporting iNKT
expansion driven by D1.DC1, while IL-15 ham
the effect of IL-7.
Fig. 3C shows data from long-term culture
several iNKT lines that were initially generated
D1.DC1 and combinations of the above cytokineFig. 5. Cytokine secretion profiles of iNKT cell lines. iNKT cell lines
ml). Supernatants were analyzed for the presence of IFN-γ, GM-CSF
beads. Black bars represent the Th1 cytokines IFN-γ and GM-CSF, wh
IL-2 and IL-17 were detected in none of the supernatants tested. Ba
106l
-
.
t
l
f
3.4. iNKT cell lines obtained with D1.DC1 and
secrete both Th1 and Th2 cytokines
The most notable characteristic of iNKT cells is
capacity to rapidly secrete large amounts of IFN-γ
IL-4 upon activation. We investigated here whethe
trait was retained after in vitro culture with D1.DC
exogenous IL-7. First, intracellular expression of I
and IL-4 was assessed in four iNKT cell lines (N
purity, Fig. 4A) after 4 h of αGalCer stimulation
flow-cytometry. All cell lines displayed αG
reactivity as shown by αGalCer-CD1d dimer reac
and by an increased percentage of IL-4 and/or I
positive cells (Fig. 4) when cells were treated
αGalCer (bottom) as compared to vehicle (top).
we investigated the T helper (Th)1/Th2 cyto
secretion profile after 24 h of αGalCer stimulwere co-cultured for 24 h with Hela-CD1d in the presence of αGalCer (100 ng/
, TNF-α, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10 and IL-17 using flow cytometry
ite bars represent the Th2 cytokines IL-4, IL-5, IL-6, and IL-10. TNF-α, IL-1α,
rs represent means, error bars represent SEM (n=4).
 
 
 
 
 
 
(Fig. 5). In addition to IFN-γ and IL-4, all iNKT cell
lines secreted GM-CSF, IL-5, IL-6 and IL-10. TNF-α,
IL-1α, IL-2, IL-17 and IL-21 were not detectable in the
cel
both
3.5. The IFN-γ/IL-4 balance is reflected in the surface
marker expression profile
rface
lines
d the
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lines had retained the capacity to swiftly secrete
Th1 and Th2 cytokines. 
Fig. 6. Expression of surface markers on iNKT cell lines. Expression
on iNKT cell lines using flow cytometry (open histograms). The gre
depicted in the upper right corner of each histogram. Data are from one
the iNKT lines are depicted above the histogram plots (means of thr 
 
 
 
 
l Next, we analyzed TCR-Vβ chain usage and su
receptor expression on the selected iNKT cell
(Fig. 6). The iNKT lines predominantly expresse 
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of TCR-Vβ2, -Vβ7, -Vβ8.2, CD44, CD49b, NK1.1 and CD4 was determined
y histograms represent the isotype controls. The percentage of positive cells is
experiment representative of three. The mean IFN-γ/IL-4 production ratios for
ee intracellular cytokine staining experiments as depicted in Fig. 4).
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TCR-Vβ8.2 or -Vβ7 chain, indicating that iNKT lines
primarily using the low avidity TCR-Vβ2 chain most
likely can not be obtained using the method described
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were treated with αGalCer, LPS and IFN-γ, since this
combination has previously been described to support
their maturation into Th1-oriented APC (Desmedt et al.,
-γ or
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stage during iNKT cell maturation is reflected
gradual shift in their cytokine profile upon activ
from the predominant production of IL-4 towards
γ. Throughout their development iNKT cells seq
tially enhance CD44 expression, acquire CD49b
NK1.1 and presumably finally lose CD4 expre
(Benlagha et al., 2002, 2005; Coles and Raulet, 2
Gadue and Stein, 2002; Pellicci et al., 2002)
therefore assessed expression of these markers o
four iNKT cell lines selected above to determine w
er their surface marker phenotypes fitted their IFN-
4 balance. All lines consisted of a high numb
CD44high cells (mean [SD]=89 [3], 81 [3], 75 [3] a
[5] %) (n=4), similar to the levels observed in wil
(Wt) spleen (Matsuda et al., 2000). However, the
differed in the expression of CD49b (mean [SD
[27], 66 [17], 33 [13] and 34 [7] %) and CD4 (
[SD]=1 [0,4], 2 [2], 50 [24] and 59 [3] %) (n
Expression of NK1.1 was very rarely found (mean [S
2 [1], 3 [3], 0 [0] and 0 [0] %) (n=3), most likely
to activation induced down-regulation of this rec
The presence of other NK markers was also investig
All iNKT cell lines were negative for the activatin
receptor Ly-49D and the inhibitory NK receptors Ly-
Ly-49C+I and Ly-49G2 (not shown). Based on
differential expression of CD49b and CD4, these
suggest that iNKTcell lines #1 and #2, with a higher
γ/IL-4 ratio (Fig. 4), indeed have a more mature su
receptor phenotype. However, we did not observe
clear cut differences in IFN-γ or IL-4 production bet
the CD4+ and CD4− subsets within individual iNK
lines as determined by intracellular cytokine staining
shown).
4. Discussion
Although other studies have demonstrated tha
possible to generate from mice either short lived
cultures containing bona fide iNKT cells (Maeda
2001; Chamoto et al., 2004; Ikarashi et al., 2005) or
lived clone derived iNKT cell hybridomas (Lantz
Bendelac, 1994; Gumperz et al., 2000; Behar e
1999), this is the first study to make available
scale, highly pure long-term oligoclonal murine i
cell lines representative of in vivo iNKT cells.
strategy was to investigate whether αGalCer lo
Mf4/4 or D1.DC could be used to generate iNKT
lines from mouse spleen T cells. Mf4/4 macroph108l
,
-
-
;
-
-
f
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,
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1998). D1 were treated with αGalCer, LPS and IFN
αGalCer, LPS and PGE2 to mature them into D1.D
D1.DC2 respectively (Kalinski et al., 1999; Lan
kamp et al., 2000). Preceding experiments with si
treatment of human moDC revealed that using DC
could generate more Th1-oriented iNKT cell
whereas using DC2 induced more potent expansi
iNKT cells (van der Vliet et al., 2003). All
expressed co-stimulatory molecules and did not rem
ably differ in their capacity to secrete TNF-α, IL-
IL-10. Surprisingly, no IL-12p70 was detecte
supernatants of CD40 triggered APC. IL-12p70 s
tion might depend on additional signaling and th
more potent during co-culture with iNKT cells, as e
vitro CD1d triggering of human monocytes also ind
IL-12 (Yue SC et al. PNAS 102(33): 11811, 2005
in vitro IL-12p70 secretion by TNF-α matured
cells, also required antigen presentation to antigen
cific T cell clones (Winzler et al., 1997).
Expression of CD1d on the investigated APC
low to undetectable using our staining method. H
ever, surface levels might increase during co-cu
with iNKT cells allowing D1.DC2 and Mf4/4 to pr
αGalCer, since it has been reported that GM-CSF
IL-4 (both secreted swiftly by iNKT cells) can inc
mouse CD1d expression (Mandal et al., 1998). In
with this, here, all APC induced an αGalCer depe
activation of the iNKT cell hybridoma DN32.D3.
only D1.DC1 and D1.DC2 could be used to gen
iNKT cell lines from mouse spleen. The diff
efficacy of the APC in inducing iNKT cell activ
and expansion may be related to the limited in vitr
span of Mf4/4 upon maturation (not shown), w
might not be sufficiently long to allow the p
activation of iNKT cells. Furthermore, D1.DC1
superior to D1.DC2 in mediating in vitro iNKT
expansion and were the only APC that allowed
term cultures, as the iNKTcell lines generated usin
DC2 could not be maintained for more than four w
(not shown). One could speculate that the relat
strong expression of CD1d on D1.DC2 compared t
DC1 induces in vitro contraction of the iNKT
response to αGalCer as described for the repeat
vivo stimulation of iNKT cells with this ligand (Ul
et al., 2005). However, iNKT cells have been show
be relatively resistant to apoptosis as a result of i
sically elevated levels of anti-apoptotic proteins (H
et al., 2004; Seino et al., 2004). An evaluation o
expression profiles of pro- and anti-apoptotic gen
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iNKT cells stimulated with D1.DC1 or D1.DC2 might
lead to further clarification.
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vivo homeostasis of iNKT cells, whereas IL-2
redundant. Indeed, IL-7 was more effective than IL
enhancing iNKT cell expansion. Remarkably, I
hampered the effects of IL-7. This negative effect o
15 was unforeseen since this cytokine has been desc
to be the predominantmediator of in vivo (invariant)
cell homeostasis (Golden-Mason et al., 2004; Ma
et al., 2002). IL-15 can perform its functions by
binding to the IL-15 receptor (IL-15R) complex
cells, which consists of IL-15Rα, IL-2/IL-15Rβ chai
the common-γ-chain (γC). Alternatively, and likely
physiologically more important, IL-15Rα+ APC
“transpresent” surface bound IL-15 to the IL
complex on T, NK and (i)NKT cells (Dubois e
2002; Schluns et al., 2004). The iNKT cell line
expected to be susceptible to IL-15 signaling because
expressed IL-15Rα (not shown). We found no IL-1
expression by D1.DC1 (not shown), suggesting th
antagonizing effect of IL-15 on IL-7 in our system
caused by competition for γC. iNKT cell expa
experiments comparing the effects of IL-7 and I
using IL-15Rα+ and IL-15Rα− APC might pr
confirmation of this hypothesis.
The most notable characteristic of iNKT cells in
is their capacity to rapidly secrete large amounts of
γ and IL-4 upon activation (Matsuda et al., 2
Nakagawa et al., 2001; Crowe et al., 2003). As e
described for short term cultured iNKT cells (Ika
et al., 2005), we demonstrate here that this trait
retained after repeated stimulation with D1.DC1
exogenous IL-7. After 4 h of stimulation with αG
loaded Hela-CD1d the iNKT cell lines produced
IFN-γ and IL-4. Other Th1 and Th2 type cyto
(GM-CSF, IL-5, IL-6 and IL-10) were also prod
indicating that all lines fitted a Th0 profile. The lim
amount of cells producing both IFN-γ and IL-4 i
intracellular cytokine staining experiments was s
what surprising. One might argue that the human C
transfected APC did not provide the proper anti
and co-stimulatory signals. However, the rel
amount of iNKT cells producing both IFN-γ and
was not increased by stimulating with PMA/ionom
(not shown). Furthermore, we found no clear cu
ferences in the IFN-γ/IL-4 balance between the C
and CD4− subsets within iNKT cell cultures in co
to the finding that freshly isolated human CD4+ i
are the predominant source of IL-4 (Gumperz e
2002; Lee et al., 2002). These results indicate th
least for mouse iNKT cells, additional markers d 
 
 
 
 
 
 
 
 
 
s
-
t
,
s
-
;
r
i
s
r
s
,
-
-
-
t
,
t
-
phenotype tended to have a more prominent Th1 pr
which fits with the proposed in vivo developm
stages of iNKT cells (Benlagha et al., 2002, 2005; C
and Raulet, 2000; Gadue and Stein, 2002; Pellicci
2002). These findings correlated with the period
lines had been maintained in culture at the tim
phenotypical and functional analysis (10, 6, 4
3 months respectively). The very low numbe
NK1.1+ cells in the CD4− iNKT cell lines is in co
to the in vivo development of iNKT cells,
acquisition of this molecule has been postulate
precede loss of CD4 expression during thymic d
opment (Pellicci et al., 2002). However, the iNKT
lines presented here were chronically activate
weekly re-stimulation with αGalCer loaded DC
thus might have down-modulated NK1.1 expre
(Chen et al., 1997; Wilson et al., 2003). This la
NK1.1 was also observed recently by Ikarashi
(2005) after 6 days of in vitro iNKT cell stimul
with αGalCer. Alternatively, one can not exclud
possibility that loss of NK1.1+ cells results from
preferential in vitro expansion of the NK1.1− s
which lacks NK receptors of the Ly-49 family, sinc
49/MHC class I interactions were reported to in
iNKT proliferation in vitro (Maeda et al., 2
Tracking proliferation and surface marker expre
of sorted NK1.1− versus NK1.1+ iNKT cells d
repeated stimulation with αGalCer loaded D1
could provide further insight in this matter.
In conclusion, iNKT cell lines can be effici
generated from mouse spleen T-cells by stimulation
αGalCer loaded D1.DC1 in the presence of IL-7. U
this method up to 108 iNKT cells can be obtained
one spleen within 12 to 14 weeks, and cell lines c
continued for up to 24 months, without losing
capacity to swiftly secrete cytokines upon activatio
thus have retained their strong capacity to stren
immune responses. These iNKTcells are currently
used for adoptive transfer experiments to inves
their biology in immune responses and to translate
potentially successful immunotherapeutic strategy
Acknowledgements
We are grateful to Ms. Paola Ricciardi-Castagno
providing the D1 DC cell line and to Edward Nieu
huis for providing the DN32.D3 iNKT cell hybrid
Furthermore we would like to thank Lisette van B
Lotte Huijts, Marco Schreurs and Janneke Samsom109
theirmany advises and technical assistance.We also thank
Kirin Brewery for providing the αGalCer. Work was
supported by grant VU2002-2607 (to B.M.E.v.B., R.J.S.
by a
from
h.
M.B
61.
002. A
2005
T cel
ti, G
nitio
highl
1.
lls an
l. 287
, 1995
xpres
aki, J
act a
K cell
vivo
ls los
12.
rise i
lecule
ole fo
holan
, K.J
myth
rapi
cells
1998
1 cel
5300
jii, S
fect i
ion o
. 1667
Ralph
munit
rdi, S
. Upo
cepto
enanc
, 2003
ramid
rapidly induces the full maturation of dendritic cells in vivo and
thereby acts as an adjuvant for combined CD4 and CD8 T cell
immunity to a coadministered protein. J. Exp. Med. 267.
Gadue, P., Stein, P.L., 2002. NK T cell precursors exhibit differential
ration.
rs, M.,
an den
inedo,
ligand
solid
axter,
unol.
Entee,
epatic
l NK/
ol. 94.
a, M.,
renner,
cogni-
2002.
iller T
.
Ito, T.,
tion of
upon
ter, G.,
T cells
gen in
munol.
asugi,
anded
NKT)
tt. 101.
, 1999.
lls: the
ki, K.,
i, H.,
activa-
1626.
to, H.,
ka, Y.,
or cell
cells.
nhnia,
r, G.F.,
., Tsuji,
iller T
acteria.
Nakui,
no, T.,
ramide
NKT
80 J.W. Molling et al. / Journal of Immunological Methods 322 (2007) 70–81
María Moreno JaugeandA.J.M.v.d.E.) from theDutch Cancer Society and
talent grant and grant 920-03-142 (to H.J.J.v.d.V.)
the Netherlands Organization for Scientific Researc
References
Behar, S.M., Podrebarac, T.A., Roy, C.J., Wang, C.R., Brenner,
1999. Diverse TCRs recognize murine CD1. J. Immunol. 1
Benlagha, K., Kyin, T., Beavis, A., Teyton, L., Bendelac, A., 2
thymic precursor to the NK T cell lineage. Science 553.
Benlagha, K., Wei, D.G., Veiga, J., Teyton, L., Bendelac, A.,
Characterization of the early stages of thymic NK
development. J. Exp. Med. 485.
Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casora
Dellabona, P., Kronenberg, M., 1998. CD1d-mediated recog
of an alpha-galactosylceramide by natural killer T cells is
conserved through mammalian evolution. J. Exp. Med. 152
Brutkiewicz, R.R., Sriram, V., 2002. Natural killer T (NKT) ce
their role in antitumor immunity. Crit. Rev. Oncol./Hemato
Brutkiewicz, R.R., Bennink, J.R., Yewdell, J.W., Bendelac, A.
TAP-independent, beta 2-microglobulin-dependent surface e
sion of functional mouse CD1.1. J. Exp. Med. 1913.
Chamoto, K., Takeshima, T., Kosaka, A., Tsuji, T., Matsuz
Togashi, Y., Ikeda, H., Nishimura, T., 2004. NKT cells
regulatory cells rather than killer cells during activation of N
mediated cytotoxicity by alpha-galactosylceramide in
Immunol. Lett. 5.
Chen, H., Huang, H., Paul, W.E., 1997. NK1.1+ CD4+ T cel
NK1.1 expression upon in vitro activation. J. Immunol. 51
Coles, M.C., Raulet, D.H., 2000. NK1.1+ T cells in the liver a
the thymus and are selected by interactions with class I mo
on CD4+ CD8+ cells. J. Immunol. 2412.
Crowe, N.Y., Smyth, M.J., Godfrey, D.I., 2002. A critical r
natural killer T cells in immunosurveillance of methylc
threne-induced sarcomas. J. Exp. Med. 119.
Crowe, N.Y., Uldrich, A.P., Kyparissoudis, K., Hammond
Hayakawa, Y., Sidobre, S., Keating, R., Kronenberg, M., S
M.J., Godfrey, D.I., 2003. Glycolipid antigen drives
expansion and sustained cytokine production by NK T
J. Immunol. 4020.
Desmedt, M., Rottiers, P., Dooms, H., Fiers, W., Grooten, J.,
Macrophages induce cellular immunity by activating Th
responses and suppressing Th2 cell responses. J. Immunol.
Dhodapkar, M.V., Geller, M.D., Chang, D.H., Shimizu, K., Fu
Dhodapkar, K.M., Krasovsky, J., 2003. A reversible de
natural killer T cell function characterizes the progress
premalignant to malignant multiple myeloma. J. Exp. Med
Dubois, S., Mariner, J., Waldmann, T.A., Tagaya, Y., 2002. IL-15
recycles and presents IL-15 In trans to neighboring cells. Im
537.
Foti, M., Granucci, F., Aggujaro, D., Liboi, E., Luini, W., Mina
Mantovani, A., Sozzani, S., Ricciardi-Castagnoli, P., 1999
dendritic cell (DC) activation chemokines and chemokine re
expression are rapidly regulated for recruitment and maint
of DC at the inflammatory site. Int. Immunol. 979.
Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., Steinman, R.M.
Activation of natural killer T cells by alpha-galactosylce110.,
.
l
.,
n
y
d
.
.
-
.,
s
-
.
e
n
s
r
-
.,
,
d
.
.
l
.
.,
n
f
.
a
y
.,
n
r
e
.
e
cytokine regulation and require Itk for efficient matu
J. Immunol. 2397.
Giaccone, G., Punt, C.J., Ando, Y., Ruijter, R., Nishi, N., Pete
von Blomberg, B.M., Scheper, R.J., van der Vliet, H.J., v
Eertwegh, A.J., Roelvink, M., Beijnen, J., Zwierzina, H., P
H.M., 2002. A phase I study of the natural killer T-cell
alpha-galactosylceramide (KRN7000) in patients with
tumors. Clin. Cancer Res. 3702.
Godfrey, D.I., Hammond, K.J., Poulton, L.D., Smyth, M.J., B
A.G., 2000. NKT cells: facts, functions and fallacies. Imm
Today 573.
Golden-Mason, L., Kelly, A.M., Doherty, D.G., Traynor, O., Mc
G., Kelly, J., Hegarty, J.E., O'Farrelly, C., 2004. H
interleuklin 15 (IL-15) expression: implications for loca
NKT cell homeostasis and development. Clin. Exp. Immun
Gumperz, J.E., Roy, C., Makowska, A., Lum, D., Sugit
Podrebarac, T., Koezuka, Y., Porcelli, S.A., Cardell, S., B
M.B., Behar, S.M., 2000. Murine CD1d-restricted T cell re
tion of cellular lipids. Immunity 211.
Gumperz, J.E., Miyake, S., Yamamura, T., Brenner, M.B.,
Functionally distinct subsets of CD1d-restricted natural k
cells revealed by CD1d tetramer staining. J. Exp. Med. 625
Harada, M., Seino, K., Wakao, H., Sakata, S., Ishizuka, Y.,
Kojo, S., Nakayama, T., Taniguchi, M., 2004. Down-regula
the invariant Valpha14 antigen receptor in NKT cells
activation. Int. Immunol. 241.
Hermans, I.F., Silk, J.D., Gileadi, U., Salio, M., Mathew, B., Rit
Schmidt, R., Harris, A.L., Old, L., Cerundolo, V., 2003. NK
enhance CD4+ and CD8+ T cell responses to soluble anti
vivo through direct interaction with dendritic cells. J. Im
5140.
Ikarashi, Y., Iizuka, A., Heike, Y., Yoshida, M., Takaue, Y., Wak
H., 2005. Cytokine production and migration of in vitro-exp
NK1.1(−) invariant Valpha14 natural killer T (Valpha14i
cells using alpha-galactosylceramide and IL-2. Immunol. Le
Kalinski, P., Hilkens, C.M., Wierenga, E.A., Kapsenberg, M.L.
T-cell priming by type-1 and type-2 polarized dendritic ce
concept of a third signal. Immunol. Today 561.
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Moto
Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Kosek
Taniguchi, M., 1997. CD1d-restricted and TCR-mediated
tion of valpha14 NKT cells by glycosylceramides. Science
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Sa
Kondo, E., Harada, M., Koseki, H., Nakayama, T., Tana
Taniguchi, M., 1998. Natural killer-like nonspecific tum
lysis mediated by specific ligand-activated Valpha14 NKT
Proc. Natl. Acad. Sci. U. S. A. 5690.
Kinjo, Y., Tupin, E., Wu, D., Fujio, M., Garcia-Navarro, R., Be
M.R., Zajonc, D.M., BenMenachem, G., Ainge, G.D., Painte
Khurana, A., Hoebe, K., Behar, S.M., Beutler, B.,Wilson, I.A
M., Sellati, T.J., Wong, C.H., Kronenberg, M., 2006. Natural k
cells recognize diacylglycerol antigens from pathogenic b
Nat. Immunol. 978.
Kitamura, H., Ohta, A., Sekimoto, M., Sato, M., Iwakabe, K.,
M., Yahata, T., Meng, H., Koda, T., Nishimura, S., Kawa
Taniguchi, M., Nishimura, T., 2000. alpha-galactosylce
induces early B-cell activation through IL-4 production by
cells. Cell. Immunol. 37.
 
 
 
 
 
 
 
 
 
I 
N 
 
V 
I 
V 
O 
 
 
Langenkamp, A., Messi, M., Lanzavecchia, A., Sallusto, F., 2000.
Kinetics of dendritic cell activation: impact on priming of TH1,
TH2 and nonpolarized T cells. Nat. Immunol. 311.
Lantz, O., Bendelac, A., 1994. An invariant T cell receptor alpha chain
mple
mans
istinc
cells
ulatio
ls an
Y.H
ulatio
. Mol
iguchi
ing th
usin
eredig
of V
Zhou
e, K
, P.B
olipid
Natur
M.F
endijk
an de
cretin
cance
cer 87
C.R
heper
ulatin
me i
. Clin
ni, O
hi, M
lpha2
59.
ra, H
2001
of th
mice
uuchi
l kille
nod
er Res
ata, T
hi, M
T cel
-12 o
Exp
Pellicci, D.G., Hammond, K.J., Uldrich, A.P., Baxter, A.G., Smyth,M.J.,
Godfrey, D.I., 2002. A natural killer T (NKT) cell developmental
pathway involving a thymus-dependent NK1.1(−)CD4(+) CD1d-
dependent precursor stage. J. Exp. Med. 835.
on, L.,
ontrol
IL-15
616.
atively
, J.A.,
odfrey,
r (NK)
, D.I.,
nd NK
. Exp.
tricted
natural
, G.J.,
amma
ancer.
er, L.,
elative
tivities
ystem:
4.
an, Y.,
, D.I.,
vivo:
action,
unol.
olgen,
B.M.,
tion of
nteers
d and
1.
A.K.,
er, L.,
gens is
nsion.
a, G.,
agnoli,
rowth
llivan,
g, M.,
ds and
. Natl.
ao, Y.,
rg, S.,
n, L.,
ion by
81J.W. Molling et al. / Journal of Immunological Methods 322 (2007) 70–81
Innate and adaptive tumour immunity: Role of invariant Natural Killer T-cells 
is used by a unique subset of major histocompatibility co
class I-specific CD4+ and CD4-8− T cells in mice and hu
J. Exp. Med. 1097.
Lee, P.T., Benlagha, K., Teyton, L., Bendelac, A., 2002. D
functional lineages of human V(alpha)24 natural killer T
J. Exp. Med. 637.
Maeda, M., Lohwasser, S., Yamamura, T., Takei, F., 2001. Reg
of NKT cells by Ly49: analysis of primary NKT cel
generation of NKT cell line. J. Immunol. 4180.
Mandal, M., Chen, X.R., Alegre, M.L., Chiu, N.M., Chen,
Castano, A.R., Wang, C.R., 1998. Tissue distribution, reg
and intracellular localization of murine CD1 molecules
Immunol. 525.
Matsuda, J.L., Naidenko, O.V., Gapin, L., Nakayama, T., Tan
M., Wang, C.R., Koezuka, Y., Kronenberg, M., 2000. Track
response of natural killer T cells to a glycolipid antigen
CD1d tetramers. J. Exp. Med. 741.
Matsuda, J.L., Gapin, L., Sidobre, S., Kieper, W.C., Tan, J.T., C
R., Surh, C.D., Kronenberg, M., 2002. Homeostasis
binfNalphab/infN14i NKT cells. Nat. Immunol. 966.
Mattner, J., Debord, K.L., Ismail, N., Goff, R.D., Cantu III, C.,
D., Saint-Mezard, P., Wang, V., Gao, Y., Yin, N., Hoeb
Schneewind, O., Walker, D., Beutler, B., Teyton, L., Savage
Bendelac, A., 2005. Exogenous and endogenous glyc
antigens activate NKT cells during microbial infections.
525.
Molling, J.W., Kolgen, W., van der Vliet, H.J., Boomsma,
Kruizenga, H., Smorenburg, C.H., Molenkamp, B.G., Lang
J.A., Leemans, C.R., von Blomberg, B.M., Scheper, R.J., v
Eertwegh, A.J., 2005. Peripheral blood IFN-gamma-se
Valpha24+Vbeta11+NKT cell numbers are decreased in
patients independent of tumor type or tumor load. Int. J. Can
Molling, J.W., Langius, J.A.E., Langendijk, J.A., Leemans,
Bontkes, H.J., van der Vliet, H.J., von Blomberg, B.M.E., Sc
R.J., van den Eertwegh, A.J.M., 2007. Low levels of circ
invariant natural killer T cells predict poor clinical outco
patients with head and neck squamous cell carcinoma. J
Oncol. 25.
Motohashi, S., Kobayashi, S., Ito, T., Magara, K.K., Miku
Kamada, N., Iizasa, T., Nakayama, T., Fujisawa, T., Taniguc
2002. Preserved IFN-alpha production of circulating Va
NKT cells in primary lung cancer patients. Int. J. Cancer 1
Nakagawa, R., Nagafune, I., Tazunoki, Y., Ehara, H., Tomu
Iijima, R., Motoki, K., Kamishohara, M., Seki, S.,
Mechanisms of the antimetastatic effect in the liver and
hepatocyte injury induced by alpha-galactosylceramide in
J. Immunol. 6578.
Nakui, M., Iwakabe, K., Ohta, A., Sekimoto, M., Sato, M., Mak
H., Kawano, T., Taniguchi, M., Nishimura, T., 1999. Natura
T cell ligand alpha-galactosylceramide inhibited lymph
metastasis of highly metastatic melanoma cells. Jpn. J. Canc
801.
Nakui, M., Ohta, A., Sekimoto, M., Sato, M., Iwakabe, K., Yah
Kitamura, H., Koda, T., Kawano, T., Makuuchi, H., Taniguc
Nishimura, T., 2000. Potentiation of antitumor effect of NK
ligand, alpha-galactosylceramide by combination with IL
lung metastasis of malignant melanoma cells. Clin.
Metastasis 147. 
 
 
 
 
 
 
 
 
 
x
.
t
.
n
d
.,
n
.
,
e
g
,
,
.,
.,
e
.,
,
n
g
r
.
.,
,
g
n
.
.,
.,
4
.,
.
e
.
,
r
e
.
.,
.,
l
n
.
Schluns, K.S., Nowak, E.C., Cabrera-Hernandez, A., Puddingt
Lefrancois, L., Aguila, H.L., 2004. Distinct cell types c
lymphoid subset development by means of IL-15 and
receptor alpha expression. Proc. Natl. Acad. Sci. U. S. A. 5
Seino, K., Harada, M., Taniguchi, M., 2004. NKT cells are rel
resistant to apoptosis. Trends Immunol. 219.
Smyth, M.J., Thia, K.Y., Street, S.E., Cretney, E., Trapani
Taniguchi, M., Kawano, T., Pelikan, S.B., Crowe, N.Y., G
D.I., 2000. Differential tumor surveillance by natural kille
and NKT cells. J. Exp. Med. 661.
Smyth, M.J., Wallace, M.E., Nutt, S.L., Yagita, H., Godfrey
Hayakawa, Y., 2005. Sequential activation of NKT cells a
cells provides effective innate immunotherapy of cancer. J
Med. 1973.
Spada, F.M., Koezuka, Y., Porcelli, S.A., 1998. CD1d-res
recognition of synthetic glycolipid antigens by human
killer T cells. J. Exp. Med. 1529.
Tahir, S.M., Cheng, O., Shaulov, A., Koezuka, Y., Bubley
Wilson, S.B., Balk, S.P., Exley, M.A., 2001. Loss of IFN-g
production by invariant NK T cells in advanced c
J. Immunol. 4046.
Takeda, K., Hayakawa, Y., Atsuta, M., Hong, S., Van Ka
Kobayashi, K., Ito, M., Yagita, H., Okumura, K., 2000. R
contribution of NK and NKT cells to the anti-metastatic ac
of IL-12. Int. Immunol. 909.
Taniguchi, M., Seino, K., Nakayama, T., 2003. The NKT cell s
bridging innate and acquired immunity. Nat. Immunol. 116
Uldrich, A.P., Crowe, N.Y., Kyparissoudis, K., Pellicci, D.G., Zh
Lew, A.M., Bouillet, P., Strasser, A., Smyth, M.J., Godfrey
2005. NKT cell stimulation with glycolipid antigen in
costimulation-dependent expansion, Bim-dependent contr
and hyporesponsiveness to further antigenic challenge. J. Imm
3092.
van der Vliet, H.J., Molling, J.W., Nishi, N., Masterson, A.J., K
W., Porcelli, S.A., van den Eertwegh, A.J., von Blomberg,
Pinedo, H.M., Giaccone, G., Scheper, R.J., 2003. Polariza
Valpha24+ Vbeta11+ natural killer T cells of healthy volu
and cancer patients using alpha-galactosylceramide-loade
environmentally instructed dendritic cells. Cancer Res. 410
Wilson, M.T., Johansson, C., Olivares-Villagomez, D., Singh,
Stanic, A.K., Wang, C.R., Joyce, S., Wick, M.J., Van Ka
2003. The response of natural killer T cells to glycolipid anti
characterized by surface receptor down-modulation and expa
Proc. Natl. Acad. Sci. U. S. A. 10913.
Winzler, C., Rovere, P., Rescigno, M., Granucci, F., Penn
Adorini, L., Zimmermann, V.S., Davoust, J., Ricciardi-Cast
P., 1997. Maturation stages of mouse dendritic cells in g
factor-dependent long-term cultures. J. Exp. Med. 317.
Wu, D., Xing, G.W., Poles, M.A., Horowitz, A., Kinjo, Y., Su
B., Bodmer-Narkevitch, V., Plettenburg, O., Kronenber
Tsuji, M., Ho, D.D., Wong, C.H., 2005. Bacterial glycolipi
analogs as antigens for CD1d-restricted NKT cells. Proc
Acad. Sci. U. S. A. 1351.
Zhou, D., Mattner, J., Cantu III, C., Schrantz, N., Yin, N., G
Sagiv, Y., Hudspeth, K., Wu, Y.P., Yamashita, T., Tenebe
Wang, D., Proia, R.L., Levery, S.B., Savage, P.B., Teyto
Bendelac, A., 2004. Lysosomal glycosphingolipid recognit
NKT cells. Science 1786.111
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6b 
 
Chronically stimulated mouse invariant NKT cell lines have a 
preserved capacity to enhance protection against experimental 
tumor metastases 
 
Johan W. Molling, María Moreno, Jan de Groot, Hans J.J. van der Vliet,  
B. Mary E. von Blomberg, Alfons J.M. van den Eertwegh, Rik J. Scheper, Hetty J. Bontkes 
Immunological Letters 2008; 118(1): 36-43 
 
 
 
 
 
Immunology Letters 118 (2008) 36–43
Contents lists available at ScienceDirect
Immunology Letters
journa l homepage: www.e lsev ier .com/ locate /
Chronically stimulated mouse invariant NKT cell lines have a preserved
capacity to enhance protection against experimental tumor metastases
Johan W. Molling c,a,1, Marı´a Moreno c,b, Jan de Groot c, Hans J.J. van der Vliet a, B. Mary E. von Blomberg c,
Alfons J.M. van den Eertwegh a, Rik J. Scheper c,a, Hetty J. Bontkes c,∗
a Cancer Center Amsterdam, VUMC Institute for Cancer and Immunology (V-ICI), Division of Immune Therapy, Department of Medical Oncology,
Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
b Cancer Center Amsterdam, VUMC Institute for Cancer and Immunology (V-ICI), Division of Immune Therapy, Department of Gynecology,
Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
c Cancer Center Amsterdam, VUMC Institute for Cancer and Immunology (V-ICI), Division of Immune Therapy, Department of Pathology,
Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
a r t i c l e i n f o
Article history:
Received 25 April 2007
Received in revised form 18 February 2008
Accepted 25 February 2008
Available online 24 March 2008
Keywords:
Mouse
Natural Killer T cell lines
Adoptive transfer
Tumor immunity
a b s t r a c t
In pre-clinical models, CD1d restricted invariant Natural Killer T (iNKT) cells play a pivotal role in natural
anti-tumor immune responses, mainly by trans-activating cells of both the innate and adaptive arms via
swift and potent cytokine secretion. We have previously reported that patients with a severely reduced
circulating iNKT cell pool have a poor clinical response to radio therapy of head and neck squamous
cell carcinoma. Therefore, these patients might benefit from an immunotherapeutic approach aimed at
the increase of circulating levels of iNKT cells. Furthermore, we have generated both human and mouse
iNKT cell lines, and demonstrated that they had retained the capacity to release both Th1 and Th2 type
cytokines even after long-term in vitro expansion using -galactosylceramide (GalCer) pulsed dendritic
cells (DC). Here, we establish, in a pre-clinical tumor model that the large scale long lived polyclonal iNKT
cell lines we generated have a preserved capacity to evoke an in vivo cytokine storm upon adoptive transfer,
independently of supplemental GalCer administration. This results in an augmented NK cell mediated
protection against B16.F10 experimental lung metastases in vivo. These findings underscore the potential
of autologous adoptive transfer of ex vivo expanded iNKT cells as a strategy to enhance immunotherapeutic
modalities for the treatment of cancer patients.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
iNKT cells are T lymphocytes, characterized by an invariant
TCR  chain gene rearrangement (V24-J18 in human and V14-
J18 in mouse) and co-expression of NK cell receptors [1]. The
iNKT cell TCR recognizes glycolipid ligands presented by the MHC
class-I homologue CD1d such as the putative endogenous ligand
isoglobotrihexosylceramide (iGb3), bacterial glycosphingolipids or
the artificial ligand GalCer [2–7].
In vivo activation of iNKT cells induces a cytokine storm in which
iNKT cells rapidly produce large amounts of e.g. IFN- and IL-4 [1],
leading to the trans-activation of other immune cells (e.g. NK, T,
∗ Corresponding author. Tel.: +31 204444063; fax: +31 204442964.
E-mail address: hj.bontkes@vumc.nl (H.J. Bontkes).
1 Present address: Department of Tumor Immunology, Nijmegen Centre for Molec-
ular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The
Netherlands.
B cells and DC) [8–11]. Hence, the therapeutic potential of iNKT
cells as powerful regulators of immune responses in a broad variety
of diseases is under thorough investigation [12,13]. In pre-clinical
cancer models these cells appear to play a pivotal role in natural
tumor immune surveillance [11,14–19]. Furthermore, activation of
resident iNKT cells by treatment of mice with GalCer or GalCer
loaded DC induces potent anti-tumor immune responses in various
tumor models [20–24].
In humans, we and others have demonstrated that cancer
patients have reduced circulating iNKT cell levels compared to age
and gender matched healthy individuals [25–28]. In addition, in
a prospective study we recently observed that reduced numbers
of circulating iNKT cells predict poor clinical outcome in individ-
uals with squamous cell carcinoma of the head and neck [29].
These findings suggest that cancer patients might benefit from
immunotherapy aimed at the expansion of their peripheral blood
iNKT cell pool.
Clinical phase I studies in cancer patients have revealed that
administration of GalCer, GalCer pulsed DC or autologous
0165-2478/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.imlet.2008.02.007
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peripheral blood lymphocyte cultures enriched for iNKT cells can
be performed safely, leading to limited iNKT cell activation but no
consistent and robust anti-tumor effects [30–34]. Patients might
benefit more from adoptive transfer of well defined high purity
pro-inflammatory autologous iNKT cell lines. However, in order to
obtain therapeutically sufficient amounts of iNKT cells repeated in
vitro re-stimulation, potentially altering their in vivo functionality,
is necessary. We previously described the in vitro generation of high
purity pro-inflammatory iNKT cell lines from cancer patients using
GalCer loaded DC [35].
In addition, we recently developed a method for the genera-
tion and sustained in vitro expansion of iNKT cell lines from mouse
spleen using GalCer loaded DC. These chronically stimulated cells
preserved their capacity to readily secrete a variety of cytokines in
vitro [36].
Here we show that upon adoptive transfer, chronically stimu-
lated iNKT cell lines mice have retained the intrinsic capacity to
enhance the innate immune response against experimental B16.F10
lung metastases. Notably, the anti-tumor response, though initiated
by the adoptively transferred iNKT cells, was predominantly carried
out by secondarily activated NK cells and was independent of sup-
plemental systemic GalCer administration. These findings add to
the view that autologous adoptive transfer of ex vivo expanded iNKT
cells might exert beneficial effects in cancer patients.
2. Materials and methods
2.1. Mice
6–10 week old female C57Bl/6 mice were obtained from Har-
lan (Harlan Netherlands B.V., Horst, The Netherlands). Mouse care
was in line with the guidelines provided by the VU Animal Ethical
Committee, who approved the study.
2.2. Cell lines and culture media
IMDM (Cambrex Bio Science,Verviers, Belgium) was sup-
plemented with 10% Foetal Calf Serum (Hyclone, Logan, UT,
USA), 0.01 mM -mercaptoethanol and 50 units/ml penicillin–
streptomycin (IMDMc) and used to culture B16.F10 melanoma cells
or CD1d transfected HeLa cells (HeLa-CD1d) [44]. D1, an immature
DC line was cultured as described in IMDMc supplemented with
supernatants from the GM-CSF transfected cell line R1 as described
previously [37].
2.3. iNKT cell expansion from mouse spleen
3–4 days prior to isolation of splenocytes, mice received
100 g/kg GalCer by way of intra-peritoneal injection, to increase
the binding to GalCer loaded CD1d:mouse-IgG1 dimers (BD Bio-
sciences). When spleens were harvested, single cell suspensions
were obtained by gently pressing the spleens through 100 m fil-
ters. Mononuclear cells were then obtained by Lympholyte®-M
density gradient centrifugation for 15 min at 1000× g (Cedarlane,
Burlington, NC, USA). Cells were incubated for 5 min at 4 ◦C with
Fc-R II/III blocking antibody (clone 2.4G2) and subsequently incu-
bated for 10 min at 37 ◦C with saturating amounts of GalCer
loaded CD1d:mouse-IgG1 dimers (BD Biosciences). Next, cells were
washed and labeled with magnetic goat-anti-mouse-IgG1 beads.
Finally, iNKT cells were isolated by positive selection using the
MiniMACS system (Miltenyi Biotec, Bergisch-Gladbach, Germany).
The isolated iNKT cells were directly co-cultured and weekly re-
stimulated at a 10/1 iNKT/DC ratio in the presence of 10–20 ng/ml
mouse IL-7 (R&D systems, Minneapolis, MN, USA), with D1 DC that
were first matured for 3–6 h in the presence of LPS (100 ng/ml),
GalCer (100 ng/ml; provided by Kirin Breweries Pharmaceuti-
cal Research Laboratories, Gunma, Japan) and IFN- (400 U/ml) as
described previously [36].
2.4. Evaluation of cytokine secretion
For determination of cytokine secretion by iNKT cell lines, super-
natants of co-cultures of 4×105 iNKT cells and 4×104 D1 DC per
ml were harvested 24 h after re-stimulation.2 For determination of
serum cytokines upon iNKT cell transfer, mice received i.v. injec-
tions of PBS or 1×105 B16.F10 cells and, 3 h later, of 106 cultured
iNKT cells or PBS as indicated. Serum samples were collected by
orbita-punction under a light isoflurane anesthesia. For determina-
tion of cytokine secretion by splenocytes of tumor inoculated mice,
single cell suspensions were obtained by gently pressing mouse
spleens through 100 m filters (BD FALCONTM; BD Biosciences).
Mononuclear cells were then obtained by Lympholyte®-M density
gradient centrifugation for 15 min at 1000× g (Cedarlane). Next,
2×106 cells/well were incubated for 48 h at 37 ◦C in 500 l IMDMc
in 48 well plates (triplicates for each spleen) before harvesting the
supernatants. All samples were stored at −20 ◦C before analyzing
for the presence of IL-4 and IFN- by ELISA according to the man-
ufacturer’s protocol (BD Biosciences).
2.5. Intra-dermal B16.F10 melanoma assay
To determine the direct effects of iNKT cells on B16.F10
melanoma in vivo, B16.F10 target cells (105 cells/injection) and
cultured iNKT cells or naı¨ve spleen lymphocytes (effectors) were
mixed at the indicated E/T ratios and injected i.d. in 100 l PBS
in the flanks of mice. Prior to injection all cells were extensively
washed (3 times) with PBS and reconstituted in PBS. The tumor
diameter was measured daily, starting at day 6 after injection, to
determine tumor growth kinetics.
2.6. B16.F10 lung metastasis model
To determine the effect of cultured iNKT cells on the systemic
immune response against tumors, the B16.F10 lung metastasis
model was used. Prior to injection all cells were extensively washed
(3 times) with PBS and reconstituted in PBS. Mice were injected
i.v. with B16.F10 cells and, 3 h later, with cultured iNKT cells
as indicated. In some cases, 30–60 min after iNKT transfer mice
received 100 g/kg GalCer or vehicle control by way of i.p. injec-
tion. Transfer of iNKT cells was performed 4 days after in vitro
re-stimulation with GalCer loaded DC. TCR expression, known to
be down-regulated upon activation [38], was restored at this time
and the injected cells contained no contaminating DC (not shown).
Mice were sacrificed on day 11; lungs were harvested, bleached in
Fekete’s fixative and subsequently fixed for >2 days in formalde-
hyde. Next, all lobes were dissected, digitally photographed and
the amount of surface metastases was determined by counting
or by determining the relative tumor load through a point to
point method, using Leica Qprodit software (Leica Microsystems,
Rijswijk, The Netherlands). Data were recorded as the mean num-
ber of tumor colonies or % of tumor positive lung surface ±S.E.M.
of 5 lobes.
2.7. In vivo depletion of CD8+ T cells or NK cells
In some cases in the B16.F10 lung metastasis model, mice were
depleted from CD8+ T cells or NK cells by i.p. injection of 200 g
2 Alternatively, 1×106 iNKT cells and 1×106 Hela-CD1d were co-cultured for
24 h in the presence of 100 ng/ml [alpha]GalCer in 48 well plates before collecting
supernatants.
Innate and adaptive tumour immunity: Role of invariant Natural Killer T-cells
115
38 J.W. Molling et al. / Immunology Letters 118 (2008) 36–43
anti-CD8 hybridoma supernatant (clone 2.43) or i.v. injection of
50 l of polyclonal anti-asialo-GM1 (Wako Pure Chemicals GmbH,
Neuss, Germany), respectively, 2 days prior to tumor inoculation.
PBS control injections were given i.p. Depletion of CD8+ T cells or
NK cells was confirmed by flowcytometric analysis (antibody clones
H35-17.2 and PK136, respectively) of peripheral blood samples and
was shown to exceed 90% for up to 11 days (not shown).
2.8. Flowcytometry
For evaluation of iNKT cell purity, cells were incubated for 10 min
at 37 ◦C with GalCer or vehicle loaded CD1d:mouse-IgG1 dimers
(BD Biosciences), washed twice and subsequently stained with PE
labeled rat-anti-mouse IgG1 (clone A85-1) and APC labeled anti
CD3 (clone 145-2C11) or Armenian hamster IgG1 isotype control
(clone A19-3) (BD Biosciences).
For evaluation of TCR-V-chain expression and for the confir-
mation that no contaminating non-V14 (V8, V7 or V2) T cells
were present, the BD Pharmingen TCR V screening panelTM was
used (BD Biosciences).
For evaluation of lung infiltrating CD8+ T or NK cells, mice were
euthanized and lungs were processed by gently pressing them
through 100 m filters. The obtained cells were washed in PBS con-
taining 0.1% bovine serum albumin (BSA) (Hyclone, Logan, UT, USA)
and pellets were incubated for 5 min in ice cold isotonic NH4Cl solu-
tion (0.155 M NH4Cl, 0.01 M KHCO3, 0.1 mM EDTA; pH 7.4) to lyse
erythrocytes and granulocytes. Next, cells were washed in IMDMc
and subsequently stained in flowcytometry buffer (PBS, 0.1% BSA,
0.05% NaN3) for >15 min on ice with a combination of allophyco-
cyanin (APC)-labeled Armenian hamster-anti-mouse CD3 (clone
145-2C11) and phycoerythrin (PE)-labeled rat-anti-mouse CD8
(clone H35-17.2) or CD49b (clone DX5) to identify CD3+CD8+ T
cells or CD3-CD49b+ NK cells, respectively. Cells were identified
as viable lymphocytes on basis of light scatter field gating. Flowcy-
tometry was performed on a FACSCALIBURTM apparatus and data
were analyzed using CellQuestTM software (BD Biosciences).
For evaluation of CD69 expression on peripheral blood lym-
phocytes, blood samples were acquired by puncturing the orbital
venous plexus. Samples were incubated for 5 min in ice cold iso-
tonic NH4Cl solution. Next, cells were washed in IMDMc and
subsequently stained in flowcytometry buffer for >15 min on ice
with a combination of APC-labeled Armenian hamster-anti-mouse
CD3 (clone 145-2C11); fluorescein isothiocyanate (FITC) labeled
Armenian hamster-anti-mouse CD69 (clone H1.2F3) and PE-labeled
rat-anti-mouse CD8 (clone H35-17.2) or CD49b (clone DX5) to
identify CD3+CD8+ T cells or CD3−CD49b+ NK cells, respectively.
2.9. Statistical analyses
Variables fitted a Gaussian distribution. Statistical analyses per-
formed were Student’s T-test, linear regression and Log Rank
statistics. p-Values below 0.05 were considered significant.
3. Results
3.1. Limited direct effects of cultured iNKT cells on B16.F10
melanoma
To study direct in vivo anti-tumor activity of long-term stimu-
lated iNKT cell lines, mice received i.d. injections of three different
iNKT cell lines (characterized in Table 1) and B16.F10 melanoma
cells mixed at two different E/T ratios (30:1 and 5:1) (Fig. 1).
One out of three iNKT cell lines tested (iNKT #III), significantly
delayed the average time to detection of palpable tumors at the
highest E/T ratio (mean± standard error = 10±1 days) compared
to the control (6±0 days) (p = 0.0082 Log Rank test) (n = 4 per
group). Furthermore, using iNKT #III, the average tumor size at
an E/T ratio of 30/1 was significantly reduced at day 12 after
injection compared to the control (splenocytes/B16.F10 = 30/1)
(mean diameter± S.D. = 1.3±2.0 mm and 6.6±0.7 mm, respec-
tively) (p = 0.0026 Student’s T) (n = 4 per group). Although tumor
outgrowth was delayed, the tumors did progressively grow (not
shown). The delay was not associated with any apparent direct
cytolytic activity of the iNKT cell lines against B16.F10 in vitro (not
shown).
3.2. Intravenous injection of chronically stimulated iNKT cell lines
reduces B16.F10 lung metastases
Next, we investigated whether long-term in vitro stimulated
iNKT cell lines could inhibit B16.F10 lung metastasis development
when transferred into mice shortly (3 h) after tumor inoculation.
While counting the total number of tumor colonies is the more gen-
eral approach to determine the tumor load, this method becomes
unreliable at a high tumor load (e.g. in NK depleted mice, Fig. 4)
due to overlapping of colonies. Therefore, we utilized the point by
point counting method to determine the percentage of affected
lung surface in tumor bearing mice. To determine how these
approaches correlate we first used both quantification methods in
lungs with <20% tumor load. Indeed, there was a strong correlation
with every 10% increase in affected lung surface accounting for an
addition of 110±16 colonies (p < 0.0001, linear regression) (n = 23)
(Fig. 2A).
Table 1
Characteristics of the iNKT lines investigated at time of in vivo application
In vivo model Cultured in vitro TCR-V usage CD4+/CD4− (% cells) IFN- (pg/ml± S.D.) IL-4 (pg/ml± S.D.)
iNKT #I -i.d. B16.F10a 12 monthsb V7 0/100 2572 ± 1284c Not detectedc
iNKT #III -i.d. B16.F10 3 months V8.1/8.2 50/50 17,815 ± 8279 18,166±3711
iNKT #IV -i.d. B16.F10 4 months V8.1/8.2 (89%)/V7 (7%)/V2 (4%) 59/41 9791 ± 5202 25,225±14,829
iNKT #I -B16.F10 lungd 24 months V7 0/100 12,913 ± 6874e Not detectede
iNKT #II -B16.F10 lung 20 months V8.1/8.2 2/98 5317 ± 1957 423±640
iNKT #V -B16.F10 lung 1 month V8.3 0/100 12,345 ± 3699 1214±1102
iNKT #VI -B16.F10 lung 5 months V2 46/54 8496 ± 5539 40,959±3002
Prior to their application in anti-tumor models in vivo, the iNKT cell lines were characterized regarding phenotypical and functional aspects. All lines used were established
to be bona fide >99% pure iNKT cell lines by flowcytometry using aGalCer loaded mouse IgG1:CD1d dimers.
a Monitor tumor growth kinetics after i.d. B16.F10 melanoma with or without co-injection of iNKT cells as indicated in manuscript.
b Duration of weekly in vitro stimulation with aGalCer pulsed mature D1 dendritic cells in the presence of mIL-7 at time of first in vivo application.
c Cytokines in supernatant after 24 h stimulation of 1×106 iNKT with 1×106 aGalCer pulsed CD1d transfected HeLa cells/ml (n = 4).
d Determine tumor load in lungs 11 days after i.v. injection of B16.F10 melanoma, followed by i.v. PBS or iNKT cells as indicated in manuscript.
e Cytokines in supernatant of 24 h co-cultures of 4×105 iNKT + 4×104 aGalCer pulsed mature D1 dendritic cells/ml in the presence of mIL-7 (n = 2).
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Fig. 1. Direct effects of iNKT cells on intra-dermal B16.F10 melanoma outgrowth
on day 0, mice received i.d. injections of 105 B16.F10 mixed with effector cells
at the indicated E/T ratios. Plot indicates tumor growth kinetics: dots represent
mean; error bars indicate standard error of mean (n = 4 per group). **p < 0.01, tumor
diameter compared to B16.F10 + spleen, Student’s T. Data are from one experiment
representative of two.
Four different iNKT cell lines were tested for their capacity to
inhibit B16.F10 lung metastases when injected 3 h after tumor cell
inoculation (characterized in Table 1). Unfortunately, iNKT #III was
lost for these experiments due to technical issues. First, whereas
iNKT #II was only capable of inhibiting lung metastases when
injecting a dose of 106 cells (mean tumor load± S.D. = 7.5±1.6%)
compared to PBS treated mice (mean tumor load± S.D. = 16±3.9%)
(p = 0.0026, Student’s T), iNKT #V did so when injecting 106
cells as well as a lower dose of 2×105 cells (mean tumor
load± S.D. = 5.8±4.0% and 8.4±2.0%, respectively) (p = 0.0075 and
0.0063, Student’s T) (n = 5 per group) (Fig. 2B). In a follow up
experiment (Fig. 2C), two additional iNKT cell lines (iNKT #I
and #VI) gave similar results when injecting 106 cells (mean
tumor load± S.D.; PBS control = 25±5.9%, iNKT #I = 15±3.0%, iNKT
#VI = 12±5.7%) (p = 0.0070 and 0.0036, respectively, Student’s T)
(n = 6 per group). When transferring these 4 lines at 106 cells per
mouse, there was no correlation between the amount of in vitro
released IFN- or IL-4 and the effects on B16.F10 lung metastases
(not shown).
Next, using iNKT #V, we investigated whether i.p. GalCer
injection following iNKT cell transfer could enhance the protec-
tion against B16.F10 (Fig. 2D). While administration of GalCer
alone resulted in a significant reduction of metastases (mean tumor
load± S.D. = 15±3.0%) compared to control mice (mean tumor
load± S.D. = 19±1.9%) (p = 0.0164, Student’s T), transfer of iNKT
#V was superior (mean tumor load± S.D. = 8.2±2.4%) (p < 0.0001,
Student’s T). This inhibiting effect of iNKT cell transfer could
not be further enhanced by subsequent GalCer administra-
tion (mean tumor load± S.D. = 9.3±4.5%) (p = 0.6221, Student’s T)
(n = 6 per group). In an additional experiment, NKT cell medi-
ated tumor reduction was not observed when iNKT cell lines
were injected at a later stage, i.e. 4 days after tumor inocula-
tion, either with or without subsequent GalCer treatment (not
shown).
In summary, 4 out of 4 iNKT cell lines tested were able to sig-
nificantly impair B16.F10 lung metastasis development by their
adoptive transfer shortly after tumor inoculation, independently
of subsequent systemic GalCer administration.
3.3. Intravenous injection of chronically stimulated iNKT cell lines
induces a cytokine storm
The hallmark of iNKT cells is their capacity to readily release
cytokines upon activation including IL-4 and IFN-, hereby swiftly
trans-activating other immune cells leading to a systemic cytokine
storm. Adoptive transfer of chronically stimulated iNKT cell lines
resulted in similar events. 24 h after adoptive transfer of iNKT
#II into naı¨ve or B16.F10 inoculated mice IFN-, but not IL-4,
was detectable in the serum (mean serum IFN-± S.D.; naı¨ve
mice = 790±312 pg/ml and tumor bearing mice = 766±444 pg/ml)
(n = 6 per group) (Fig. 3A). Subsequently, IFN- levels dropped to
undetectable within the next 24 h (not shown). However, spleno-
cytes taken at day 11 after tumor inoculation, from mice that
received iNKT cells (iNKT #I, #II, #V or #VI) (n = 22) 3 h after tumor
inoculation, but not from PBS treated mice (n = 6), were secret-
ing some IL-4 and substantial amounts of IFN- in vitro without
exogenous activation (median [range]; IL-4 = 15 [0–47] pg/ml and
IFN- = 891 [124–8536] pg/ml) (Fig. 3B). These results indicate that
adoptive transfer of chronically stimulated iNKT cells into tumor
bearing mice induces a donor iNKT cell dependent cytokine storm
lasting up to 11 days.
3.4. NK cells are required for the protective anti-tumor effects of
iNKT cell transfer
Next, we determined the contribution of CD8+ T cells and
NK cells to the inhibition of tumor metastases after adoptive
transfer of chronically stimulated iNKT cells (Fig. 4). Transfer of
iNKT cells into control mice (mean tumor load± S.D.; PBS con-
trol = 39±10%, i.v. iNKT = 19±7%) (p = 0.0037, Student’s T) or CD8+ T
cell depleted mice (mean tumor load± S.D.; PBS control = 31±11%,
i.v. iNKT = 17±11%) (p = 0.0497, Student’s T) significantly hampered
lung metastasis development. However, treatment of NK depleted
mice had no apparent effect on B16.F10 lung metastases (mean
tumor load± S.D.; PBS control = 69±14%, i.v. iNKT = 57±11%)
(p = 0.146, Student’s T) (n = 6 per group). In accordance, we observed
an up-regulation of the activation marker CD69 on both circulating
CD8+ T and especially NK cells within 24 h of iNKT cell trans-
fer, which was more pronounced on the latter. (Supplementary
Fig. 1). The high tumor load in NK depleted mice underscores
their importance in the first line of defense against B16.F10. These
findings were accentuated in a follow up experiment (Fig. 5).
Herein iNKT treated mice (n = 14) had a larger fraction of NK cells
within lung lymphocytes, compared to PBS treated mice (n = 7) at
day 4 after adoptive transfer (mean% of NK cells± S.D.; PBS con-
trol = 8.8±5.6%, i.v. iNKT = 17±7.7%) (p = 0.0235, Student’s T). This
was not the case for CD8+ T cells (mean% of CD8+ T cells± S.D.;
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Fig. 2. Effects of adoptive iNKT cell transfer on B16.F10 lung metastasis development. (A) Mice received 105 B16.F10 cells i.v. on day 0, followed after 3 h by i.v. iNKT. On day
11, lungs were harvested and the tumor load was determined by determining the % tumor of total lung surface (X-axis) and by counting surface metastases (Y-axis). Line
indicates linear regression model, dots represent individual mice (n = 23). (B and C) Mice received 105 B16.F10 i.v. on day 0, followed after 3 h by i.v. PBS or iNKT as indicated.
On day 11, lungs were harvested and the % tumor of total lung surface was determined. Bars indicate mean; error bars indicate standard error of mean (B: n = 5; C: n = 6 per
group). **p < 0.01 compared to PBS, Student’s T. (D) Mice received 105 B16.F10 i.v. on day 0, followed after 3 h by i.v. PBS or 106 iNKT, followed after 30–60 min by i.p. vehicle
or GalCer (100 g/kg) as indicated. On day 11, lungs were harvested and the % tumor of total lung surface was determined. Bars indicate mean; error bars indicate standard
error of mean (n = 6 per group, except PBS + GalCer (n = 4)). *p < 0.05 and ***p < 0.001, respectively compared to PBS + vehicle, Student’s T.
PBS control = 10±9.0%, i.v. iNKT = 9.0±4.2%) (p = 0.6336, Student’s
T). We therefore conclude that NK cells were the predominant
effector cells activated by iNKT cell adoptive transfer in this
model.
4. Discussion
Depending on the model, resident iNKT cells can augment innate
as well as adaptive anti-tumor immune responses upon systemic
treatment with GalCer or GalCer loaded DC in C57Bl/6 mice.
For instance, a single i.v. injection of dying hematologic tumor
cells together with GalCer induces long lasting protective immu-
nity, depending on both CD4+ and CD8+ T cells. This as a result
of enhanced maturation of cross priming DC by resident iNKT cells
[39]. On the other hand, treatment with GalCer or GalCer loaded
DC can partially protect mice against experimental metastases of
B16.F10 melanoma as a result of NK cell trans-activation by iNKT
cells [11,21,22].
Here, we first investigated the direct effect of chronically stim-
ulated iNKT cell lines on intra-dermal B16.F10 tumors. In two
independent experiments, only 1 out of 3 lines investigated was
capable of significantly inhibiting tumor outgrowth for up to 12
days after injection compared to control mice, when mixed with
B16.F10 melanoma cells at a high effector/target ratio prior to i.d.
inoculation. We did not observe any potent direct in vitro cytotox-
icity against B16.F10 by these 3 iNKT cell lines (not shown). As
shown in Table 1, the iNKT cell line that delayed tumor develop-
ment (iNKT #III) was capable of secreting substantially more IFN-
upon activation than the other 2 lines tested here (iNKT #I and
#IV). The transient inhibition might therefore be caused by an anti-
angiogenic effect of locally released IFN- by the injected iNKT cells,
as has been described for mice systemically treated with GalCer
[40], and not by direct cytotoxicity against the tumor. Alternatively,
iNKT derived cytokines might have a direct inhibitory effect on
tumor outgrowth and/or the intra-dermal co-injection with iNKT
cells might cause a transient influx of e.g. NK cells. In contrast to
our results, Chamoto et al. demonstrated that CD3+NK1.1+ T cells
do acquire direct NK like cytotoxic ability in vitro after 5 days of
culture with GalCer loaded DC in the presence of exogenously
added IL-2 [15]. This discrepancy could be explained by the use of
IL-7 in our culture system, although both IL-2 and IL-7 have been
shown to enhance the NK like cytotoxic capacity of in vitro CD3
activated killer cells [41]. Furthermore, one cannot exclude that the
actual killing in the study of Chamoto et al. was performed by non-
CD1d restricted instead of invariant NKT cells, since no distinction
was made between the two. Alternatively, the acquired cytotoxic-
ity of iNKT cells might again be lost after chronic re-stimulation in
vitro. However, in that same study Chamoto et al. demonstrated that
despite the in vitro cytolytic activity of short-term cultured iNKT
cells, in vivo activated iNKT cells predominantly enhanced NK cell
mediated killing of tumors rather than they exerted direct tumor
cell killing [15].
Secondly, we demonstrate here that long-term chronically in
vitro stimulated iNKT cell lines retain the capacity to augment anti-
tumor immune responses. Crowe et al. previously reported the
partial inhibition of B16.F10 lung metastases via adoptive transfer
of freshly isolated splenic iNKT cells in combination with systemic
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Fig. 3. Cytokine secretion by splenocytes of tumor bearing mice. (A) On day 0 mice
received i.v. injections as indicated with PBS or B16.F10 melanoma and 3 h later
with PBS or 106 iNKT cells. Serum samples were collected prior to the first injection
and on days 1, 2 and 4. Bars indicate mean serum IFN- level at day 1; error bars
indicate standard error of mean (n = 3 per group). No IFN- was detected on the
other time points. (B) On day 0 mice received i.v. injections with B16.F10 melanoma
and 3 h later with PBS (n = 6) or 106 iNKT cells (n = 22). On day 11 splenocytes were
isolated and cultured for 48 h in IMDMc. The amount of IL-4 and IFN- in the culture
supernatants was determined by ELISA. Dots indicate individual mice, horizontal
lines indicate median. Data are from 1 experiment representative of 2.
Fig. 4. Anti-tumor effects of adoptive iNKT cell transfer in CD8+ T or NK cell depleted
mice. On day 2, mice were depleted of CD8+ T cells (CD8 depl) or of NK cells (NK depl)
by means of systemic antibody injection or received PBS (control) as indicated. On
day 0, mice received 2×105 B16.F10 i.v. followed after 3 h by i.v. injection of PBS or
106 iNKT as indicated. On day 11, lungs were harvested and the % tumor of total lung
surface was determined. Bars indicate mean; error bars indicate standard error of
mean (n = 6 per group). % Next to bars indicates mean reduction in tumor load iNKT
treated mice compared to PBS control. *p < 0.05 and **p < 0.01, respectively, Student’s
T.
Fig. 5. Effect of iNKT cell transfer on proportion of lung CD8+ T and NK cell fractions.
On day 0 mice received i.v. injections with PBS or B16.F10 melanoma and 3 h later
with PBS (n = 7) or 106 iNKT cells (either iNKT #II or #V) (n = 14). On day 4 lung
lymphocytes were analyzed for the percentage of CD8+ T cells (A) or NK cells (B) by
flowcytometry. Bars indicate mean; error bars indicate standard error of mean. Data
are pooled from two independent experiments. *p < 0.05, Student’s T.
GalCer treatment [42]. In addition, Shin et al. successfully inhib-
ited B16.F10 liver metastases when transferring iNKT cells that were
pre-activated with IL-12 in vivo into recipient mice in the absence
of GalCer [43]. Here, in multiple independent experiments, 4 out
of 4 iNKT cell lines investigated were able to significantly hamper
B16.F10 lung metastasis development compared to control mice
when administered shortly after tumor cell inoculation (50–60%
reduction in tumor load). In our hands, additional GalCer treat-
ment did not enhance the anti-tumor effects observed. Transfer
of these pre-activated iNKT cells was performed 4 days after in
vitro re-stimulation with GalCer loaded DC. As day 4 pre-activated
iNKT can display substantial IFN-y production without GalCer
triggering ([36] and unpublished results), the finding here might
reflect that the injected iNKT cells were already sufficiently acti-
vated to trans-activate immune effector cells, which is in line with
the results by Shin et al. Interestingly, they also established that
iNKT cell transfer therapy was far superior to injecting high dose
IL-2, IL-4 or IFN-. Even though there was no direct correlation
between the IFN levels in the tumor bearing animals after iNKT
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cell adoptive transfer (either in serum on day 1 or produced by
splenocytes on day 11) and anti-tumor effects, the fact that the
low IFN producing iNKT cell line #II was only effective at the
higher dose level, while the high IFN producing iNKT cell line
#V was already effective at a 5 times lower dose suggests a role
for iNKT cell derived soluble factors in the observed protective
effects.
We next set out to investigate how downstream anti-tumor
immunity might commence upon transfer of chronically stimulated
iNKT cell lines. Within 24 h after iNKT cell transfer we could detect
serum IFN- which was already undetectable at 48 h after trans-
fer. This relatively short-term peak suggests that the cytokine was
a donor iNKT cell product and that the transferred cells quickly
disappeared from circulation. Splenocytes from iNKT cell treated
mice (but not from control mice) were still secreting IFN- and
also IL-4 at day 11 after transfer without an additional stimu-
lus. Four days after transfer the injected iNKT cells were not back
traceable in lungs, livers or spleens after labeling with carboxy
fluorescein diacetate succinimidyl ester (CFSE) or 5-(and-6)-(((4-
chloromethyl)benzoyl) amino) tetramethyl rhodamine (CMTMR)
(not shown) suggesting that the cytokines secreted at day 11 were
produced by resident cells, activated by the transferred iNKT cells.
In line with previous reports, we established that NK cells but not
CD8+ T cells were required for the anti-tumor effects of adoptive
iNKT cell transfer [11,18,22]. In addition, we found that lung lym-
phocytes of iNKT recipient mice (both tumor inoculated and naı¨ve
mice) were enriched for NK cells but not CD8+ T cells at day 4 after
transfer. It remains to be elucidated whether this recruitment of
NK cells is mediated by direct local chemokine release from the
injected iNKT cells or indirectly via their secretion of inflammatory
mediators.
While the present results are promising, no total protection
against B16.F10 was established and the outgrowth of established
metastases was not inhibited (not shown). Crowe et al. have previ-
ously demonstrated that, in contrast to adoptive transfer of spleen
derived iNKT cells which leads to a partial protection similar to as
we have described here, adoptive transfer with liver derived iNKT
cells leads to a full protection against B16 tumors. Thus, the origin
of iNKT cells clearly affects their activity in anti-tumor responses.
Since it will be difficult to obtain liver derived iNKT cells in a
human setting we have focused on spleen derived iNKT cells which
have the same origin as circulating iNKT cells. Our results show
that further optimization of iNKT cell mediated treatment is war-
ranted. Smyth et al. demonstrated that moderate iNKT cell driven
innate immunity against B16.F10 can be dramatically enhanced
when GalCer loaded DC are combined with systemic IL-21 treat-
ment [11]. We have recently demonstrated in a human setting
that iNKT cells expanded with DC over-expressing IL-12 produce
increased levels of IFN-. These iNKT cells drive the expansion
and activation of tumor antigen specific CTL in an IFN- depen-
dent fashion when tumor antigen was presented (Moreno et al.,
submitted for publication). Thus, the efficacy of iNKT cell adop-
tive transfer may be strongly increased if combined with additional
IL-21 treatment or tumor antigen vaccination and/or aGC-pulsed
DC.
In summary, we describe here that the unique large scale
long lived polyclonal iNKT cell lines, whose generation we have
described previously [36], have a preserved capacity to evoke an in
vivo cytokine storm upon adoptive transfer, which is measurable
in the spleen up to 11 days after iNKT cell injection. This results
in an augmented, NK cell mediated, partial protection against
B16.F10 experimental lung metastases. These combined findings
underscore the potential of autologous adoptive transfer of ex vivo
expanded iNKT cells to enhance immunotherapeutic strategies for
the treatment of cancer patients.
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Chapter 7 
 
Discussion 
Harnessing invariant Natural Killer T cells  
for the treatment of cancer 
 
  
 Pre-clinical studies illustrate the potential of invariant Natural Killer T (iNKT) cells as 
regulators of immune responses to tumours [reviewed in chapter 1] and suggest the benefit of 
exploiting iNKT cells for the treatment of cancer. Analyses in patients with malignant 
melanoma, primary lung cancer, advanced prostate cancer and other progressing solid 
tumours demonstrated a numerical deficiency of iNKT cells in the peripheral blood of these 
patients when compared with healthy volunteers [1-5]. Whether this deficiency represents a 
cause or an effect of the disease is not yet clear. Although iNKT cells from cancer patients 
have functional defects, i.e. impaired proliferation and cytokine secretion [4-6], they still 
possess the capacity to proliferate and to secrete IFN-γ when properly stimulated in vitro [7]. 
This suggests that iNKT cells of cancer patients, though reduced in number, may still be 
capable of enhancing anti-tumour responses, particularly after therapies aiming at their 
expansion and activation. Here, different therapeutic approaches to exploit human iNKT cells 
to improve the anti-tumour immunity are discussed. 
 
1 In vivo activation of human iNKT cells 
a-Galactosylceramide injection 
Recognizing the promise of iNKT cell activation in immunotherapy of cancer, 
attempts have been made to target them in vivo in clinical phase I studies, based on the use of 
α-Galactosylceramide (α-GC) as a stimulatory ligand. In murine models, resident iNKT cells 
can augment anti-tumour immune responses upon systemic treatment with the strong agonist 
α-GC, mainly as a result of Natural Killer (NK) cell trans-activation and IFN-γ production [8-
10].  
In humans, in vitro stimulation of peripheral blood mononuclear cells (PBMC) with α-
GC strongly promoted iNKT cell activation, as evidenced by an increased proportion of iNKT 
cells expressing CD69 and CD25. In contrast, α-GC induced only a modest increase in IFN-γ 
production. Although NK cells became phenotypically activated, functional activity of NK 
cells was not enhanced by this approach. No increase in NK cell-mediated cytotoxicity 
against K562, a NK-sensitive cell line, was detected (chapter 4). Likewise, no enhancement 
of NK cell-mediated antibody dependent cell-mediated cytotoxicity (ADCC) could be 
observed (chapter 5b). These results indicate that iNKT cell stimulation with free antigen is 
not sufficient to translate phenotypical into functional activation, in vitro. 
In vivo, weekly intravenous (i.v.) injections of α-GC (KRN7000, a pharmaceutical-
grade synthetic analogue of α-GC) have been shown to be safe in clinical phase I studies 
[11;12]. In parallel to the in vitro observations, administration of α-GC to cancer patients with 
advanced disease induced a transient and limited increase in serum levels of 
immunostimulatory cytokines (IL-12, IFN-γ, TNF-α and GM-CSF) only in patients with 
relatively high iNKT cell levels, without enhancing NK cell cytolytic activity [12]. Moreover, 
rapid loss of detectable iNKT cells from the circulation was observed within 24 h after α-GC 
administration and iNKT cell levels remained low for at least 3 weeks after the first 
administration. The lack of detectable iNKT cells shortly after i.v. injection of the glycolipid 
may reflect their antigen-specific activation by α-GC, leading to T-cell receptor (TCR) 
internalization, as it has been previously demonstrated in mice [13;14]. In line with the 
decline in iNKT cell levels, no increase in serum cytokines was observed after a second and 
third weekly injection with α-GC [12]. Similarly, systemic treatment with free α-GC in mice 
induced iNKT cell anergy, rendering iNKT cells unresponsive to subsequent α-GC treatment 
[15]. This anergy may be related to the relatively high dose of the glycolipid injected and the 
short interval between repeated injections. In a clinical phase I/II trial in chronic Hepatitis C 
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patients, re-appearance, close to baseline levels, of circulating iNKT cells was observed 
within 2 weeks after i.v. injection of low dose α-GC. In this trial, α-GC exerted moderate 
immunomodulatory effects, i.e. cytokine responses (TNF-α and IFN-γ), again only in patients 
with relatively high iNKT cell levels [16]. Of note, no α-GC-induced clinical responses were 
observed in either study [12;16].  
Taken together, these results suggest that inappropriate scheduling of α-GC 
administration may prohibit effective immunotherapy. Indeed, chronic activation of iNKT 
cells in mice by repetitive treatment with α-GC resulted in the generation of anergic iNKT 
cells with a defective cytokine production [17-19]. This poses a problem when considering 
repeated iNKT cell activation as a therapeutic approach. Furthermore, it has been reported 
that previous exposure to α-GC favours a type 2 immune response [20;21], which can be 
counterproductive for the development of a successful anti-tumour response. Therefore, the 
clinical use of α-GC needs to be carefully evaluated with respect to achieving maximal iNKT 
cell activation without inducing tolerance or an undesirable cytokine secretion profiles.  
 
IL-2 administration 
IL-2, in combination with α-GC, induces in vitro expansion of peripheral blood iNKT 
cells of healthy controls, as well as advanced cancer patients. As such, it could be considered 
a putative adjuvant to promote in vivo iNKT cell proliferation.  
In a clinical study in HIV-1-infected patients, who have a numerical deficiency of 
iNKT cells, subcutaneous administration of IL-2 in addition to the standard antiretroviral 
treatment, led to an expansion of iNKT cells, as well as other CD4+ T cells [22]. No 
significant change in the CD4+/CD4- ratio within the iNKT cell population was observed, 
indicating an expansion of both subsets. Sustained IL-2 treatment was necessary in order to 
maintain the increased iNKT cell levels.   
In patients with advanced melanoma and renal cell cancer, i.v. injection of high-dose 
of IL-2 led to a transient decrease in the frequency and absolute number of iNKT cells. This 
decline was accompanied by an increase in the proportion of potentially pro-inflammatory 
double-negative iNKT cells, though without detectable augment in IFN-γ secretion, and was 
followed by an increase in the total number of circulating iNKT cells [23]. 
Interestingly, iNKT cell expansion occurred in the absence of iNKT cell antigen. 
Standard protocols for in vitro expansion of peripheral blood iNKT cells of healthy controls, 
as well as advanced cancer patients, include iNKT cell antigen, in addition to IL-2. In view of 
this, IL-2 therapy aiming at restoring and maintaining the iNKT cell population in vivo could 
benefit from the combination with α-GC treatment. The effect of this approach has not yet 
been addressed in cancer patients.  
 
TLR stimulation 
Because iNKT cell - dendritic cell (DC) cross-talk is an important step in linking and 
regulating the innate and adaptive immune responses, understanding the molecules capable of 
fine-tuning this interaction is of great importance for harnessing iNKT cells for the treatment 
of cancer. Microbial-derived glycolipid antigens other than α-GC presented by CD1d on DC 
have been shown to directly modulate iNKT cell activation [24-27]. Furthermore, other 
microbial-derived molecules, such as Toll-Like Receptor (TLR) ligands, can induce iNKT 
cell activation through IL-12 production by TLR-stimulated DC in the presence of a weak 
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 CD1d/TCR signal [24;28]. TLR agonists are of great interest in the field of cancer 
immunotherapy due to their immunostimulatory properties. Particularly, their capacity to 
promote iNKT cell-DC interaction could be exploited to increase the efficacy of iNKT cell-
based immunotherapy. However, it is still not clear whether iNKT cells can be directly 
regulated by TLR ligands. 
We determined that human iNKT cells from healthy donors expressed TLR1, 2, 4, 6, 7 
and 9 mRNA, whereas TLR3, 5 and 10 mRNA expression was low and TLR8 mRNA was 
absent (chapter 2). Although iNKT cells express most TLR at the mRNA level, iNKT cells 
do not respond directly to TLR agonists [29] (and chapter 2). Upon PBMC stimulation with 
the TLR ligands PGN, CL075 and ODN A (ligands for TLR2, TLR7 and 8, and TLR9, 
respectively), iNKT cell activation, as evidenced by up-regulation of CD69 expression and 
IFN-γ production, was induced as a result from cross-talk between iNKT cells and DC 
(chapter 2). Interestingly, in contrast to the results from Mattner and co-workers [24], who 
demonstrated iNKT cell activation upon DC stimulation with LPS, we did not observe iNKT 
cell activation after PBMC stimulation with LPS. This discrepancy may be explained by the 
complex network of activating and inhibiting signals induced by TLR agonists on different 
immune cells, such as activation of Tregs that may modulate the activation of iNKT cells 
[30], influencing the net effect. All TLR agonists tested have been shown to activate NK cells 
upon PBMC stimulation. However, only PGN, CL075 and ODN A, the three TLR agonists 
that induced the strongest iNKT cell activation, have an appreciable effect on NK cell-
mediated cytotoxic function, determined as antibody-dependent NK cell-mediated ADCC 
(chapter 5b). These observations highlight the relevance of defining and considering the in 
vivo effect of TLR ligands not only on iNKT cells but also on the final desirable outcome, 
when exploiting TLR ligands for iNKT cell activation as a therapeutic approach. 
Our in vitro results demonstrate an indirect activation of iNKT cells by TLR2/6, 7, 8 or 
9 rather than TLR3, 4 or 5 agonists. Combinations of these TLR ligands with α-GC may act 
as strong adjuvants for cancer immunotherapy, as they have been shown to enhance iNKT 
cell activation and type 1 IFN-γ-mediated immune responses, such as NK cell activation and 
cytolytic activity in vitro. However, their ability to activate iNKT cells in vivo has not yet 
been tested in humans.  
These data, demonstrating a limited effect on iNKT cell numbers and effector 
functions upon stimulation with free α-GC, IL-2 or TLR agonists even of PBMC derived 
from healthy donors, with relatively high numbers of iNKT cells, exemplify that alternative 
treatments to expand and activate iNKT cells in vivo or in vitro are necessary. Vaccination 
with α-GC-pulsed mature monocyte-derived DC (moDC) or adoptive transfer of in vitro 
expanded iNKT cells are possible alternative methods to increase iNKT cell numbers in vivo. 
 
DC activation 
The relatively low in vivo responsiveness of circulating iNKT cells upon i.v. injection 
of free α-GC parallels the reduced in vitro responsiveness of cancer patient derived iNKT 
cells when stimulated with autologous α-GC-loaded PBMC [4-6]. Both phenomena may be 
explained by the impaired function of antigen presenting cells (APC) in cancer patients. On 
the other hand, α-GC-loaded, in vitro generated, fully functional mature DC restore iNKT cell 
proliferation in vitro [31]. Consequently, the injection of α-GC-pulsed DC is expected to 
induce a more effective in vivo expansion of iNKT cells. 
Three independent groups have now shown that this approach is well tolerated in 
humans. In two consecutive studies in Australia, a total of 16 patients with metastatic 
María Moreno Jauge
126
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
I 
S 
C 
U 
S 
S 
I 
O 
N 
 
 
malignancies were treated with autologous α-GC-pulsed immature moDC. The treatment 
resulted in a mild, albeit not sustained, increase in circulating iNKT cell numbers [32;33]. In 
the second study, transient but potent pro-inflammatory effects were observed in peripheral 
blood samples after DC treatment, consisting of elevated levels of IL-12 and IFN-γ, in 
contrast to reduced levels of IL-4, and activation of T cells. Moreover, they found a transient 
increase in NK cell number, activation and cytotoxicity [33]. A second injection of immature 
moDC pulsed with α-GC produced the same immunological effects.  Further, it was found 
that serum tumour markers were significantly decreased in two patients with adenocarcinoma, 
indicating some anti-tumour effect of α-GC-pulsed DC. 
Mature DC are far more efficient in activating T cells and inducing their proliferation 
than immature DC [34]. Thus, in vivo activation of iNKT cells with properly matured DC is 
expected to be a more appropriate approach. Indeed, Chang and co-workers were able to 
induce dramatic expansion of circulating iNKT cells in all 5 advanced cancer patients who 
received i.v. injections with pure, properly matured, α-GC-pulsed autologous moDC (>100 
fold expansion at peak level) [35]. Strikingly, despite having undetectable peripheral blood 
iNKT cell counts at the time of enrolment, the iNKT cell level remained above baseline after 
DC treatment for more than 85 days in all patients and for up to 6 months in two patients with 
longer follow up. In addition, indirect proof that iNKT cell activation was followed by 
myeloid DC activation (elevated serum levels of myeloid DC associated soluble factors IL-
12p40, MIP-1β and IP-10) was observed, and an expansion of CD8+ memory T cells specific 
for viral antigens was measured. These findings strongly suggest an adjuvant effect of the 
treatment on existing adaptive immunity. On the other hand, DC treatment was not sufficient 
to overcome the impaired iNKT cell IFN-γ secretion. In parallel with the absence of IFN-γ 
response, no NK cell activation was observed. Moreover, there was a transient decline in NK 
cell numbers after DC treatment, either with unloaded or α-GC-loaded moDC.  
Ishikawa and co-workers also reported activation and transient expansion of resident 
iNKT cells in 3 out of 12 advanced lung cancer patients upon injection of α-GC-pulsed 
autologous PBMC cultured for 7 to 14 days in the presence of GM-CSF, IL-2 and α-GC [36].  
These clinical studies show that vaccination with α-GC-pulsed DC results in an 
increase in circulating iNKT cell numbers and IFN-γ producing PBMC however, hardly any 
clinical responses were observed. The α-GC-induced anti-tumour effect has been shown to be 
primarily dependent on IL-12 in various tumour models. For that reason, the efficacy of DC 
treatment may be enhanced by using α-GC loaded, IL-12 over-expressing DC. We 
demonstrated that PBMC cultures stimulated with α-GC-loaded moDC transfected with IL-12 
contained significantly higher numbers of iNKT cells. As previously described, stimulation 
with IL-12 over-expressing moDC leads to an increased tumour specific cytotoxic T 
lymphocyte (CTL) response [37]. IL-12 over-expressing DC pulsed with α-GC induced 
significantly more tumour specific CTL as compared to either IL-12 over-expressing DC or 
α-GC-pulsed DC (chapter 3). This approach is expected to lead to an increased anti-tumour 
immune response mediated by tumour specific CTL, as well as IFN-γ producing iNKT cells.  
From these findings it can be concluded that injection of preparations containing α-
GC-pulsed autologous DC is feasible, as shown in phase I studies, and results in distinct 
activation of iNKT and downstream effector cells. The anti-tumour efficacy could be 
improved by combination with IL-12 treatment, although the safety of this latter approach still 
has to be explored. An alternative approach is adoptive transfer of autologous iNKT cells, 
which have been previously expanded and activated in vitro.  
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 2 iNKT cell autologous adoptive transfer 
The numerical and functional defects of iNKT cells in cancer patients [4;6], combined 
with the observed poor clinical outcome of radiotherapy in head and neck squamous cell 
carcinoma patients with low numbers of circulating iNKT cells [7], suggests that cancer 
patients may benefit from reconstitution of the iNKT cell pool. A controlled way of 
increasing the number of systemic iNKT cells, as well as restoring their function, is by the 
direct transfer of ex vivo expanded autologous iNKT cells. 
We have developed a method to expand peripheral blood iNKT cells of healthy 
controls as well as advanced cancer patients in vitro, and to polarize them towards a type 1 
cytokine profile by stimulation of isolated TCR-Vα24+ T cells with mature α-GC-pulsed 
moDC in the presence of IL-15 [38]. Using an adapted version of this method, we expanded 
iNKT cells from healthy donor PBMC to investigate their capacity to activate NK cells. In 
contrast to addition of free α-GC, addition of these in vitro expanded human iNKT cells to 
PBMC cultures promoted NK cell phenotypical and functional activation in vitro (chapter 4). 
Furthermore, addition of expanded iNKT cells enhanced the efficacy of antibody-dependent 
NK cell-mediated ADCC (chapter 5b). The enhancing effects of expanded iNKT cells were 
dependent on additional α-GC stimulation. These results suggest that additional activation of 
the previously expanded and activated iNKT cells is a prerequisite for the effect on 
downstream NK cell activation.   
Motohashi and co-workers prepared autologous PBMC cultures for adoptive transfer: 
PBMC derived from 6 non-small cell lung cancer patients were cultured in the presence of IL-
2 and α-GC, resulting in cell populations that were enriched for iNKT cells [39]. This 
approach was well tolerated and resulted in a transient increase in circulating iNKT cells and 
elevation of IFN-γ producing cells in response to α-GC. The fold-increase in the iNKT cell 
number varied among the patients (range: 50 – 5250-fold), and seemed to be partially 
dependent on the initial frequency of iNKT cells. In addition to numerical deficiency, iNKT 
cell functional defects could also affect expansion. In this regard, Yanagisawa and co-workers 
have shown that granulocyte colony stimulating factor (G-CSF) can partly restore iNKT cell 
function repressed  in cancer patients, promoting proliferation [6]. 
Since CD1d is monomorphic, DC for in vitro expansion of iNKT cells are not required 
to be autologous. Therefore, DC cell lines could be used as a standardized unlimited source of 
in vitro APC, leading to defined iNKT cell populations for adoptive transfer. It would also 
facilitate repeated stimulation of cultured iNKT cells in vitro, as it eliminates the need of 
additional blood sampling to generate sufficient amounts of DC. We have previously 
demonstrated that human iNKT cells can be expanded using α-GC-pulsed DC derived from 
the CD34+ human acute myeloid leukaemia derived cell line, MUTZ-3 (M3) [40]. Analogous 
to the moDC approach discussed above, iNKT cells successively stimulated with M3 over-
expressing CD1d (M3-CD1d) and M3 over-expressing CD1d plus IL-12 (M312-CD1d)  were 
highly activated, were capable of producing high levels of IFN-γ, and enhanced tumour 
specific CTL priming in vitro (chapter 3). Thus, M3-CD1d and M312-CD1d are attractive 
sources of DC for large scale expansion and activation of functional iNKT cells from cancer 
patients. 
In conclusion, injection of preparations containing iNKT cells is feasible, since it can 
be performed safely and results in distinct activation of iNKT and downstream effector cells. 
This promising strategy requires long-term in vitro culture in order to obtain sufficient 
numbers to repopulate patients with iNKT cells up to healthy control levels, particularly in 
those individuals who would probably benefit most from this therapy, namely those with a 
severe deficiency in circulating iNKT cells and/or a poor in vitro proliferative response 
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towards α-GC. However, the effect of long-term in vitro stimulation with DC pulsed with the 
strong agonist α-GC on in vivo iNKT cell functionality has not previously been investigated.  
We therefore developed a method to generate long-term high purity oligoclonal mouse 
iNKT cell cultures representative of in vivo iNKT cells. D1 DC cell line [41] was shortly 
treated with LPS and IFN-γ, and pulsed with α-GC to generate mature DC, capable of 
facilitating the in vitro expansion of iNKT cells isolated from mouse spleen (chapter 6a) 
[42]. In successive experiments we weekly re-stimulated iNKT cells with α-GC-loaded 
mature D1 cells in the presence of IL-7, which supports iNKT cell expansion. Previously, 
either short lived iNKT cell cultures [43-45] or long lived clone derived iNKT cell 
hybridomas [46-48] were described. Our study was the first to make highly pure, long-term 
oligoclonal mouse iNKT cell lines representative of in vivo iNKT cells available on a large 
scale. These iNKT cell lines were used in different experiments to determine whether their in 
vitro functionality and, more importantly, their capacity to enhance anti-tumour responses in 
vivo remained unaffected. 
Our iNKT cell cultures consisted of both CD4+ and CD4- cells and retained their most 
distinctive characteristics, i.e. recognition of α-GC/CD1d complexes and capacity to release 
substantial amounts of Th1 and Th2 cytokines (IFN-γ, GM-CSF, IL-4, IL-5, IL-6 and IL-10) 
upon stimulation with α-GC (chapter 6a and 6b), reflecting the dichotomous regulatory 
capacity of in vivo iNKT cells [49-51]. Intravenous injection of iNKT cell lines evoked 
systemic cytokine production, i.e. elevated IFN-γ levels in serum and induction of splenocyte 
capacity to secrete IFN-γ and IL-4 that lasted for up to 11 days. Furthermore, iNKT cell 
transfer resulted in a preferential influx of NK cells into the lungs of these mice. Most 
importantly, all four iNKT cell lines investigated, enhanced NK cell mediated protection 
against B16.F10 experimental lung metastases upon adoptive transfer into wild-type mice 
shortly after tumour injection (chapter 6b) [52].  
Subsequent studies have shown anti-tumour effects of adoptively transferred iNKT 
cells into tumour inoculated iNKT cell deficient recipients [53-55]. Crowe and co-workers 
investigated the effect of transfer of freshly isolated iNKT cells on B16.F10 lung metastases 
in iNKT cell deficient mice. The anti-tumour effects depended on the iNKT cell subtype in 
combination with systemic α-GC treatment [54]. We demonstrated that additional α-GC 
injection was not required when iNKT cells had been extensively activated in vitro with α-
GC-pulsed D1 DC. This is in line with the findings by Shin and co-workers, who observed 
inhibition of experimental B16.F10 liver metastases upon adoptive transfer of in vitro IL-12 
pre-activated iNKT cells into iNKT deficient mice without additional α-GC treatment [55].  
In summary, we demonstrated that adoptive transfer of long-term high purity 
oligoclonal mouse iNKT cells with proven maintained in vitro functionality lead to enhanced 
immune protection against an experimental tumour. In the B16.F10 lung metastasis model we 
used, protection was achieved via the trans-activation of NK cells. The potential of 
autologous adoptive transfer of ex vivo expanded iNKT cells as an immunotherapeutic 
strategy for the treatment of cancer patients is illustrated by these pre-clinical studies.  
 
Conclusion 
Clinical phase I studies showed that injection of preparations containing α-GC-pulsed 
DC and/or iNKT cells is feasible and safe. Both approaches result in an increase in circulating 
iNKT cell numbers and a limited activation of downstream effector cells. Sporadic clinical 
responses were observed in these phase I trials in cancer patients with advanced disease. We 
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 have demonstrated that the use of IL-12-transduced DC may enhance the efficacy of both 
treatment modalities. In vitro expansion of iNKT cells using IL-12 over-expressing 
(allogeneic) DC leads to an iNKT cell population for adoptive T-cell transfer, which is 
superior in providing help for antigen specific CTL, and NK cells. However, additional 
treatment with α-GC, presented by DC, may be needed to re-activate the iNKT cells in vivo. 
However, a combination of iNKT cell adoptive transfer with α-GC pulsed DC may become 
even more effective when these DC are loaded with tumour associated antigen and engineered 
to over-express IL-12. This approach is expected to lead to an increased anti-tumour immune 
response mediated by NK cells and tumour specific CTL, as well as IFN-γ producing iNKT 
cells. 
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 Summary 
Cancer is the second leading cause of death in the western world after circulatory 
diseases. To date, many approaches have been developed in order to induce an adequate 
immune response against tumour cells. In this thesis, entitled “Innate and adaptive tumour 
immunity: Role of invariant Natural Killer T-cells”, we explored the value of a relatively 
recently discovered T-cell subset, the CD1d-restricted invariant Natural Killer T (iNKT) cell, 
in cancer immune therapy. Due to their ability to coordinate both innate and adaptive immune 
responses, they are promising for the development of strategies to improve anti-tumour 
immune responses.  
 In fact, pre-clinical studies illustrate the potential of iNKT cells as regulators of the 
tumour immune response [reviewed in chapter 1] and suggest the benefit of exploiting iNKT 
cells for the treatment of cancer. iNKT cells of cancer patients have numerical and also 
functional defects, i.e. impaired proliferation and cytokine secretion. Nonetheless, they still 
possess the capacity to proliferate and to secrete IFN-γ when properly stimulated in vitro. This 
suggests that iNKT cells of cancer patients may still be capable of enhancing anti-tumour 
responses after therapies aiming at their expansion and activation. However, data obtained 
from clinical studies attempting to exploit iNKT cells are contradictory. For implementation 
of iNKT cell-based immunotherapies further studies on the role of human iNKT cells in anti-
tumour immunity are needed. 
In the first part of this thesis, we analyzed the role of human iNKT cells as enhancer of 
anti-tumour immunity in vitro, by trans-activation of both dendritic cells (DC) and effector 
cells, such as NK cells and cytotoxic T lymphocytes (CTL). 
In chapter 2, we investigated adjuvant effects of various Toll-Like Receptor (TLR) 
agonists on iNKT cell function, as an approach to enhance iNKT cell-based immunotherapies. 
First, the iNKT cell TLR profile was characterized. Although human iNKT cells express all 
TLR, apart from TLR8, they did not respond directly to TLR ligands. Nevertheless, iNKT 
cells became activated when total peripheral blood mononuclear cells (PBMC) were 
stimulated with TLR ligands triggering TLR2/6, 7 and 8, and 9, but not TLR3, 4 and 5. Our 
results suggest that the combination of TLR2/6, TLR7, 8 or 9 agonists with α-
galactosylceramide (α-GC), the prototype iNKT cell stimulatory ligand, may act as a strong 
adjuvant for immunotherapy because any of these ligands will promote cross-talk between 
DC and iNKT cells. This cross-talk is evidenced by the induction of iNKT cell-derived type 1 
cytokine production, IFN-γ in particular, and DC maturation.  
In chapter 3, we investigated the effects of human iNKT cells on antigen specific 
CTL responses in vitro. iNKT cells were expanded using α-GC-pulsed allogeneic DC derived 
from the acute myeloid leukemia cell line MUTZ3, transduced with CD1d to enhance iNKT 
cell proliferation, and with IL-12 to stimulate type 1 cytokine production. Enhanced activation 
and increased IFN-γ production were observed in iNKT cells upon stimulation with IL-12 
over-expressing DC. Via IFN-γ secretion, IL-12-stimulated iNKT cells strongly enhanced the 
tumour specific CD8+ CTL response. In a more physiological set-up, autologous IL-12 over-
expressing DC, loaded with tumour antigen as well as α-GC were superior in stimulating both 
iNKT cells and antigen specific CTL. Thus, human iNKT cells activated by IL-12 over-
expressing, α-GC-pulsed DC, provide help for antigen specific CTL responses.  
Next to tumour antigen specific CTL response induction, in chapter 4 we investigated 
whether human iNKT cells could enhance NK cell functional activity in vitro, as an approach 
to improve anti-tumour responses. We found that addition of α-GC to PBMC induced iNKT 
cell activation but did not enhance NK cell effector functions. On the other hand, addition of 
María Moreno Jauge
136
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S 
U 
M 
M 
A 
R 
Y 
 
 
in vitro expanded, pre-activated iNKT cells to PBMC enhanced NK cell-mediated 
cytotoxicity in a α-GC-dependent manner. In line with the observations with iNKT cell-
induced CTL responses, IFN-γ was sufficient, though in this case not required, for iNKT cell-
mediated NK cell activation. These results indicate that adoptive transfer of ex vivo expanded 
and activated autologous iNKT cells, in combination with treatment with α-GC, may enhance 
NK cell effector functions. 
In chapters 5a and 5b, we aimed at validating the previously suggested approaches, 
i.e. TLR agonist adjuvant function and adoptive transfer of human iNKT cells, to improve the 
efficacy of monoclonal antibody-based cancer immunotherapies. In chapter 5a, we described 
the model we employed for these experiments: huHMFG-1, a monoclonal antibody against 
MUC1 that is currently evaluated in clinical trials as a potential immunotherapy for breast 
cancer. huHMFG-1 exerts in vitro tumour cell killing through antibody-dependent cell-
mediated cytotoxicity (ADCC). We identified NK cells as the main effector cell mediating 
huHMFG-1-dependent tumour cell killing. In chapter 5b we studied the effect of TLR 
agonists and iNKT cells on the efficacy of NK cells to induce huHMFG-1-mediated ADCC. 
Analogous to NK cell activation, we found that addition of in vitro expanded iNKT cells in 
combination with α-GC, but not addition of free α-GC, to PBMC enhanced ADCC. 
Furthermore, huHMFG-1-mediated tumour killing was enhanced through PBMC stimulation 
with TLR ligands triggering TLR2/6, 7 and 8, and 9, the same TLR agonists that induced the 
strongest iNKT cell activation. These results suggest that autologous adoptive transfer of ex 
vivo expanded iNKT cells or administration of TLR agonists that induce iNKT cell and NK 
cell activation as adjuvants, may improve the efficacy of NK cell-mediated antibody-based 
tumour immunotherapies. 
The results demonstrated the value of iNKT cells to enhance the efficacy of anti-
tumour effector cells in humans in vitro. Adoptive iNKT cell transfer is one approach to 
achieve this effect in vivo. However, the effect of long-term in vitro stimulation with DC 
pulsed with the strong agonist α-GC on in vivo iNKT cell functionality has not previously 
been investigated. In the second part of this thesis, the therapeutic potential of autologous 
adoptive transfer of chronically stimulated iNKT cells for the treatment of cancer was 
addressed in vivo.  
In chapter 6a, we described the generation and characterization of long term cultured 
mouse iNKT cell lines. Using α-GC-loaded, IFN-γ/LPS-mature D1 DC cells we generated 
highly pure long-term oligoclonal mouse iNKT cell lines from iNKT cells isolated from 
spleen. These iNKT cell lines retained their capacity to recognize α-GC/CD1d complexes and 
release substantial amounts of Th1 and Th2 cytokines (IFN-γ, GM-CSF, IL-4, IL-5, IL-6 and 
IL-10) upon stimulation with α-GC.  
In chapter 6b, we checked whether the capacity of these iNKT cells to enhance anti-
tumour responses in vivo remained unaffected. Using a melanoma experimental model, we 
proved that in vitro cultured mouse iNKT cell lines were still capable of enhancing NK cell-
mediated protection against B16.F10 experimental lung metastases, upon their adoptive 
transfer into wild-type mice shortly after tumour injection, confirming their potential as anti-
tumour immune therapeutic approach.  
 In the last part of this thesis (chapter 7), the different therapeutic approaches to 
exploit human iNKT cells to improve anti-tumour immunity are discussed. Results from the 
studies described in this thesis and from various other investigators indicate that autologous 
adoptive transfer of in vitro expanded iNKT cells represents a potentially valuable approach 
for the treatment of cancer. In vitro expansion of iNKT cells using IL-12 over-expressing 
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 (allogeneic) DC will lead to an iNKT cell population for adoptive transfer which is superior in 
secreting type 1 cytokines, providing help for antigen specific CTL, and inducing NK cell 
activation. Of note, additional treatment with α-GC, preferably presented by DC, may be 
needed to re-activate the iNKT cells in vivo. In conclusion, vaccination with antigen and α-
GC- loaded, IL-12 over-expressing DC combined with adoptive transfer of ex vivo expanded 
iNKT cells may result in a clinical benefit for cancer patients, since this approach is expected 
to lead to an increased anti-tumour immune response mediated by NK cells and tumour 
specific CTL, as well as IFN-γ producing iNKT cells.  
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 Kanker is na hart en vaatziekten de tweede doodsoorzaak door ziekte in de westerse 
wereld. Er is in de laatste jaren veel vooruitgang geboekt in de behandeling van kanker met 
behulp van o.a. chemotherapie en bestraling. Bij deze vormen van kankertherapie ontstaan 
echter veel bijwerkingen omdat niet alleen kankercellen worden gedood, maar ook normale 
gezonde cellen. Een andere veelbelovende therapie is immuuntherapie. Het doel van 
immuuntherapie is het induceren en/of activeren van afweercellen zodat zij tumorcellen 
kunnen doden. De zogenaamde killer T-cel (CTL) kan stukjes eiwit die alleen, of in sterk 
verhoogde hoeveelheden in tumorcellen voorkomen en niet, of slechts in lage hoeveelheden 
aanwezig zijn in gezonde cellen [tumor geassocieerde antigenen (TAA)] herkennen als zij in 
de context van de zogenaamde transplantatie antigenen (HLA) gepresenteerd worden. HLA 
antigenen zitten op het oppervlak van alle normale kernhoudende cellen. Nadat de CTL TAA 
gepresenteerd door HLA herkent, kan deze de tumor cel doden. Echter in veel gevallen 
verdwijnt het HLA van het oppervlak van tumor cellen en kan de CTL deze niet meer 
herkennen. Op dit moment wordt een tweede type “killer” cel van belang, de zogenaamde 
natural killer (NK) cel. Dit type killer cel laat alle normale cellen met HLA op het oppervlak 
met rust, maar zal cellen die geen HLA op het oppervlak meer hebben, bijvoorbeeld door 
ontaarding als kankercel, juist actief doden. Dit kunnen zij op twee manieren, direct of via 
herkenning van antistoffen die gebonden zijn aan de tumor cel. Het laatste mechanisme wordt 
ook wel “antibody dependent cellular cytotoxicity” of ADCC genoemd. ADCC is één van de 
belangrijkste mechanismen van tumor specifieke monoklonale antistof therapie. Antistoffen 
bestaan uit een constant gedeelte en een variabel gedeelte, het variabele gedeelte is voor elke 
antistof anders en bepaalt waar deze aan zal binden, bijvoorbeeld een bepaald eiwit wat alleen 
op het oppervlakte van tumor cellen voorkomt maar niet op normale cellen. Een bekend 
voorbeeld van zo’n eiwit is MUC1, wat veel voorkomt op borst- en eierstokkanker cellen. NK 
cellen hebben een receptor voor het constante gedeelte van de antistof. Na binding van een 
antistof die met het variabele deel vast zit aan de tumor cel en met het constante deel aan de 
NK cel, wordt de NK cel aangezet tot het doden van de tumor cel.  
 Bij de zogenaamde niet-specifieke immuuntherapie wordt de patiënt behandeld met 
stoffen die een algemene activering van het afweer systeem veroorzaken (cytokinen). Omdat 
bij deze vorm van immuuntherapie het gehele immuunsysteem sterk wordt geactiveerd, gaat 
deze behandeling ook gepaard met relatief veel bijwerkingen en daarnaast zijn de resultaten 
helaas teleurstellend. Bij specifieke immuuntherapie wordt het afweersysteem gestimuleerd 
door middel van vaccinatie met TAA om TAA specifieke CTL te induceren die vervolgens 
tumor cellen kunnen doden maar gezonde cellen met rust laten. Deze vorm van 
immuuntherapie heeft dan ook relatief weinig bijwerkingen, en de eerste resultaten zijn 
veelbelovend. Om voldoende en effectieve tumorcel herkennende CTL te induceren is het 
noodzakelijk om de TAA aan te bieden op het HLA van een gespecialiseerd celtype; de 
dendritische cel (DC). Na activering is de DC het enige celtype wat in staat is primaire TAA 
specifieke CTL te induceren. Huidige vaccinatie strategieën maken dan ook vaak gebruik van 
geactiveerde DC gegenereerd uit het bloed van patiënten die met TAA eiwit zijn beladen en 
vervolgens teruggegeven worden aan de patiënt. Naast DC zijn ook bepaalde cytokinen nodig 
om een effectieve antitumor CTL respons op te wekken. Echter, zoals eerder genoemd, 
systemische behandeling met cytokinen leidt tot ernstige bijwerkingen.  
 Invariante Natural killer T (iNKT) cellen zijn afweer cellen die kort na activering zelf 
relatief grote hoeveelheden cytokinen kunnen uitscheiden. Door deze eigenschap spelen zij 
een belangrijke rol in de regulatie van afweerreacties, o.a. de versterking van de afweerreactie 
gericht tegen tumoren. iNKT cellen worden, net als CTL, geactiveerd door DC. Zij herkennen 
echter geen eiwitten maar bepaalde suikervetten (o.a. het uit een zeespons geïsoleerde α-
Innate and adaptive tumour immunity: Role of invariant Natural Killer T-cells
139
 Galactosylceramide (α-GalCer)) gepresenteerd door het CD1d molecuul. Studies in muizen 
tumormodellen hebben aangetoond dat na toediening van α-GalCer het aantal iNKT cellen 
toeneemt en het ontstaan van uitzaaiingen wordt geremd met name door activering van o.a. 
CTL en NK cellen. Wij hebben eerder aangetoond dat het aantal circulerende iNKT cellen in 
het perifere bloed verlaagd is in patiënten met kanker. Daarnaast hebben wij ook in een groep 
van patiënten met hoofd-hals tumoren, die met radiotherapie worden behandeld, aangetoond 
dat patiënten met een relatief laag aantal circulerende iNKT cellen een slechtere prognose 
hebben dan patiënten met een relatief hoog aantal circulerende iNKT cellen. Deze data 
suggereren dat kankerpatiënten baat zouden kunnen hebben bij behandeling die er op gericht 
is het aantal circulerende iNKT te verhogen. Echter, anders dan bij de muis, is bij de mens is 
gebleken dat toediening van vrij α-GalCer leidt tot een tijdelijke afname van NKT cellen. 
Activering van het immuunsysteem werd alleen gezien als het aantal iNKT cellen voor 
behandeling relatief hoog was. In tegenstelling tot de behandeling met vrij α-GalCer, had de 
behandeling met DC beladen met α-GalCer wel effect: het aantal circulerende iNKT cellen 
nam toe. Een alternatieve methode om de aantallen circulerende iNKT cellen te verhogen is 
door middel van toediening van iNKT cellen van de patiënt, welke in het laboratorium 
vermeerderd zijn met behulp van bepaalde kweektechnieken.  
 Het onderzoek beschreven in dit proefschrift is gericht op het analyseren van de 
effectiviteit van geactiveerde iNKT cellen in de antitumor immuunreactie. Hiertoe hebben wij 
in deel 1 de effecten onderzocht op NK cel en/of CTL: na iNKT cel activering door middel 
van een aantal bekende immuun potentierende reagentia (TLR liganden) en na toevoegen van 
gekweekte humane iNKT cellen. In dit deel van het onderzoek hebben wij gebruik gemaakt 
van perifere witte bloed cellen van voornamelijk gezonde donoren. In deel 2 hebben wij in 
een muizenmodel onderzocht of de toediening van gekweekte iNKT cellen ook daadwerkelijk 
leidt tot verminderde uitgroei van tumoren.  
 Uit onze resultaten beschreven in deel 1 is gebleken dat bepaalde TLR liganden in 
staat waren iNKT cellen indirect te activeren, waarna de actieve iNKT cellen vervolgens in 
staat waren DC te activeren. Deze DC activering is noodzakelijk voor het opwekken van 
effectieve CTL. Vervolgens hebben wij aangetoond dat TAA specifieke CTL met veel grotere 
efficiëntie geïnduceerd kunnen worden door TAA beladen DC wanneer gekweekte iNKT 
cellen werden toegevoegd. Dit effect was afhankelijk van de aanwezigheid van het iNKT cel 
activerende ligand α-GalCer op de DC. Een vergelijkbaar effect werd geobserveerd met 
betrekking tot NK cel activiteit. Gekweekte iNKT cellen induceerden een toegenomen 
functionele activiteit van NK cellen. Deze bleken na een kortdurende incubatie in de 
aanwezigheid van iNKT cellen en α-GalCer beter in staat tumorcellen te doden, zowel via de 
directe methode alsook via monoklonale antistoffen. 
 In deel 2 beschrijven wij een methode voor het langdurig kweken van muizen iNKT 
cellen. Deze chronisch gestimuleerde iNKT cellen bleken dezelfde karakteristieken te hebben 
als hen direct vers geïsoleerde tegenhangers. Vervolgens hebben bij 4 verschillende batches 
van iNKT cellen getest met betrekking tot antitumor effectiviteit in vivo. Onze resultaten 
tonen aan dat gekweekte iNKT cellen inderdaad in staat zijn tumorgroei te remmen en in het 
model dat wij hebben bestudeerd deden zij dat met name via NK cel activering.  
 Concluderend: toediening van gekweekte iNKT cellen bij kanker patiënten is een 
potentieel effectieve manier om het immuunsysteem te activeren. Combinatie met α-GalCer 
en TAA beladen DC vaccinatie zal de effectiviteit nog verder verhogen en leiden tot een 
sterke CTL en NK cel gemedieerde antitumor afweer reactie. De resultaten van dit onderzoek 
wijzen op nieuwe methodes om de aspecifieke afweer (“innate immunity”) in te zetten om de 
specifieke afweer (“adaptive immunity”) tegen tumoren te versterken. 
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Jan, Astrid, Duco, Deby, Floor, Anke and all those I’m forgetting today but I’ll remember 
tomorrow. En Berber, mijn studente, verdient een persoonlijke noot. Beste Berber, bedank 
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voor je onvermoeibare inzet in het onderzoek en jouw enthousiasme. Ik wens je het allerbeste. 
Y por último a Alexis, no solo por su invalorable trabajo manteniendo el orden y la limpieza 
de nuestro lugar de trabajo, sino también por cuidar tanto de nosotros. Muchísimas gracias!  
La vida en Ámsterdam no hubiese sido lo mismo… 
… sin charrúas. Sole y Yael (y con ellas, Arnout y Aldo), muchísimas gracias por su 
amistad incondicional. Fueron mi pequeña familia uruguaya en Holanda. Les deseo lo mejor 
en sus nuevos proyectos y, por supuesto, seguimos en contacto! 
… sin el extinguido grupo de la cerveza de las 5: Josean, Juan J, Miriam, Sonia, Paco, 
Marta, David, Fran, Nacho, Cora, Zoila, Verónica y Espe. El último que apague la luz! Juan, 
pensar que cuando llegué a Ámsterdam no comía mariscos. Recuerdo aquel primer almuerzo; 
apenas traspasar el umbral de tu puerta, me encontré con un pulpo en la mesa y unas langostas 
crujiendo en la sartén. Creí que sería el comienzo de una pesadilla. Sin embargo, los 
almuerzos en tu casa fueron los mejores momentos vividos en Ámsterdam. Josean, sin ti los 
almuerzos nunca fueron los mismos! Tampoco olvidaré los largos paseos en bici, sesiones 
deportivas o sencillamente las charlas en el CCA al almuerzo, con un café o un pedacito de 
chocolate (cualquier excusa era válida). Espero verlos a los dos algún día en Uruguay. 
Sacrificaré una vaca para tal evento! 
 … sin el grupo de latinos: Jorge, Manu, Juan, Salvo, Nacho, Jordi, Annemarieke, 
Timi, Daniele, Leonid, Javier, Ruben, Viney, Diego y Miriam, y sus cervezas en el Kriterion, 
cenas y fiestas. Disfrute de cada uno de esos momentos juntos. Manu, gracias por tu genuina 
amistad. Juan, gracias por tu humor! y por tantas corridas y cenas juntos (y por prestarme el 
auto para algún paseo). Jorge, sin tu apoyo nunca lo hubiese logrado. Muchas gracias por 
estar ahí!  
I also want to thank Anna for her friendship! Dear Anna, I still think a lot about our 
wonderful times at home. I really enjoyed our dinners, long talks, and sharing laughter and 
tears. I would never forget the magic Swedish Christmas! I’m looking forward to meet you in 
Uruguay. 
 Quiero agradecer a aquellos que desde Uruguay me apoyaron y acompañaron en esta 
experiencia, y que hoy me recibe con todo su cariño. Ceci, me alegra haber aprovechado la 
oportunidad para compartir increíbles momentos en Holanda, Italia, y por Paris en compañía 
de Ana. Noni, me hacía mucha ilusión recibir tus llamadas los fines de semana. Nati, que 
ilusión que puedas estar acá hoy. A todo el grupo del club, los que nos hacemos llamar 
deportistas pero que no perdemos oportunidad para disfrutar de la vida como bacanes. Los 
años pasan y pesan, pero aún tenemos tiempo para más. ¿Cuándo es el próximo desafío? 
Héctor, muchas gracias por tus constantes e-mails, manteniéndome al día de todo lo que iba 
pasando en el Bohe. 
 Esta tesis fue posible gracias a la formación inicial recibida en el LVR. Me gustaría 
agradecer en particular a Alejandro Chabalgoity, que me inició en el mundo de la 
inmunología. También a Analía por sus e-mails y a Fernanda por sus visitas a Ámsterdam. 
 Y por último quiero agradecer a mi querida familia, a cada uno de ellos. A mi abuelita 
del alma, mil gracias por las cartas enviadas, escritas a mano como aquellas que de chiquita te 
veía escribir domingo tras domingo y que tanto anhelaba recibir algún día, inconciente de que 
eso significaría estar lejos de ti. Son el mayor tesoro que guardo! Ada, Gus y Martín, muchas 
gracias por sus “sacrificadas” visitas a la fría y gris Ámsterdam. Fede, Flor y compañía, 
estamos cada vez más cerca! Chris, mamá puede estar tranquila de que cumpliste con tu 
palabra: nadie cuido tan bien de mi! No puedo imaginarme todos estos años en Europa sin 
vos. El solo hecho de saber que estabas a solo un par de horas me dieron la tranquilidad 
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necesaria para seguir adelante. Mil gracias por tu compañía! Eri, fueron tiempos muy difíciles 
los que pasamos separadas, pero ahora se vienen momentos mejores para disfrutarlos juntas! 
Te quiero mucho. Marthita, vos y mamá se intercalaban las visitas a EEUU y Europa para que 
tanto Fede, como Chris y yo, pudiéramos estar siempre acompañados. Muchas gracias por 
tanto esfuerzo y entrega! ¿Crees que podré ser para Martina y Emilia la madrina que vos sos 
para mi? 
 A papá y mamá, gracias por su incansable apoyo. Mami, esperaba cada año que 
llegará el momento de tu visita! aunque después sufriera cada vez que te veía embalar en tu 
bicicleta por las calles de Ámsterdam. ¿Quien nos quita lo bailado juntas? Barcelona, Paris, el 
sueño de Viena, Berlín, Roma y Madrid, y lo bicicleteado! Matu, mientras la rubia te 
extrañaba, indudablemente vos disfrutabas. Pipita, no te imaginas cuanto te extrañé. Siento 
mucho no haber estado ahí estos años. Me alegra poder compartir mucho tiempo juntas ahora. 
Los quiero muchísimo a todos, jusqu’au ciel!!! 
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